Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 08, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Entity Registrant Name | Metropolitan Life Insurance Co | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 000-55029 | |
Entity Incorporation, State or Country Code | NY | |
Entity Tax Identification Number | 13-5581829 | |
Entity Address, Address Line One | 200 Park Avenue, | |
Entity Address, City or Town | New York, | |
Entity Address, State or Province | NY | |
Entity Address, Postal Zip Code | 10166-0188 | |
City Area Code | 212 | |
Local Phone Number | 578-9500 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Central Index Key | 0000937834 | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 494,466,664 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Current Fiscal Year End Date | --12-31 |
Consolidated Balance Sheets (Un
Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Investments: | ||
Fixed maturity securities available-for-sale, at estimated fair value (amortized cost: $160,814 and $158,354, respectively; allowance for credit loss of $117 and $53, respectively) | $ 143,414 | $ 175,885 |
Mortgage loans (net of allowance for credit loss of $392 and $536, respectively; includes $143 and $224, respectively, relating to variable interest entities; $0 and $127, respectively, under the fair value option) | 61,603 | 60,219 |
Policy loans | 5,732 | 5,816 |
Real estate and real estate joint ventures (includes $1,017 and $1,094, respectively, relating to variable interest entities, $315 and $240, respectively, under the fair value option and $191 and $175, respectively, of real estate held-for-sale) | 8,218 | 7,873 |
Other limited partnership interests | 8,014 | 8,754 |
Short-term investments, at estimated fair value | 3,531 | 4,866 |
Other invested assets (includes $923 and $924, respectively, of leveraged and direct financing leases; $163 and $171, respectively, relating to variable interest entities; allowance for credit loss of $26 and $32, respectively) | 21,532 | 19,860 |
Total investments | 252,044 | 283,273 |
Cash and cash equivalents, principally at estimated fair value | 10,978 | 9,957 |
Accrued investment income | 1,953 | 1,767 |
Premiums, reinsurance and other receivables | 21,247 | 20,505 |
Deferred policy acquisition costs and value of business acquired | 5,379 | 2,598 |
Current income tax recoverable | 241 | 80 |
Deferred Income Tax Asset | 2,734 | 0 |
Other assets | 4,563 | 4,526 |
Separate account assets | 87,709 | 123,851 |
Total assets | 386,848 | 446,557 |
Liabilities | ||
Future policy benefits | 134,069 | 132,274 |
Policyholder account balances | 97,675 | 94,459 |
Other policy-related balances | 8,104 | 8,094 |
Policyholder dividends payable | 280 | 312 |
Policyholder dividend obligation | 0 | 1,682 |
Payables for collateral under securities loaned and other transactions | 17,595 | 24,866 |
Short-term debt | 99 | 100 |
Long-term debt | 1,616 | 1,659 |
Deferred income tax liability | 0 | 2,036 |
Other liabilities | 25,950 | 23,796 |
Separate account liabilities | 87,709 | 123,851 |
Total liabilities | 373,097 | 413,129 |
Contingencies, Commitments and Guarantees (Note 11) | ||
Metropolitan Life Insurance Company stockholder’s equity: | ||
Common stock, par value $0.01 per share; 1,000,000,000 shares authorized; 494,466,664 shares issued and outstanding | 5 | 5 |
Additional paid-in capital | 12,476 | 12,464 |
Retained earnings | 11,171 | 10,868 |
Accumulated other comprehensive income (loss) | (10,058) | 9,917 |
Total Metropolitan Life Insurance Company stockholder’s equity | 13,594 | 33,254 |
Noncontrolling interests | 157 | 174 |
Total equity | 13,751 | 33,428 |
Total liabilities and equity | $ 386,848 | $ 446,557 |
Consolidated Balance Sheets (_2
Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Assets | ||
Amortized Cost | $ 160,814 | $ 158,354 |
Amortized cost of fixed maturity securities valuation allowances | 117 | 53 |
Mortgage loans valuation allowances | 392 | 536 |
Residential mortgage loans — FVO | 61,603 | 60,219 |
Real Estate Held-for-sale | 191 | 175 |
Real estate and real estate joint ventures (includes $1,017 and $1,094, respectively, relating to variable interest entities, $315 and $240, respectively, under the fair value option and $191 and $175, respectively, of real estate held-for-sale) | 8,218 | 7,873 |
Other Invested Assets - Leveraged and Direct Financing Leases | 923 | 924 |
Other invested assets relating to variable interest entities | 21,532 | 19,860 |
Net Investment in Lease, Allowance for Credit Loss | $ 26 | $ 32 |
Metropolitan Life Insurance Company stockholder’s equity: | ||
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 1,000,000,000 | 1,000,000,000 |
Common stock, shares issued | 494,466,664 | 494,466,664 |
Common stock, shares outstanding | 494,466,664 | 494,466,664 |
Residential mortgage loans — FVO | ||
Assets | ||
Residential mortgage loans — FVO | $ 0 | $ 127 |
Real estate and real estate joint ventures (includes $1,017 and $1,094, respectively, relating to variable interest entities, $315 and $240, respectively, under the fair value option and $191 and $175, respectively, of real estate held-for-sale) | 315 | 240 |
Variable interest entity | ||
Assets | ||
Residential mortgage loans — FVO | 143 | 224 |
Real estate and real estate joint ventures (includes $1,017 and $1,094, respectively, relating to variable interest entities, $315 and $240, respectively, under the fair value option and $191 and $175, respectively, of real estate held-for-sale) | 1,017 | 1,094 |
Other invested assets relating to variable interest entities | $ 163 | $ 171 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues | ||||
Premiums | $ 13,769 | $ 5,715 | $ 25,347 | $ 17,971 |
Universal life and investment-type product policy fees | 484 | 506 | 1,523 | 1,555 |
Net investment income | 2,260 | 3,331 | 7,528 | 9,552 |
Other revenues | 501 | 368 | 1,286 | 1,225 |
Net investment gains (losses) | (82) | 190 | (391) | 692 |
Net derivative gains (losses) | 454 | 84 | 980 | (906) |
Total revenues | 17,386 | 10,194 | 36,273 | 30,089 |
Expenses | ||||
Policyholder benefits and claims | 14,178 | 6,628 | 26,675 | 20,336 |
Interest credited to policyholder account balances | 624 | 512 | 1,645 | 1,535 |
Policyholder dividends | 119 | 154 | 432 | 559 |
Other expenses | 1,418 | 1,825 | 4,136 | 4,216 |
Total expenses | 16,339 | 9,119 | 32,888 | 26,646 |
Income (loss) before provision for income tax | 1,047 | 1,075 | 3,385 | 3,443 |
Provision for income tax expense (benefit) | 174 | 153 | 539 | 510 |
Net income (loss) | 873 | 922 | 2,846 | 2,933 |
Less: Net income (loss) attributable to noncontrolling interests | 2 | 1 | 4 | 5 |
Net income (loss) attributable to Metropolitan Life Insurance Company | 871 | 921 | 2,842 | 2,928 |
Comprehensive income (loss) | (5,408) | 1,340 | (17,129) | 1,568 |
Less: Comprehensive income (loss) attributable to noncontrolling interests, net of income tax | 2 | 1 | 4 | 5 |
Comprehensive income (loss) attributable to Metropolitan Life Insurance Company | $ (5,410) | $ 1,339 | $ (17,133) | $ 1,563 |
Consolidated Statements of Equi
Consolidated Statements of Equity (Unaudited) - USD ($) $ in Millions | Total | Common Stock | Additional Paid-in Capital | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Total Metropolitan Life Insurance Company Stockholder’s Equity | Noncontrolling Interests |
Beginning Balance at Dec. 31, 2020 | $ 34,858 | $ 5 | $ 12,460 | $ 10,548 | $ 11,662 | $ 34,675 | $ 183 |
Capital contributions from MetLife, Inc. | 2 | 2 | 2 | ||||
Dividends to MetLife, Inc. | (1,430) | (1,430) | (1,430) | ||||
Change in equity of noncontrolling interests | 2 | 0 | 2 | ||||
Net income (loss) | 2,011 | 2,007 | 2,007 | 4 | |||
Other comprehensive income (loss), net of income tax | (1,783) | (1,783) | (1,783) | ||||
Ending Balance at Jun. 30, 2021 | 33,660 | 5 | 12,462 | 11,125 | 9,879 | 33,471 | 189 |
Beginning Balance at Dec. 31, 2020 | 34,858 | 5 | 12,460 | 10,548 | 11,662 | 34,675 | 183 |
Net income (loss) | 2,933 | ||||||
Ending Balance at Sep. 30, 2021 | 34,236 | 5 | 12,463 | 11,283 | 10,297 | 34,048 | 188 |
Beginning Balance at Jun. 30, 2021 | 33,660 | 5 | 12,462 | 11,125 | 9,879 | 33,471 | 189 |
Capital contributions from MetLife, Inc. | 1 | 1 | 1 | ||||
Dividends to MetLife, Inc. | (763) | (763) | (763) | ||||
Change in equity of noncontrolling interests | (2) | 0 | (2) | ||||
Net income (loss) | 922 | 921 | 921 | 1 | |||
Other comprehensive income (loss), net of income tax | 418 | 418 | 418 | ||||
Ending Balance at Sep. 30, 2021 | 34,236 | 5 | 12,463 | 11,283 | 10,297 | 34,048 | 188 |
Beginning Balance at Dec. 31, 2021 | 33,428 | 5 | 12,464 | 10,868 | 9,917 | 33,254 | 174 |
Capital contributions from MetLife, Inc. | 12 | 12 | 12 | ||||
Dividends to MetLife, Inc. | (1,562) | (1,562) | (1,562) | ||||
Change in equity of noncontrolling interests | (22) | 0 | (22) | ||||
Net income (loss) | 1,973 | 1,971 | 1,971 | 2 | |||
Other comprehensive income (loss), net of income tax | (13,694) | (13,694) | (13,694) | ||||
Ending Balance at Jun. 30, 2022 | 20,135 | 5 | 12,476 | 11,277 | (3,777) | 19,981 | 154 |
Beginning Balance at Dec. 31, 2021 | 33,428 | 5 | 12,464 | 10,868 | 9,917 | 33,254 | 174 |
Net income (loss) | 2,846 | ||||||
Ending Balance at Sep. 30, 2022 | 13,751 | 5 | 12,476 | 11,171 | (10,058) | 13,594 | 157 |
Beginning Balance at Jun. 30, 2022 | 20,135 | 5 | 12,476 | 11,277 | (3,777) | 19,981 | 154 |
Dividends to MetLife, Inc. | (977) | (977) | (977) | ||||
Change in equity of noncontrolling interests | 1 | 0 | 1 | ||||
Net income (loss) | 873 | 871 | 871 | 2 | |||
Other comprehensive income (loss), net of income tax | (6,281) | (6,281) | (6,281) | ||||
Ending Balance at Sep. 30, 2022 | $ 13,751 | $ 5 | $ 12,476 | $ 11,171 | $ (10,058) | $ 13,594 | $ 157 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Statement of Cash Flows [Abstract] | ||
Net cash provided by (used in) operating activities | $ 2,637 | $ 2,224 |
Cash flows from investing activities | ||
Sales, maturities and repayments of fixed maturity securities available-for-sale | 40,626 | 36,842 |
Sales, maturities and repayments of equity securities | 159 | 370 |
Sales, maturities and repayments of mortgage loans | 7,511 | 11,027 |
Sales, maturities and repayments of real estate and real estate joint ventures | 453 | 1,217 |
Sales, maturities and repayments of other limited partnership interests | 846 | 365 |
Purchases of fixed maturity securities available-for-sale | (35,440) | (38,191) |
Purchases of equity securities | (88) | (21) |
Purchases of mortgage loans | (9,578) | (6,845) |
Purchases of real estate and real estate joint ventures | (487) | (963) |
Purchases of other limited partnership interests | (737) | (1,339) |
Cash received in connection with freestanding derivatives | 2,043 | 1,510 |
Cash paid in connection with freestanding derivatives | (2,966) | (4,885) |
Cash received from the redemption of an investment in affiliated preferred stock | 0 | 315 |
Purchases of loans to affiliates | (19) | 0 |
Net change in policy loans | 84 | 118 |
Net change in short-term investments | 1,307 | (1,786) |
Net change in other invested assets | 72 | 14 |
Net change in property, equipment and leasehold improvements | 7 | 12 |
Other, net | 14 | 5 |
Net cash provided by (used in) investing activities | 3,807 | (2,235) |
Cash flows from financing activities | ||
Policyholder account balances: Deposits | 69,678 | 61,556 |
Policyholder account balances: Withdrawals | (65,450) | (62,391) |
Net change in payables for collateral under securities loaned and other transactions | (7,271) | 1,289 |
Long-term debt issued | 4 | 0 |
Long-term debt repaid | (57) | (21) |
Financing element on certain derivative instruments and other derivative related transactions, net | 241 | 173 |
Dividends paid to MetLife, Inc. | (2,539) | (2,193) |
Other, net | (17) | (27) |
Net cash provided by (used in) financing activities | (5,411) | (1,614) |
Effect of change in foreign currency exchange rates on cash and cash equivalents balances | (12) | (6) |
Change in cash and cash equivalents | 1,021 | (1,631) |
Cash and cash equivalents, beginning of period | 9,957 | 11,337 |
Cash and cash equivalents, end of period | 10,978 | 9,706 |
Supplemental disclosures of cash flow information | ||
Net cash paid for Interest | 59 | 57 |
Net cash paid (received) for Income tax | 220 | 410 |
Non-cash transactions: | ||
Capital contributions from MetLife, Inc. | 12 | 3 |
Real estate and real estate joint ventures acquired in satisfaction of debt | 153 | 172 |
Fixed maturity securities available-for-sale received in connection with pension risk transfer transactions | 7,450 | 0 |
Increase in equity securities due to in-kind distributions received from other limited partnership interests | 75 | 243 |
Transfer of fixed maturity securities available-for-sale from an affiliate | 139 | 0 |
Transfer of fixed maturity securities available-for-sale to an affiliate | 328 | 0 |
Transfer of fair value option securities from an affiliate | 186 | 0 |
Increase in other invested assets in connection with an affiliated reinsurance transaction | $ 0 | $ 822 |
Business, Basis of Presentation
Business, Basis of Presentation and Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business, Basis of Presentation and Summary of Significant Accounting Policies | 1. Business, Basis of Presentation and Summary of Significant Accounting Policies Business Metropolitan Life Insurance Company and its subsidiaries (collectively, “MLIC” or the “Company”) is a provider of insurance, annuities, employee benefits and asset management and is organized into two segments: U.S. and MetLife Holdings. Metropolitan Life Insurance Company is a wholly-owned subsidiary of MetLife, Inc. (MetLife, Inc., together with its subsidiaries and affiliates, “MetLife”). Basis of Presentation The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain, including uncertainties associated with the COVID-19 pandemic. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates. The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2021 consolidated balance sheet data was derived from audited consolidated financial statements included in Metropolitan Life Insurance Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2021 Annual Report. Consolidation The accompanying interim condensed consolidated financial statements include the accounts of MLIC, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated. The Company uses the equity method of accounting or the fair value option (“FVO”) for real estate joint ventures and other limited partnership interests (“investee”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. Since the Company is a member of a controlled group of affiliated companies, its results may not be indicative of those of a stand-alone entity. Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following tables provide a description of ASUs recently issued by the FASB and the impact of their adoption on the Company’s interim condensed consolidated financial statements. Adopted Accounting Pronouncements The table below describes the impacts of the ASUs recently adopted by the Company. Standard Description Effective Date and Method of Adoption Impact on Financial Statements ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting; as clarified and amended by ASU 2021-01, Reference Rate Reform (Topic 848):Scope The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, with certain exceptions. ASU 2021-01 amends the scope of the recent reference rate reform guidance. New optional expedients allow derivative instruments impacted by changes in the interest rate used for margining, discounting, or contract price alignment to qualify for certain optional relief. Effective for contract modifications made between March 12, 2020 and December 31, 2022. The guidance has reduced the operational and financial impacts of contract modifications that replace a reference rate, such as London Interbank Offered Rate (“LIBOR”), affected by reference rate reform. Contract modifications for invested assets and derivative instruments occurred during 2021 and have continued into 2022. Based on actions taken to date, the adoption of the guidance has not had a material impact on the Company’s interim condensed consolidated financial statements. The Company does not expect the adoption of this guidance to have a material ongoing impact and will continue to evaluate the impacts of reference rate reform on contract modifications and hedging relationships through December 31, 2022. ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance The guidance requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy and can include tax credits and other forms of government assistance. Entities are required to disclose information about (i) the nature of the transactions and the related accounting policy used to account for the transactions; (ii) the line items on the balance sheet and income statement that are affected by the transactions, including the associated amounts; and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. Effective for annual periods beginning January 1, 2022, to be applied prospectively. The adoption of the guidance will not have a material impact on the Company’s annual consolidated financial statements. Future Adoption of Accounting Pronouncements ASUs not listed below were assessed and either determined to be not applicable or are not expected to have a material impact on the Company’s interim condensed consolidated financial statements or disclosures. ASUs issued but not yet adopted as of September 30, 2022 that are currently being assessed and may or may not have a material impact on the Company’s interim condensed consolidated financial statements or disclosures are summarized in the table below. Standard Description Effective Date and Method of Adoption Impact on Financial Statements ASU 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, as amended by ASU 2019-09, Financial Services—Insurance (Topic 944): Effective Date, as amended by ASU 2020-11 , Financial Services—Insurance (Topic 944): Effective Date and Early Application The guidance (i) prescribes the discount rate to be used in measuring the liability for future policy benefits for traditional and limited payment long-duration contracts, and requires assumptions for those liability valuations to be updated after contract inception, (ii) requires more market-based product guarantees (“market risk benefits”) on certain separate account and other account balance long-duration contracts to be accounted for at fair value, (iii) simplifies the amortization of deferred policy acquisition costs (“DAC”) for virtually all long-duration contracts, and (iv) introduces certain financial statement presentation requirements, as well as significant additional quantitative and qualitative disclosures. The amendments in ASU 2019-09 defer the effective date of ASU 2018-12 to January 1, 2022 for all entities, and the amendments in ASU 2020-11 further defer the effective date of ASU 2018-12 for an additional year to January 1, 2023 for all entities. January 1, 2023, to be applied retrospectively to January 1, 2021 (with early adoption permitted). Estimated impacts from adoption as of the transition date of January 1, 2021 are measured using market assumptions appropriate as of that date. Such estimates do not reflect changes in market assumptions subsequent to January 1, 2021. The Company’s implementation efforts and the evaluation of the impacts of the guidance on its consolidated financial statements, as well as its systems, processes, and controls, continue to progress. Given the nature and extent of the required changes to a significant portion of the Company’s operations, the adoption of this guidance is expected to have a material impact on its financial position, results of operations, and disclosures. The Company will adopt the guidance effective January 1, 2023. The modified retrospective approach will be used, except in regard to market risk benefits where the Company will use the full retrospective approach. Based upon these transition methods, the Company currently estimates that the January 1, 2021 transition date impact from adoption is expected to result in a decrease to total equity in a range of approximately $16.0 billion to $18.5 billion, net of income tax. The expected decrease in total equity includes the estimated impact to Accumulated other comprehensive income (loss) (“AOCI”) which, as of the transition date, is expected to result in a decrease in a range of approximately $12.5 billion to $14.0 billion, net of income tax. The most significant drivers of the expected decrease in AOCI are the anticipated impacts of the changes in the discount rates as of the transition date to be used in measuring the liability for future policy benefits for traditional and limited payment contracts and the non-performance risk in the valuation of the Company’s market risk benefits. The expected decrease in AOCI is expected to be partially offset by the removal of loss recognition balances recorded in AOCI related to unrealized investment gains associated with certain long-duration products. The expected decrease in total equity also includes the estimated impact to retained earnings which, from adoption, is expected to result in a decrease in a range of approximately $3.5 billion to $4.5 billion, net of income tax. This decrease results from the requirement to account for variable annuity guarantees as market risk benefits measured at fair value (except for the changes in fair value already recognized under an existing accounting model) and other valuation impacts to the liability for future policy benefits. The changes in market conditions from January 1, 2021 to September 30, 2022 are estimated to cause the initial transition date reduction in total equity (as discussed in the preceding paragraphs) to largely reverse as of September 30, 2022. Standard Description Effective Date and Method of Adoption Impact on Financial Statements ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions The amendments in this update clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. In addition, the amendments clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments also require entities that hold equity securities subject to contractual sale restrictions to make disclosures about the fair value of such equity securities, the nature and remaining duration of the restriction(s) and the circumstances that could cause a lapse in the restriction(s). January 1, 2024, to be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption (with early adoption permitted). The Company is continuing to evaluate the impact of the guidance, and it does not expect the adoption of the guidance to have a material impact on its interim condensed consolidated financial statements. ASU 2022-02, Financial Instruments—Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures The amendments in the new ASU eliminate the accounting guidance for troubled debt restructurings (“TDRs”) by creditors that have adopted the current expected credit loss guidance while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. In addition, the amendments require that a public business entity disclose current-period gross write-offs by year of origination for financing receivables and net investment in leases. January 1, 2023, to be applied prospectively; however, for the transition method related to the recognition and measurement of TDRs, an entity can apply a modified retrospective transition method, resulting in a cumulative-effect adjustment to retained earnings in the period of adoption. Entities are permitted to early adopt these amendments, including adoption in any interim period, provided that the amendments are adopted as of the beginning of the annual reporting period that includes the interim period of adoption. In addition, entities are permitted to elect to early adopt the amendments related to TDRs accounting and related disclosure enhancements separately from the amendments related to certain vintage disclosures. The Company is continuing to evaluate the impact of the guidance and the alternative methods of adoption. Also, the Company is in the process of finalizing the updates to its loan administration systems, as well as updating its accounting policies and controls to comply with the new disclosure requirements. The Company does not expect the adoption of the guidance to have a material impact on its interim condensed consolidated financial statements. ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers The guidance indicates how to determine whether a contract liability is recognized by the acquirer in a business combination and provides specific guidance on how to recognize and measure acquired contract assets and contract liabilities from revenue contracts in a business combination. January 1, 2023, to be applied prospectively (with early adoption permitted). The Company is currently evaluating the impact of the guidance on its interim condensed consolidated financial statements. |
Segment Information
Segment Information | 9 Months Ended |
Sep. 30, 2022 | |
Segment Reporting [Abstract] | |
Segment Information | 2. Segment Information The Company is organized into two segments: U.S. and MetLife Holdings. In addition, the Company reports certain of its results of operations in Corporate & Other. U.S. The U.S. segment offers a broad range of protection products and services aimed at serving the financial needs of customers throughout their lives. These products are sold to corporations and their respective employees, other institutions and their respective members, as well as individuals. The U.S. segment is organized into two businesses: Group Benefits and Retirement and Income Solutions (“RIS”). • The Group Benefits business offers products such as term, variable and universal life insurance, dental, group and individual disability and accident & health insurance. • The RIS business offers a broad range of life and annuity-based insurance and investment products, including stable value and pension risk transfer products, institutional income annuities, structured settlements, benefit funding solutions and capital markets investment products. MetLife Holdings The MetLife Holdings segment consists of operations relating to products and businesses that the Company no longer actively markets. These include variable, universal, term and whole life insurance, variable, fixed and index-linked annuities and long-term care insurance. Corporate & Other Corporate & Other contains various start-up, developing and run-off businesses, including the Company’s ancillary non-U.S. operations. Also included in Corporate & Other are: the excess capital, as well as certain charges and activities, not allocated to the segments (including enterprise-wide strategic initiative restructuring charges), interest expense related to the majority of the Company’s outstanding debt, expenses associated with certain legal proceedings and income tax audit issues, and the elimination of intersegment amounts (which generally relate to affiliated reinsurance and intersegment loans, bearing interest rates commensurate with related borrowings). Financial Measures and Segment Accounting Policies Adjusted earnings is used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings is also the Company’s GAAP measure of segment performance and is reported below. Adjusted earnings should not be viewed as a substitute for net income (loss). The Company believes the presentation of adjusted earnings, as the Company measures it for management purposes, enhances the understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business. Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. The financial measures of adjusted revenues and adjusted expenses focus on the Company’s primary businesses principally by excluding the impact of market volatility, which could distort trends, and revenues and costs related to non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP and other businesses that have been or will be sold or exited by MLIC but do not meet the discontinued operations criteria under GAAP and are referred to as divested businesses. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MLIC that do not meet the criteria to be included in results of discontinued operations under GAAP. Adjusted revenues also excludes net investment gains (losses) and net derivative gains (losses). The following additional adjustments are made to revenues, in the line items indicated, in calculating adjusted revenues: • Universal life and investment-type product policy fees excludes the amortization of unearned revenue related to net investment gains (losses) and net derivative gains (losses) and certain variable annuity guaranteed minimum income benefits (“GMIBs”) fees (“GMIB fees”); and • Net investment income: (i) includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment, (ii) excludes post-tax adjusted earnings adjustments relating to insurance joint ventures accounted for under the equity method, (iii) excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP and (iv) includes distributions of profits from certain other limited partnership interests that were previously accounted for under the cost method, but are now accounted for at estimated fair value, where the change in estimated fair value is recognized in net investment gains (losses) under GAAP. The following additional adjustments are made to expenses, in the line items indicated, in calculating adjusted expenses: • Policyholder benefits and claims and policyholder dividends excludes: (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) changes in the policyholder dividend obligation related to net investment gains (losses) and net derivative gains (losses), (iii) amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments, (iv) benefits and hedging costs related to GMIBs (“GMIB costs”) and (v) market value adjustments associated with surrenders or terminations of contracts (“Market value adjustments”); • Interest credited to policyholder account balances includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of policyholder account balances but do not qualify for hedge accounting treatment; • Amortization of DAC and value of business acquired (“VOBA”) excludes amounts related to: (i) net investment gains (losses) and net derivative gains (losses), (ii) GMIB fees and GMIB costs and (iii) Market value adjustments; • Interest expense on debt excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and • Other expenses excludes: (i) noncontrolling interests, (ii) acquisition, integration and other costs, and (iii) goodwill impairments. The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms. Set forth in the tables below is certain financial information with respect to the Company’s segments, as well as Corporate & Other, for the three months and nine months ended September 30, 2022 and 2021. The segment accounting policies are the same as those used to prepare the Company’s interim condensed consolidated financial statements, except for adjusted earnings adjustments as defined above. In addition, segment accounting policies include the method of capital allocation described below. Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in MetLife’s and the Company’s businesses. MetLife’s economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. MetLife’s management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards. Segment net investment income is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company’s consolidated net investment income, net income (loss) or adjusted earnings. Net investment income is based upon the actual results of each segment’s specifically identifiable investment portfolios adjusted for allocated equity. Other costs are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company’s product pricing. Three Months Ended September 30, 2022 U.S. MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 13,158 $ 611 $ — $ 13,769 $ — $ 13,769 Universal life and investment-type product policy fees 277 188 — 465 19 484 Net investment income 1,482 990 (62) 2,410 (150) 2,260 Other revenues 356 36 109 501 — 501 Net investment gains (losses) — — — — (82) (82) Net derivative gains (losses) — — — — 454 454 Total revenues 15,273 1,825 47 17,145 241 17,386 Expenses Policyholder benefits and claims and policyholder dividends 13,107 1,397 — 14,504 (207) 14,297 Interest credited to policyholder account balances 445 160 19 624 — 624 Capitalization of DAC (21) 1 (38) (58) — (58) Amortization of DAC and VOBA 14 (24) 1 (9) (110) (119) Interest expense on debt 3 2 22 27 — 27 Other expenses 883 199 483 1,565 3 1,568 Total expenses 14,431 1,735 487 16,653 (314) 16,339 Provision for income tax expense (benefit) 175 15 (133) 57 117 174 Adjusted earnings $ 667 $ 75 $ (307) 435 Adjustments to: Total revenues 241 Total expenses 314 Provision for income tax (expense) benefit (117) Net income (loss) $ 873 $ 873 Three Months Ended September 30, 2021 U.S. MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 5,058 $ 657 $ — $ 5,715 $ — $ 5,715 Universal life and investment-type product policy fees 267 219 — 486 20 506 Net investment income 1,889 1,587 7 3,483 (152) 3,331 Other revenues 217 53 98 368 — 368 Net investment gains (losses) — — — — 190 190 Net derivative gains (losses) — — — — 84 84 Total revenues 7,431 2,516 105 10,052 142 10,194 Expenses Policyholder benefits and claims and policyholder dividends 5,317 1,349 — 6,666 116 6,782 Interest credited to policyholder account balances 346 166 — 512 — 512 Capitalization of DAC (15) 1 (2) (16) — (16) Amortization of DAC and VOBA 25 63 — 88 11 99 Interest expense on debt 2 2 20 24 — 24 Other expenses 768 207 742 1,717 1 1,718 Total expenses 6,443 1,788 760 8,991 128 9,119 Provision for income tax expense (benefit) 207 148 (204) 151 2 153 Adjusted earnings $ 781 $ 580 $ (451) 910 Adjustments to: Total revenues 142 Total expenses (128) Provision for income tax (expense) benefit (2) Net income (loss) $ 922 $ 922 Nine Months Ended September 30, 2022 U.S. MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 23,492 $ 1,855 $ — $ 25,347 $ — $ 25,347 Universal life and investment-type product policy fees 840 626 — 1,466 57 1,523 Net investment income 4,588 3,416 (76) 7,928 (400) 7,528 Other revenues 819 106 361 1,286 — 1,286 Net investment gains (losses) — — — — (391) (391) Net derivative gains (losses) — — — — 980 980 Total revenues 29,739 6,003 285 36,027 246 36,273 Expenses Policyholder benefits and claims and policyholder dividends 23,646 3,911 — 27,557 (450) 27,107 Interest credited to policyholder account balances 1,138 482 25 1,645 — 1,645 Capitalization of DAC (56) 1 (65) (120) — (120) Amortization of DAC and VOBA 40 95 2 137 (82) 55 Interest expense on debt 6 5 65 76 — 76 Other expenses 2,567 590 963 4,120 5 4,125 Total expenses 27,341 5,084 990 33,415 (527) 32,888 Provision for income tax expense (benefit) 499 181 (305) 375 164 539 Adjusted earnings $ 1,899 $ 738 $ (400) 2,237 Adjustments to: Total revenues 246 Total expenses 527 Provision for income tax (expense) benefit (164) Net income (loss) $ 2,846 $ 2,846 Nine Months Ended September 30, 2021 U.S. MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 15,955 $ 2,016 $ — $ 17,971 $ — $ 17,971 Universal life and investment-type product policy fees 828 668 — 1,496 59 1,555 Net investment income 5,540 4,478 (22) 9,996 (444) 9,552 Other revenues 663 177 385 1,225 — 1,225 Net investment gains (losses) — — — — 692 692 Net derivative gains (losses) — — — — (906) (906) Total revenues 22,986 7,339 363 30,688 (599) 30,089 Expenses Policyholder benefits and claims and policyholder dividends 16,685 3,932 — 20,617 278 20,895 Interest credited to policyholder account balances 1,037 500 — 1,537 (2) 1,535 Capitalization of DAC (44) 1 (2) (45) — (45) Amortization of DAC and VOBA 47 132 — 179 (8) 171 Interest expense on debt 5 4 63 72 — 72 Other expenses 2,377 638 1,010 4,025 (7) 4,018 Total expenses 20,107 5,207 1,071 26,385 261 26,646 Provision for income tax expense (benefit) 600 433 (353) 680 (170) 510 Adjusted earnings $ 2,279 $ 1,699 $ (355) 3,623 Adjustments to: Total revenues (599) Total expenses (261) Provision for income tax (expense) benefit 170 Net income (loss) $ 2,933 $ 2,933 The following table presents total assets with respect to the Company’s segments, as well as Corporate & Other, at: September 30, 2022 December 31, 2021 (In millions) U.S. $ 222,531 $ 256,381 MetLife Holdings 133,791 161,614 Corporate & Other 30,526 28,562 Total $ 386,848 $ 446,557 |
Insurance
Insurance | 9 Months Ended |
Sep. 30, 2022 | |
Insurance [Abstract] | |
Insurance | 3. Insurance Guarantees As discussed in Notes 1 and 3 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report, the Company issues directly and assumes through reinsurance variable annuity products with guaranteed minimum benefits. Guaranteed minimum accumulation benefits (“GMABs”), the non-life contingent portion of guaranteed minimum withdrawal benefits (“GMWBs”) and certain non-life contingent portions of GMIBs are accounted for as embedded derivatives in policyholder account balances and are further discussed in Note 6. The Company also issues other annuity contracts that apply a lower rate on funds deposited if the contractholder elects to surrender the contract for cash and a higher rate if the contractholder elects to annuitize. These guarantees include benefits that are payable in the event of death, maturity or at annuitization. Certain other annuity contracts contain guaranteed annuitization benefits that may be above what would be provided by the current account value of the contract. Additionally, the Company issues universal and variable life contracts where the Company contractually guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit. Information regarding the Company’s guarantee exposure, which includes direct business, but excludes offsets from hedging or reinsurance, if any, was as follows at: September 30, 2022 December 31, 2021 In the Event of Death At Annuitization In the Event of Death At Annuitization (Dollars in millions) Annuity Contracts: Variable Annuity Guarantees: Total account value (1), (2) $ 36,100 $ 14,185 $ 48,868 $ 20,140 Separate account value (1) $ 27,465 $ 13,427 $ 39,882 $ 19,347 Net amount at risk $ 5,139 (3) $ 638 (4) $ 1,160 (3) $ 461 (4) Average attained age of contractholders 69 years 69 years 69 years 66 years Other Annuity Guarantees: Total account value (1), (2) N/A $ 135 N/A $ 135 Net amount at risk N/A $ 66 (5) N/A $ 70 (5) Average attained age of contractholders N/A 56 years N/A 55 years September 30, 2022 December 31, 2021 Secondary Guarantees Paid-Up Guarantees Secondary Guarantees Paid-Up Guarantees (Dollars in millions) Universal and Variable Life Contracts: Total account value (1), (2) $ 4,622 $ 798 $ 5,935 $ 826 Net amount at risk (6) $ 37,546 $ 4,929 $ 37,482 $ 5,181 Average attained age of policyholders 59 years 66 years 59 years 65 years __________________ (1) The Company’s annuity and life contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed above may not be mutually exclusive. (2) Includes the contractholders’ investments in the general account and separate account, if applicable. (3) Defined as the death benefit less the total account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date and includes any additional contractual claims associated with riders purchased to assist with covering income taxes payable upon death. (4) Defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. This amount represents the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date, even though the contracts contain terms that allow annuitization of the guaranteed amount only after the 10th anniversary of the contract, which not all contractholders have achieved. (5) Defined as either the excess of the upper tier, adjusted for a profit margin, less the lower tier, as of the balance sheet date or the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. These amounts represent the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date. (6) Defined as the guarantee amount less the account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date. Liabilities for Unpaid Claims and Claim Expenses Rollforward of Claims and Claim Adjustment Expenses Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows: Nine Months 2022 2021 (In millions) Balance, beginning of period $ 15,059 $ 13,523 Less: Reinsurance recoverables 2,263 1,639 Net balance, beginning of period 12,796 11,884 Incurred related to: Current period 15,527 15,300 Prior periods (1) 378 511 Total incurred 15,905 15,811 Paid related to: Current period (10,018) (10,249) Prior periods (5,226) (4,785) Total paid (15,244) (15,034) Net balance, end of period 13,457 12,661 Add: Reinsurance recoverables 2,044 2,099 Balance, end of period (included in future policy benefits and other policy-related balances) $ 15,501 $ 14,760 __________________ (1) The nine months ended September 30, 2022 and 2021 include incurred claim activity and claim adjustment expenses associated with prior periods but reported in the respective current period, which contain impacts related to the COVID-19 pandemic, partially offset by additional premiums recorded for experience-rated contracts that are not reflected in the table above. |
Closed Block
Closed Block | 9 Months Ended |
Sep. 30, 2022 | |
Closed Block Disclosure [Abstract] | |
Closed Block | 4. Closed BlockOn April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving Metropolitan Life Insurance Company’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, Metropolitan Life Insurance Company established a closed block for the benefit of holders of certain individual life insurance policies of Metropolitan Life Insurance Company. Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon cumulative actual and expected earnings within the closed block. Accordingly, the Company’s net income continues to be sensitive to the actual performance of the closed block. Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item. Information regarding the closed block liabilities and assets designated to the closed block was as follows at: September 30, 2022 December 31, 2021 (In millions) Closed Block Liabilities Future policy benefits $ 37,385 $ 38,046 Other policy-related balances 257 290 Policyholder dividends payable 219 253 Policyholder dividend obligation — 1,682 Deferred income tax liability — 210 Other liabilities 444 263 Total closed block liabilities 38,305 40,744 Assets Designated to the Closed Block Investments: Fixed maturity securities available-for-sale, at estimated fair value 19,515 25,669 Mortgage loans 6,624 6,417 Policy loans 4,096 4,191 Real estate and real estate joint ventures 604 565 Other invested assets 924 556 Total investments 31,763 37,398 Cash and cash equivalents 344 126 Accrued investment income 386 384 Premiums, reinsurance and other receivables 38 50 Current income tax recoverable 82 81 Deferred income tax asset 460 — Total assets designated to the closed block 33,073 38,039 Excess of closed block liabilities over assets designated to the closed block 5,232 2,705 AOCI: Unrealized investment gains (losses), net of income tax (1,609) 2,562 Unrealized gains (losses) on derivatives, net of income tax 408 107 Allocated to policyholder dividend obligation, net of income tax — (1,329) Total amounts included in AOCI (1,201) 1,340 Maximum future earnings to be recognized from closed block assets and liabilities $ 4,031 $ 4,045 Information regarding the closed block policyholder dividend obligation was as follows: Nine Months Year (In millions) Balance, beginning of period $ 1,682 $ 2,969 Change in unrealized investment and derivative gains (losses) (1,682) (1,287) Balance, end of period $ — $ 1,682 Information regarding the closed block revenues and expenses was as follows: Three Months Nine Months 2022 2021 2022 2021 (In millions) Revenues Premiums $ 267 $ 310 $ 816 $ 955 Net investment income 326 390 1,039 1,165 Net investment gains (losses) (4) (7) (52) (12) Net derivative gains (losses) 28 12 39 19 Total revenues 617 705 1,842 2,127 Expenses Policyholder benefits and claims 459 522 1,404 1,588 Policyholder dividends 91 127 352 478 Other expenses 22 24 68 73 Total expenses 572 673 1,824 2,139 Revenues, net of expenses before provision for income tax expense (benefit) 45 32 18 (12) Provision for income tax expense (benefit) 10 6 4 (3) Revenues, net of expenses and provision for income tax expense (benefit) $ 35 $ 26 $ 14 $ (9) Metropolitan Life Insurance Company charges the closed block with federal income taxes, state and local premium taxes and other state or local taxes, as well as investment management expenses relating to the closed block as provided in the Plan of Reorganization. Metropolitan Life Insurance Company also charges the closed block for expenses of maintaining the policies included in the closed block. |
Investments
Investments | 9 Months Ended |
Sep. 30, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Investments | 5. Investments Fixed Maturity Securities Available-for-Sale Fixed Maturity Securities Available-for-Sale by Sector The following table presents fixed maturity securities available-for-sale (“AFS”) by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. Residential mortgage-backed securities (“RMBS”) includes agency, prime, alternative and sub-prime mortgage-backed securities. Asset-backed securities and collateralized loan obligations (“ABS & CLO”), previously disclosed as ABS in the 2021 Annual Report, includes securities collateralized by consumer loans, corporate loans and broadly syndicated bank loans. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.” September 30, 2022 December 31, 2021 Amortized Gross Unrealized Estimated Amortized Gross Unrealized Estimated Sector Allowance for Gains Losses Allowance for Gains Losses (In millions) U.S. corporate $ 55,430 $ (30) $ 432 $ 5,729 $ 50,103 $ 51,328 $ (30) $ 7,257 $ 153 $ 58,402 U.S. government and agency 23,718 — 531 2,209 22,040 26,782 — 4,568 128 31,222 Foreign corporate 28,681 (3) 113 5,929 22,862 27,475 (10) 2,651 431 29,685 RMBS 22,297 — 207 2,414 20,090 22,082 — 1,198 135 23,145 ABS & CLO 12,450 — 11 889 11,572 12,787 — 127 35 12,879 Municipals 7,741 — 217 720 7,238 6,884 — 1,849 5 8,728 CMBS 6,532 (15) 3 582 5,938 6,686 (13) 237 32 6,878 Foreign government 3,965 (69) 136 461 3,571 4,330 — 698 82 4,946 Total fixed maturity securities AFS $ 160,814 $ (117) $ 1,650 $ 18,933 $ 143,414 $ 158,354 $ (53) $ 18,585 $ 1,001 $ 175,885 The Company held non-income producing fixed maturity securities AFS with an estimated fair value of $107 million and $19 million at September 30, 2022 and December 31, 2021, respectively, with unrealized gains (losses) of ($13) million and $10 million at September 30, 2022 and December 31, 2021, respectively. Maturities of Fixed Maturity Securities AFS The amortized cost, net of allowance for credit loss (“ACL”), and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at September 30, 2022: Due in One Due After Due After Due After Structured Total Fixed (In millions) Amortized cost, net of ACL $ 3,091 $ 26,418 $ 28,564 $ 61,360 $ 41,264 $ 160,697 Estimated fair value $ 2,878 $ 24,706 $ 25,593 $ 52,637 $ 37,600 $ 143,414 Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity. Continuous Gross Unrealized Losses for Fixed Maturity Securities AFS by Sector The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position. September 30, 2022 December 31, 2021 Less than 12 Months Equal to or Greater Less than 12 Months Equal to or Greater Sector & Credit Quality Estimated Gross Estimated Gross Estimated Gross Estimated Gross (Dollars in millions) U.S. corporate $ 37,447 $ 5,166 $ 2,031 $ 563 $ 4,503 $ 83 $ 784 $ 70 U.S. government and agency 13,035 1,846 1,560 363 10,063 78 523 49 Foreign corporate 18,150 4,744 2,774 1,185 4,079 199 1,348 232 RMBS 14,946 1,800 2,393 614 7,481 111 314 24 ABS & CLO 9,520 741 1,367 148 5,643 25 593 10 Municipals 3,980 701 49 19 154 4 17 1 CMBS 4,955 460 793 121 1,613 20 355 12 Foreign government 2,005 346 232 114 497 37 148 45 Total fixed maturity securities AFS $ 104,038 $ 15,804 $ 11,199 $ 3,127 $ 34,033 $ 557 $ 4,082 $ 443 Investment grade $ 97,820 $ 14,938 $ 9,742 $ 2,686 $ 31,419 $ 454 $ 3,273 $ 353 Below investment grade 6,218 866 1,457 441 2,614 103 809 90 Total fixed maturity securities AFS $ 104,038 $ 15,804 $ 11,199 $ 3,127 $ 34,033 $ 557 $ 4,082 $ 443 Total number of securities in an 12,614 1,284 2,549 427 Evaluation of Fixed Maturity Securities AFS for Credit Loss Evaluation and Measurement Methodologies Management considers a wide range of factors about the security issuer and uses its best judgment in evaluating the cause of the decline in the estimated fair value of the security and in assessing the prospects for near-term recovery. Inherent in management’s evaluation of the security are assumptions and estimates about the operations of the issuer and its future earnings potential. Considerations used in the credit loss evaluation process include, but are not limited to: (i) the extent to which the estimated fair value has been below amortized cost, (ii) adverse conditions specifically related to a security, an industry sector or sub-sector, or an economically depressed geographic area, adverse change in the financial condition of the issuer of the security, changes in technology, discontinuance of a segment of the business that may affect future earnings, and changes in the quality of credit enhancement, (iii) payment structure of the security and likelihood of the issuer being able to make payments, (iv) failure of the issuer to make scheduled interest and principal payments, (v) whether the issuer, or series of issuers or an industry has suffered a catastrophic loss or has exhausted natural resources, (vi) whether the Company has the intent to sell or will more likely than not be required to sell a particular security before the decline in estimated fair value below amortized cost recovers, (vii) with respect to Structured Products, changes in forecasted cash flows after considering the changes in the financial condition of the underlying loan obligors and quality of underlying collateral, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying assets backing a particular security, and the payment priority within the tranche structure of the security, (viii) changes in the rating of the security by a rating agency, and (ix) other subjective factors, including concentrations and information obtained from regulators. The methodology and significant inputs used to determine the amount of credit loss are as follows: • The Company calculates the recovery value by performing a discounted cash flow analysis based on the present value of future cash flows. The discount rate is generally the effective interest rate of the security at the time of purchase for fixed-rate securities and the spot rate at the date of evaluation of credit loss for floating-rate securities. • When determining collectability and the period over which value is expected to recover, the Company applies considerations utilized in its overall credit loss evaluation process which incorporates information regarding the specific security, fundamentals of the industry and geographic area in which the security issuer operates, and overall macroeconomic conditions. Projected future cash flows are estimated using assumptions derived from management’s single best estimate, the most likely outcome in a range of possible outcomes, after giving consideration to a variety of variables that include, but are not limited to: payment terms of the security; the likelihood that the issuer can service the interest and principal payments; the quality and amount of any credit enhancements; the security’s position within the capital structure of the issuer; possible corporate restructurings or asset sales by the issuer; any private and public sector programs to restructure foreign government securities and municipals; and changes to the rating of the security or the issuer by rating agencies. • Additional considerations are made when assessing the unique features that apply to certain Structured Products including, but not limited to: the quality of underlying collateral, historical performance of the underlying loan obligors, historical rent and vacancy levels, changes in the financial condition of the underlying loan obligors, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying loans or assets backing a particular security, changes in the quality of credit enhancement and the payment priority within the tranche structure of the security. With respect to securities that have attributes of debt and equity (“perpetual hybrid securities”), consideration is given in the credit loss analysis as to whether there has been any deterioration in the credit of the issuer and the likelihood of recovery in value of the securities that are in a severe unrealized loss position. Consideration is also given as to whether any perpetual hybrid securities with an unrealized loss, regardless of credit rating, have deferred any dividend payments. In periods subsequent to the recognition of an initial ACL on a security, the Company reassesses credit loss quarterly. Subsequent increases or decreases in the expected cash flow from the security result in corresponding decreases or increases in the ACL which are recognized in earnings and reported within net investment gains (losses); however, the previously recorded ACL is not reduced to an amount below zero. Full or partial write-offs are deducted from the ACL in the period the security, or a portion thereof, is considered uncollectible. Recoveries of amounts previously written off are recorded to the ACL in the period received. When the Company has the intent-to-sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost, any ACL is written off and the amortized cost is written down to estimated fair value through a charge within net investment gains (losses), which becomes the new amortized cost of the security. Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position Gross unrealized losses on securities without an ACL increased $17.9 billion for the nine months ended September 30, 2022 to $18.9 billion primarily due to increases in interest rates, widening credit spreads, and the impact of weaken ing foreign currencies on certain non-functional currency denominated fixed maturity securities. Gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater wer e $3.1 billion at September 30, 2022, or 17% of the total gross unrealized losses on securities without an ACL. Investment Grade Fixed Maturity Securities AFS Of the $3.1 billion of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater, $2.7 billion, or 86%, were related to 1,052 investment grade securities. Unrealized losses on investment grade securities are principally related to widening credit spreads since purchase and, with respect to fixed-rate securities, rising interest rates since purchase. Below Investment Grade Fixed Maturity Securities AFS Of the $3.1 billion of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater, $441 million, or 14%, were related to 232 below investment grade securities. Unrealized losses on below investment grade securities are principally related to foreign corporate and U.S. corporate securities (primarily industrial and consumer) and are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainty, as well as with respect to fixed-rate securities, rising interest rates since purchase. Management evaluates U.S. corporate and foreign corporate securities based on several factors such as expected cash flows, financial condition and near-term and long-term prospects of the issuers. Current Period Evaluation At September 30, 2022, with respect to securities in an unrealized loss position without an ACL, the Company did not intend to sell these securities, and it was not more likely than not that the Company would be required to sell these securities before the anticipated recovery of the remaining amortized cost. Based on the Company’s current evaluation of its securities in an unrealized loss position without an ACL, the Company concluded th at these securities had not incurred a credit loss and should not have an ACL at September 30, 2022. Future provisions for credit loss will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings and collateral valuation. Rollforward of Allowance for Credit Loss for Fixed Maturity Securities AFS by Sector The rollforward of ACL for fixed maturity securities AFS by sector is as follows: U.S. Foreign Corporate CMBS Foreign Total Three Months Ended September 30, 2022 (In millions) Balance, at beginning of period $ 27 $ 7 $ 13 $ 77 $ 124 Additions: ACL not previously recorded — 1 2 — 3 Reductions: Changes for securities with previously recorded ACL 3 — — (8) (5) Securities sold or exchanged — (5) — — (5) Write-offs — — — — — Balance, at end of period $ 30 $ 3 $ 15 $ 69 $ 117 Three Months Ended September 30, 2021 Balance, at beginning of period $ 39 $ 14 $ 6 $ — $ 59 Additions: ACL not previously recorded 18 — — — 18 Reductions: Changes for securities with previously recorded ACL — (2) 1 — (1) Securities sold or exchanged (26) (2) — — (28) Write-offs (13) — — — (13) Balance, at end of period $ 18 $ 10 $ 7 $ — $ 35 U.S. Foreign Corporate CMBS Foreign Total Nine Months Ended September 30, 2022 (In millions) Balance, at beginning of period $ 30 $ 10 $ 13 $ — $ 53 Additions: ACL not previously recorded 13 12 2 104 131 Changes for securities with previously recorded ACL 17 3 — (15) 5 Reductions: Securities sold or exchanged (8) (22) — (20) (50) Write-offs (22) — — — (22) Balance, at end of period $ 30 $ 3 $ 15 $ 69 $ 117 Nine Months Ended September 30, 2021 Balance, at beginning of period $ 43 $ 8 $ — $ — $ 51 Additions: ACL not previously recorded 18 12 9 — 39 Reductions: Changes for securities with previously recorded ACL 3 (5) (2) — (4) Securities sold or exchanged (33) (5) — — (38) Write-offs (13) — — — (13) Balance, at end of period $ 18 $ 10 $ 7 $ — $ 35 Mortgage Loans Mortgage Loans by Portfolio Segment Mortgage loans are summarized as follows at: September 30, 2022 December 31, 2021 Portfolio Segment Carrying % of Carrying % of (Dollars in millions) Commercial $ 37,038 60.1 % $ 35,772 59.4 % Agricultural 15,668 25.4 15,450 25.7 Residential 9,289 15.1 9,406 15.6 Total amortized cost 61,995 100.6 60,628 100.7 Allowance for credit loss (392) (0.6) (536) (0.9) Subtotal mortgage loans, net 61,603 100.0 60,092 99.8 Residential — FVO — — 127 0.2 Total mortgage loans held-for-investment, net 61,603 100.0 60,219 100.0 Total mortgage loans, net $ 61,603 100.0 % $ 60,219 100.0 % The Company elects the FVO for certain residential mortgage loans that are managed on a total return basis, with changes in estimated fair value included in net investment income. See Note 7 for further information. The amount of net (discounts) premiums and deferred (fees) expenses, included within total amortized cost, primarily attributable to residential mortgage loans was ($656) million and ($736) million at September 30, 2022 and December 31, 2021, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at September 30, 2022 was $161 million, $127 million and $68 million, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at December 31, 2021 was $140 million, $136 million and $77 million, respectively. Purchases of mortgage loans, consisting primarily of residential mortgage loans, were $182 million and $1.3 billion for the three months and nine months ended September 30, 2022, respectively, and $262 million and $1.1 billion for the three months and nine months ended September 30, 2021, respectively. See “— Related Party Investment Transactions” for information regarding transfers of mortgage loans from affiliates. Rollforward of Allowance for Credit Loss for Mortgage Loans by Portfolio Segment The rollforward of ACL for mortgage loans, by portfolio segment, is as follows: Nine Months Ended September 30, 2022 2021 Commercial Agricultural Residential Total Commercial Agricultural Residential Total (In millions) Balance, beginning of period $ 260 $ 79 $ 197 $ 536 $ 199 $ 97 $ 221 $ 517 Provision (release) (8) 48 (77) (37) 18 1 (34) (15) Initial credit losses on PCD loans (1) — — — — — — 3 3 Charge-offs, net of recoveries (83) (22) (2) (107) — (13) (2) (15) Balance, end of period $ 169 $ 105 $ 118 $ 392 $ 217 $ 85 $ 188 $ 490 ________________ (1) Represents the initial credit losses on purchased mortgage loans accounted for as purchased financial assets with credit deterioration (“PCD”). Allowance for Credit Loss Methodology The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable) and reasonably expected TDRs (i.e., the Company grants concessions to borrower that is experiencing financial difficulties) are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses). Commercial and Agricultural Mortgage Loan Portfolio Segments Commercial and agricultural mortgage loan ACL are calculated in a similar manner. Within each loan portfolio segment, commercial and agricultural, loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. The Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans. Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans. For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio. For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated. Commitments to lend: After loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that are not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly. Residential Mortgage Loan Portfolio Segment The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and pooled by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company immediately reverts to industry historical loss experience. For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss. Troubled Debt Restructuring The Company may grant concessions to borrowers experiencing financial difficulties and if significant, these concessions are classified as TDRs. Generally, the types of concessions include: reduction of contractual interest rates, extension of the maturity date at an interest rate lower than current market interest rates, and/or a reduction of accrued interest. The amount, timing and extent of the concessions granted are considered in determining any ACL recorded. For the three months and nine months ended September 30, 2022, the Company had one and two commercial mortgage loans modified in a TDR, respectively, with both pre-modification and post-modification carrying value, after ACL, of $31 million and $123 million, respectively. Credit Quality of Mortgage Loans by Portfolio Segment The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2022: Credit Quality Indicator 2022 2021 2020 2019 2018 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 2,872 $ 3,309 $ 2,285 $ 3,347 $ 3,551 $ 10,813 $ 2,756 $ 28,933 78.1 % 65% to 75% 1,412 903 612 996 769 1,418 — 6,110 16.5 76% to 80% — — 18 252 223 204 — 697 1.9 Greater than 80% 142 39 — 43 90 984 — 1,298 3.5 Total $ 4,426 $ 4,251 $ 2,915 $ 4,638 $ 4,633 $ 13,419 $ 2,756 $ 37,038 100.0 % DSCR: > 1.20x $ 4,108 $ 3,819 $ 2,709 $ 4,502 $ 4,156 $ 11,526 $ 2,756 $ 33,576 90.6 % 1.00x - 1.20x 285 235 18 9 152 803 — 1,502 4.1 <1.00x 33 197 188 127 325 1,090 — 1,960 5.3 Total $ 4,426 $ 4,251 $ 2,915 $ 4,638 $ 4,633 $ 13,419 $ 2,756 $ 37,038 100.0 % The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2022: Credit Quality Indicator 2022 2021 2020 2019 2018 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 1,603 $ 1,474 $ 1,928 $ 1,516 $ 2,103 $ 4,331 $ 1,133 $ 14,088 89.9 % 65% to 75% 144 228 296 180 51 491 40 1,430 9.1 76% to 80% — — — — — 12 — 12 0.1 Greater than 80% — — 14 76 — 44 4 138 0.9 Total $ 1,747 $ 1,702 $ 2,238 $ 1,772 $ 2,154 $ 4,878 $ 1,177 $ 15,668 100.0 % The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2022: Credit Quality Indicator 2022 2021 2020 2019 2018 Prior Revolving Total % of (Dollars in millions) Performance indicators: Performing $ 740 $ 703 $ 158 $ 619 $ 341 $ 6,282 $ — $ 8,843 95.2 % Nonperforming (1) 2 3 4 37 12 388 — 446 4.8 Total $ 742 $ 706 $ 162 $ 656 $ 353 $ 6,670 $ — $ 9,289 100.0 % __________________ (1) Includes residential mortgage loans in process of foreclosure of $142 million and $69 million at September 30, 2022 and December 31, 2021, respectively. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. The amortized cost of commercial and agricultural mortgage loans with an LTV ratio in excess of 100% was $565 million, or 1% of total commercial and agricultural mortgage loans, at September 30, 2022. Past Due and Nonaccrual Mortgage Loans The Company has a high quality, well performing mortgage loan portfolio, with 99% of all mortgage loans classified as performing at both September 30, 2022 and December 31, 2021. The Company defines delinquency consistent with industry practice, when mortgage loans are past due more than two or more months, as applicable, by portfolio segment. The past due and nonaccrual mortgage loans at amortized cost, prior to ACL, by portfolio segment, were as follows: Past Due Greater than 90 Days Past Due Nonaccrual Portfolio Segment September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 (In millions) Commercial $ — $ — $ — $ — $ 142 $ 146 Agricultural 115 124 27 16 207 225 Residential 446 418 2 — 449 418 Total $ 561 $ 542 $ 29 $ 16 $ 798 $ 789 The amortized cost for nonaccrual commercial, agricultural and residential mortgage loans at beginning of year 2021 was $293 million, $261 million and $503 million, respectively. The amortized cost for nonaccrual agricultural mortgage loans with no ACL was $88 million and $134 million at September 30, 2022 and December 31, 2021, respectively. There were no nonaccrual commercial or residential mortgage loans without an ACL at either September 30, 2022 or December 31, 2021. Real Estate and Real Estate Joint Ventures The Company’s real estate investment portfolio is diversified by property type, geography and income stream, including income from operating leases, operating income and equity in earnings from equity method real estate joint ventures. Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated: September 30, 2022 December 31, 2021 Three Months Nine Months 2022 2021 2022 2021 Income Type Carrying Value Income (In millions) Wholly-owned real estate: Leased real estate $ 1,763 $ 1,934 $ 47 $ 53 $ 151 $ 160 Other real estate 478 473 88 53 184 133 Real estate joint ventures 5,977 5,466 49 70 281 107 Total real estate and real estate joint ventures $ 8,218 $ 7,873 $ 184 $ 176 $ 616 $ 400 The |
Derivatives
Derivatives | 9 Months Ended |
Sep. 30, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivatives | 6. Derivatives Accounting for Derivatives See Note 1 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for a description of the Company’s accounting policies for derivatives and Note 7 for information about the fair value hierarchy for derivatives. Derivative Strategies Types of Derivative Instruments and Derivative Strategies The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives. Commonly used derivative instruments include, but are not limited to: • Interest rate derivatives: swaps, total return swaps, caps, floors, futures, swaptions, forwards and synthetic guaranteed interest contracts (“GICs”); • Foreign currency exchange rate derivatives: swaps and forwards; • Credit derivatives: purchased or written single name or index credit default swaps, and forwards; and • Equity derivatives: index options, variance swaps, exchange-traded futures and total return swaps. For detailed information on these contracts and the related strategies, see Note 8 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report. Primary Risks Managed by Derivatives The following table presents the primary underlying risk exposure, gross notional amount, and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at: September 30, 2022 December 31, 2021 Primary Underlying Risk Exposure Gross Notional Amount Estimated Fair Value Gross Notional Amount Estimated Fair Value Assets Liabilities Assets Liabilities (In millions) Derivatives Designated as Hedging Instruments: Fair value hedges: Interest rate swaps Interest rate $ 4,115 $ 1,435 $ 425 $ 3,540 $ 2,163 $ 6 Foreign currency swaps Foreign currency exchange rate 593 123 — 764 8 22 Subtotal 4,708 1,558 425 4,304 2,171 28 Cash flow hedges: Interest rate swaps Interest rate 3,740 6 19 4,079 4 1 Interest rate forwards Interest rate 2,783 — 448 3,058 69 1 Foreign currency swaps Foreign currency exchange rate 27,786 3,319 2,126 28,772 1,317 966 Subtotal 34,309 3,325 2,593 35,909 1,390 968 Total qualifying hedges 39,017 4,883 3,018 40,213 3,561 996 Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate swaps Interest rate 17,596 1,670 685 21,565 3,206 59 Interest rate floors Interest rate 16,170 58 — 7,701 145 — Interest rate caps Interest rate 63,659 1,012 — 64,309 117 — Interest rate futures Interest rate 418 — 2 515 — — Interest rate options Interest rate 20,367 601 — 9,703 364 — Interest rate forwards Interest rate 265 — 102 265 — 20 Interest rate total return swaps Interest rate 1,048 — 99 1,048 9 4 Synthetic GICs Interest rate 11,808 — — 11,307 — — Foreign currency swaps Foreign currency exchange rate 6,336 1,318 — 4,800 340 75 Foreign currency forwards Foreign currency exchange rate 1,222 27 8 1,902 11 13 Credit default swaps — purchased Credit 902 29 — 956 12 8 Credit default swaps — written Credit 10,569 73 77 6,074 111 12 Equity futures Equity market 1,155 14 1 1,751 5 — Equity index options Equity market 20,799 901 144 26,800 714 166 Equity variance swaps Equity market 425 12 10 425 12 10 Equity total return swaps Equity market 2,108 178 — 2,148 11 46 Total non-designated or nonqualifying derivatives 174,847 5,893 1,128 161,269 5,057 413 Total $ 213,864 $ 10,776 $ 4,146 $ 201,482 $ 8,618 $ 1,409 Based on gross notional amounts, a substantial portion of the Company’s derivatives was not designated or did not qualify as part of a hedging relationship at both September 30, 2022 and December 31, 2021. The Company’s use of derivatives includes (i) derivatives that serve as macro hedges of the Company’s exposure to various risks and that generally do not qualify for hedge accounting due to the criteria required under the portfolio hedging rules, (ii) derivatives that economically hedge insurance liabilities that contain mortality or morbidity risk and that generally do not qualify for hedge accounting because the lack of these risks in the derivatives cannot support an expectation of a highly effective hedging relationship, (iii) derivatives that economically hedge embedded derivatives that do not qualify for hedge accounting because the changes in estimated fair value of the embedded derivatives are already recorded in net income, and (iv) written credit default swaps and interest rate swaps that are used to synthetically create investments and that do not qualify for hedge accounting because they do not involve a hedging relationship. For these nonqualified derivatives, changes in market factors can lead to the recognition of fair value changes on the statement of operations without an offsetting gain or loss recognized in earnings for the item being hedged. The Effects of Derivatives on the Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) The following table presents the interim condensed consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, nonqualifying hedging relationships and embedded derivatives: Three Months Ended September 30, 2022 Net Net Net Policyholder Interest Credited to Policyholder Account Balances OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 2 $ — $ — $ (292) $ (16) N/A Hedged items — — — 264 15 N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 64 — — — — N/A Hedged items (65) — — — — N/A Subtotal 1 — — (28) (1) N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (324) Amount of gains (losses) reclassified from AOCI into income 15 (16) — — — 1 Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 608 Amount of gains (losses) reclassified from AOCI into income 1 (485) — — — 484 Foreign currency transaction gains (losses) on hedged items — 485 — — — — Subtotal 16 (16) — — — 769 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — — (395) — — N/A Foreign currency exchange rate derivatives (1) — — 476 — — N/A Credit derivatives — purchased (1) — — 4 — — N/A Credit derivatives — written (1) — — 1 — — N/A Equity derivatives (1) 8 — 163 62 — N/A Foreign currency transaction gains (losses) on hedged items — — (189) — — N/A Subtotal 8 — 60 62 — N/A Earned income on derivatives 100 — 144 33 (41) — Embedded derivatives (2) N/A N/A 250 — N/A N/A Total $ 125 $ (16) $ 454 $ 67 $ (42) $ 769 Three Months Ended September 30, 2021 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to Policyholder Account Balances OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 1 $ — $ — $ (53) $ — N/A Hedged items (2) — — 48 — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 28 — — — — N/A Hedged items (22) — — — — N/A Subtotal 5 — — (5) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ 27 Amount of gains (losses) reclassified from AOCI into income 14 8 — — — (22) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 201 Amount of gains (losses) reclassified from AOCI into income 2 (257) — — — 255 Foreign currency transaction gains (losses) on hedged items — 254 — — — — Subtotal 16 5 — — — 461 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) (1) — (276) — — N/A Foreign currency exchange rate derivatives (1) — — 181 — — N/A Credit derivatives — purchased (1) — — 2 — — N/A Credit derivatives — written (1) — — (1) — — N/A Equity derivatives (1) — — 34 8 — N/A Foreign currency transaction gains (losses) on hedged items — — (50) — — N/A Subtotal (1) — (110) 8 — N/A Earned income on derivatives 63 — 165 53 (43) — Embedded derivatives (2) N/A N/A 29 — N/A N/A Total $ 83 $ 5 $ 84 $ 56 $ (43) $ 461 Nine Months Ended September 30, 2022 Net Net Net Policyholder Interest Credited to Policyholder Account Balances OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 8 $ — $ — $ (1,137) $ (26) N/A Hedged items (8) — — 1,072 24 N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 154 — — — — N/A Hedged items (152) — — — — N/A Subtotal 2 — — (65) (2) N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (1,434) Amount of gains (losses) reclassified from AOCI into income 46 55 — — — (101) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 1,232 Amount of gains (losses) reclassified from AOCI into income 3 (1,117) — — — 1,114 Foreign currency transaction gains (losses) on hedged items — 1,104 — — — — Subtotal 49 42 — — — 811 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) 3 — (1,998) — — N/A Foreign currency exchange rate derivatives (1) 2 — 985 — — N/A Credit derivatives — purchased (1) — — 62 — — N/A Credit derivatives — written (1) — — (189) — — N/A Equity derivatives (1) 37 — 724 320 — N/A Foreign currency transaction gains (losses) on hedged items — — (431) — — N/A Subtotal 42 — (847) 320 — N/A Earned income on derivatives 325 — 403 130 (113) — Embedded derivatives (2) N/A N/A 1,424 — N/A N/A Total $ 418 $ 42 $ 980 $ 385 $ (115) $ 811 Nine Months Ended September 30, 2021 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to Policyholder Account Balances OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 4 $ — $ — $ (418) $ — N/A Hedged items (4) — — 379 — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 39 — — — — N/A Hedged items (32) — — — — N/A Subtotal 7 — — (39) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (676) Amount of gains (losses) reclassified from AOCI into income 41 56 — — — (97) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 503 Amount of gains (losses) reclassified from AOCI into income 4 (265) — — — 261 Foreign currency transaction gains (losses) on hedged items — 258 — — — — Subtotal 45 49 — — — (9) Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) 1 — (1,463) — — N/A Foreign currency exchange rate derivatives (1) — — 224 — — N/A Credit derivatives — purchased (1) — — 6 — — N/A Credit derivatives — written (1) — — 20 — — N/A Equity derivatives (1) (2) — (793) (174) — N/A Foreign currency transaction gains (losses) on hedged items — — (62) — — N/A Subtotal (1) — (2,068) (174) — N/A Earned income on derivatives 141 — 499 155 (120) — Embedded derivatives (2) N/A N/A 663 — N/A N/A Total $ 192 $ 49 $ (906) $ (58) $ (120) $ (9) __________________ (1) Excludes earned income on derivatives. (2) The valuation of guaranteed minimum benefits includes a nonperformance risk adjustment. The amounts included in net derivative gains (losses) in connection with this adjustment w ere $42 million and $41 million for the three months and nine months ended September 30, 2022, respectively, and $5 million and ($10) million for the three months and nine months ended September 30, 2021, respectively. Fair Value Hedges The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities and (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities. The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges: Balance Sheet Line Item Carrying Amount of the Cumulative Amount September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 (In millions) Fixed maturity securities AFS $ 300 $ 366 $ 1 $ (1) Mortgage loans $ 276 $ 617 $ (20) $ 3 Future policy benefits $ (3,626) $ (4,735) $ 215 $ (877) Policyholder account balances $ (1,074) $ — $ 24 $ — __________________ (1) Includes ($142) million and ($161) million of hedging adjustments on discontinued hedging relationships at September 30, 2022 and December 31, 2021, respectively. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness. Cash Flow Hedges The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments. In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into income. These amounts were $18 million and $22 million for the three months and nine months ended September 30, 2022, respectively, and $0 and $6 million for the three months and nine months ended September 30, 2021, respectively. At both September 30, 2022 and December 31, 2021, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed seven years. At September 30, 2022 and December 31, 2021, the balance in AOCI associated with cash flow hedges was $3.2 billion and $2.4 billion, respectively. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness. At September 30, 2022, the Company expected to reclassify $301 million of deferred net gains (losses) on derivatives in AOCI to earnings within the next 12 months. Credit Derivatives In connection with synthetically created credit investment transactions, the Company writes credit default swaps for which it receives a premium to insure credit risk. Such credit derivatives are included within the effects of derivatives on the interim condensed consolidated statements of operations and comprehensive income (loss) table. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the Company paying the counterparty the specified swap notional amount in exchange for the delivery of par quantities of the referenced credit obligation. The Company can terminate these contracts at any time through cash settlement with the counterparty at an amount equal to the then current estimated fair value of the credit default swaps. The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at: September 30, 2022 December 31, 2021 Rating Agency Designation of Referenced Estimated Maximum Weighted Estimated Maximum Weighted (Dollars in millions) Aaa/Aa/A Single name credit default swaps (3) $ — $ 10 1.7 $ — $ 10 2.5 Credit default swaps referencing indices 51 4,404 3.5 17 1,191 2.5 Subtotal 51 4,414 3.5 17 1,201 2.5 Baa Single name credit default swaps (3) — 40 2.7 1 60 3.3 Credit default swaps referencing indices (45) 5,977 5.4 90 4,698 5.1 Subtotal (45) 6,017 5.4 91 4,758 5.1 Ba Single name credit default swaps (3) 2 45 0.9 1 65 0.5 Credit default swaps referencing indices 1 25 4.2 (1) 20 5.0 Subtotal 3 70 2.1 — 85 1.5 B Credit default swaps referencing indices (1) 38 4.7 — — — Subtotal (1) 38 4.7 — — — Caa3 Credit default swaps referencing indices (12) 30 3.7 (9) 30 4.5 Subtotal (12) 30 3.7 (9) 30 4.5 Total $ (4) $ 10,569 4.6 $ 99 $ 6,074 4.6 __________________ (1) The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P Global Ratings (“S&P”) and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used. (2) The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts. (3) Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals. Credit Risk on Freestanding Derivatives The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements. Derivatives may be exchange-traded or contracted in the over-the-counter (“OTC”) market. Certain of the Company’s OTC derivatives are cleared and settled through central clearinghouses (“OTC-cleared”), while others are bilateral contracts between two counterparties (“OTC-bilateral”). The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s OTC-bilateral derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of Dodd-Frank) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, effective September 1, 2021, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third party custodians. The Company’s OTC-cleared derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives. See Note 7 for a description of the impact of credit risk on the valuation of derivatives. The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at: September 30, 2022 December 31, 2021 Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement Assets Liabilities Assets Liabilities (In millions) Gross estimated fair value of derivatives: OTC-bilateral (1) $ 10,871 $ 4,072 $ 8,602 $ 1,379 OTC-cleared (1) 25 94 104 8 Exchange-traded 14 3 5 — Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1) 10,910 4,169 8,711 1,387 Gross amounts not offset on the interim condensed consolidated balance sheets: Gross estimated fair value of derivatives: (2) OTC-bilateral (3,968) (3,968) (1,364) (1,364) OTC-cleared (7) (7) (3) (3) Exchange-traded (1) (1) — — Cash collateral: (3), (4) OTC-bilateral (5,577) — (6,414) — OTC-cleared (1) (41) (91) — Securities collateral: (5) OTC-bilateral (1,274) (102) (767) (14) OTC-cleared — (45) — (5) Exchange-traded — (2) — — Net amount after application of master netting agreements and collateral $ 82 $ 3 $ 72 $ 1 __________________ (1) At September 30, 2022 and December 31, 2021, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $134 million and $93 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of $23 million and ($22) million, respectively. (2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals. (3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the centralized clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. (4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At September 30, 2022 and December 31, 2021, the Company received excess cash collateral of $797 million and $60 million, respectively, and provided excess cash collateral of $3 million and $0, respectively, which is not included in the table above due to the foregoing limitation. (5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at September 30, 2022, none of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At September 30, 2022 and December 31, 2021, the Company received excess securities collateral with an estimated fair value of $261 million and $47 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At September 30, 2022 and December 31, 2021, the Company provided excess securities collateral with an estimated fair value of $951 million and $95 million, respectively, for its OTC-bilateral derivatives, $493 million and $584 million, respectively, for its OTC-cleared derivatives, and $80 million and $106 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation. The Company’s collateral arrangements for its OTC-bilateral derivatives generally require the counterparty in a net liability position, after considering the effect of netting agreements, to pledge collateral when the collateral amount owed by that counterparty reaches a minimum transfer amount. All of the Company’s netting agreements for derivatives contain provisions that require both Metropolitan Life Insurance Company and the counterparty to maintain a specific investment grade financial strength or credit rating from each of Moody’s and S&P. If a party’s financial strength or credit rating were to fall below that specific investment grade financial strength or credit rating, that party would be in violation of these provisions, and the other party to the derivatives could terminate the transactions and demand immediate settlement and payment based on such party’s reasonable valuation of the derivatives. The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged. Derivatives Subject to Financial September 30, 2022 December 31, 2021 (In millions) Estimated fair value of derivatives in a net liability position (1) $ 105 $ 15 Estimated fair value of collateral provided: Fixed maturity securities AFS $ 107 $ 17 __________________ (1) After taking into consideration the existence of netting agreements. Embedded Derivatives The Company issues certain products or purchases certain investments that contain embedded derivatives that are required to be separated from their host contracts and accounted for as freestanding derivatives. The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at: Balance Sheet Location September 30, 2022 December 31, 2021 (In millions) Embedded derivatives within asset host contracts: Assumed on affiliated reinsurance Other invested assets $ 174 $ — Embedded derivatives within liability host contracts: Direct guaranteed minimum benefits Policyholder account balances $ 536 $ 257 Assumed guaranteed minimum benefits Policyholder account balances 5 5 Funds withheld and guarantees on reinsurance (including affiliated) Other liabilities (401) 1,072 Fixed annuities with equity indexed returns Policyholder account balances 126 165 Embedded derivatives within liability host contracts $ 266 $ 1,499 |
Fair Value
Fair Value | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value | 7. Fair Value Considerable judgment is often required in interpreting the market data used to develop estimates of fair value, and the use of different assumptions or valuation methodologies may have a material effect on the estimated fair value amounts. Recurring Fair Value Measurements The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at: September 30, 2022 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 43,788 $ 6,315 $ 50,103 U.S. government and agency 9,078 12,962 — 22,040 Foreign corporate — 17,328 5,534 22,862 RMBS 94 17,860 2,136 20,090 ABS & CLO — 10,048 1,524 11,572 Municipals — 7,238 — 7,238 CMBS — 5,637 301 5,938 Foreign government — 3,546 25 3,571 Total fixed maturity securities AFS 9,172 118,407 15,835 143,414 Short-term investments 3,302 224 5 3,531 Residential mortgage loans — FVO — — — — Other investments 252 280 936 1,468 Derivative assets: (1) Interest rate — 4,782 — 4,782 Foreign currency exchange rate — 4,787 — 4,787 Credit — 33 69 102 Equity market 14 1,084 7 1,105 Total derivative assets 14 10,686 76 10,776 Embedded derivatives within asset host contracts (4) — — 174 174 Separate account assets (2) 16,081 70,602 1,026 87,709 Total assets (3) $ 28,821 $ 200,199 $ 18,052 $ 247,072 Liabilities Derivative liabilities: (1) Interest rate $ 2 $ 1,252 $ 526 $ 1,780 Foreign currency exchange rate — 2,134 — 2,134 Credit — 41 36 77 Equity market 1 154 — 155 Total derivative liabilities 3 3,581 562 4,146 Embedded derivatives within liability host contracts (4) — — 266 266 Separate account liabilities (2) 12 17 21 50 Total liabilities $ 15 $ 3,598 $ 849 $ 4,462 December 31, 2021 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 51,290 $ 7,112 $ 58,402 U.S. government and agency 15,041 16,181 — 31,222 Foreign corporate — 21,862 7,823 29,685 RMBS 7 20,333 2,805 23,145 ABS & CLO — 11,455 1,424 12,879 Municipals — 8,728 — 8,728 CMBS — 6,507 371 6,878 Foreign government — 4,934 12 4,946 Total fixed maturity securities AFS 15,048 141,290 19,547 175,885 Short-term investments 4,187 677 2 4,866 Residential mortgage loans — FVO — — 127 127 Other investments 328 192 894 1,414 Derivative assets: (1) Interest rate — 5,982 95 6,077 Foreign currency exchange rate — 1,676 — 1,676 Credit — 106 17 123 Equity market 5 730 7 742 Total derivative assets 5 8,494 119 8,618 Embedded derivatives within asset host contracts (4) — — — — Separate account assets (2) 28,231 93,656 1,964 123,851 Total assets (3) $ 47,799 $ 244,309 $ 22,653 $ 314,761 Liabilities Derivative liabilities: (1) Interest rate $ — $ 70 $ 21 $ 91 Foreign currency exchange rate — 1,076 — 1,076 Credit — 8 12 20 Equity market — 222 — 222 Total derivative liabilities — 1,376 33 1,409 Embedded derivatives within liability host contracts (4) — — 1,499 1,499 Separate account liabilities (2) 7 12 6 25 Total liabilities $ 7 $ 1,388 $ 1,538 $ 2,933 __________________ (1) Derivative assets are presented within other invested assets on the interim condensed consolidated balance sheets and derivative liabilities are presented within other liabilities on the interim condensed consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the interim condensed consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables. (2) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities. (3) Total assets included in the fair value hierarchy exclude other limited partnership interests that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. At September 30, 2022 and December 31, 2021, the estimated fair value of such investments was $68 million and $95 million, respectively. (4) Embedded derivatives within asset host contracts are presented within other invested assets on the interim condensed consolidated balance sheets. Embedded derivatives within liability host contracts are presented within policyholder account balances and other liabilities on the interim condensed consolidated balance sheets. The following describes the valuation methodologies used to measure assets and liabilities at fair value. Investments Securities, Short-term Investments and Other Investments When available, the estimated fair value of these financial instruments is based on quoted prices in active markets that are readily and regularly obtainable. Generally, these are the most liquid of the Company’s securities holdings and valuation of these securities does not involve management’s judgment. When quoted prices in active markets are not available, the determination of estimated fair value of securities is based on market standard valuation methodologies, giving priority to observable inputs. The significant inputs to the market standard valuation methodologies for certain types of securities with reasonable levels of price transparency are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. When observable inputs are not available, the market standard valuation methodologies rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs can be based in large part on management’s judgment or estimation and cannot be supported by reference to market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such investments. The estimated fair value of short-term investments and other investments is determined on a basis consistent with the methodologies described herein. The valuation approaches and key inputs for each category of assets or liabilities that are classified within Level 2 and Level 3 of the fair value hierarchy are presented below. The primary valuation approaches are the market approach, which considers recent prices from market transactions involving identical or similar assets or liabilities, and the income approach, which converts expected future amounts (e.g. cash flows) to a single current, discounted amount. The valuation of most instruments listed below is determined using independent pricing sources, matrix pricing, discounted cash flow methodologies or other similar techniques that use either observable market inputs or unobservable inputs. Instrument Level 2 Observable Inputs Level 3 Unobservable Inputs Fixed maturity securities AFS U.S. corporate and Foreign corporate securities Valuation Approaches: Principally the market and income approaches. Valuation Approaches: Principally the market approach. Key Inputs: Key Inputs: • quoted prices in markets that are not active • illiquidity premium • benchmark yields; spreads off benchmark yields; new issuances; issuer ratings • delta spread adjustments to reflect specific credit-related issues • trades of identical or comparable securities; duration • credit spreads • privately-placed securities are valued using the additional key inputs: • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • market yield curve; call provisions • observable prices and spreads for similar public or private securities that incorporate the credit quality and industry sector of the issuer • independent non-binding broker quotations • delta spread adjustments to reflect specific credit-related issues U.S. government and agency securities, Municipals and Foreign government securities Valuation Approaches: Principally the market approach. Valuation Approaches: Principally the market approach. Key Inputs: Key Inputs: • quoted prices in markets that are not active • independent non-binding broker quotations • benchmark U.S. Treasury yield or other yields • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • the spread off the U.S. Treasury yield curve for the identical security • issuer ratings and issuer spreads; broker-dealer quotations • credit spreads • comparable securities that are actively traded Structured Products Valuation Approaches: Principally the market and income approaches. Valuation Approaches: Principally the market and income approaches. Key Inputs: Key Inputs: • quoted prices in markets that are not active • credit spreads • spreads for actively traded securities; spreads off benchmark yields • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • expected prepayment speeds and volumes • current and forecasted loss severity; ratings; geographic region • independent non-binding broker quotations • weighted average coupon and weighted average maturity • credit ratings • average delinquency rates; DSCR • credit ratings • issuance-specific information, including, but not limited to: • collateral type; structure of the security; vintage of the loans • payment terms of the underlying assets • payment priority within the tranche; deal performance Instrument Level 2 Observable Inputs Level 3 Unobservable Inputs Short-term investments and Other investments • Certain short-term investments and certain other investments are of a similar nature and class to the fixed maturity securities AFS described above; while certain other investments are similar to equity securities. The valuation approaches and observable inputs used in their valuation are also similar to those described above. Other investments contain equity securities valued using quoted prices in markets that are not considered active. • Certain short-term investments and certain other investments are of a similar nature and class to the fixed maturity securities AFS described above, while certain other investments are similar to equity securities. The valuation approaches and unobservable inputs used in their valuation are also similar to those described above. Other investments contain equity securities that use key unobservable inputs such as credit ratings; issuance structures, in addition to those described above for fixed maturities AFS. Other investments also include certain real estate joint ventures and use the valuation approach and key inputs as described for other limited partnership interests below. Residential mortgage loans — FVO • N/A Valuation Approaches: Principally the market approach. Valuation Techniques and Key Inputs: These investments are based primarily on matrix pricing or other similar techniques that utilize inputs from mortgage servicers that are unobservable or cannot be derived principally from, or corroborated by, observable market data. Separate account assets and Separate account liabilities (1) Mutual funds and hedge funds without readily determinable fair values as prices are not published publicly Key Input: • N/A • quoted prices or reported NAV provided by the fund managers Other limited partnership interests • N/A Valued giving consideration to the underlying holdings Key Inputs: • liquidity; bid/ask spreads; performance record of the fund manager • other relevant variables that may impact the exit value of the particular partnership interest __________________ (1) Estimated fair value equals carrying value, based on the value of the underlying assets, including: mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, other limited partnership interests, short-term investments and cash and cash equivalents. The estimated fair value of fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents is determined on a basis consistent with the assets described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.” Derivatives The estimated fair value of derivatives is determined through the use of quoted market prices for exchange-traded derivatives, or through the use of pricing models for OTC-bilateral and OTC-cleared derivatives. The determination of estimated fair value, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments. Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models. The significant inputs to the pricing models for most OTC-bilateral and OTC-cleared derivatives are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. Certain OTC-bilateral and OTC-cleared derivatives may rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs may involve significant management judgment or estimation. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such derivatives. Most inputs for OTC-bilateral and OTC-cleared derivatives are mid-market inputs but, in certain cases, liquidity adjustments are made when they are deemed more representative of exit value. Market liquidity, as well as the use of different methodologies, assumptions and inputs, may have a material effect on the estimated fair values of the Company’s derivatives and could materially affect net income. The credit risk of both the counterparty and the Company are considered in determining the estimated fair value for all OTC-bilateral and OTC-cleared derivatives, and any potential credit adjustment is based on the net exposure by counterparty after taking into account the effects of netting agreements and collateral arrangements. The Company values its OTC-bilateral and OTC-cleared derivatives using standard swap curves which may include a spread to the risk-free rate, depending upon specific collateral arrangements. This credit spread is appropriate for those parties that execute trades at pricing levels consistent with similar collateral arrangements. As the Company and its significant derivative counterparties generally execute trades at such pricing levels and hold sufficient collateral, additional credit risk adjustments are not currently required in the valuation process. The Company’s ability to consistently execute at such pricing levels is, in part, due to the netting agreements and collateral arrangements that are in place with all of its significant derivative counterparties. An evaluation of the requirement to make additional credit risk adjustments is performed by the Company each reporting period. Freestanding Derivatives Level 2 Valuation Approaches and Key Inputs: This level includes all types of derivatives utilized by the Company with the exception of exchange-traded derivatives included within Level 1 and those derivatives with unobservable inputs as described in Level 3. Level 3 Valuation Approaches and Key Inputs: These valuation methodologies generally use the same inputs as described in the corresponding sections for Level 2 measurements of derivatives. However, these derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. Freestanding derivatives are principally valued using the income approach. Valuations of non-option-based derivatives utilize present value techniques, whereas valuations of option-based derivatives utilize option pricing models. Key inputs are as follows: Instrument Interest Rate Foreign Currency Credit Equity Market Inputs common to Level 2 and Level 3 by instrument type • swap yield curves • swap yield curves • swap yield curves • swap yield curves • basis curves • basis curves • credit curves • spot equity index levels • interest rate volatility (1) • currency spot rates • recovery rates • dividend yield curves • cross currency basis curves • equity volatility (1) Level 3 • swap yield curves (2) • swap yield curves (2) • swap yield curves (2) • dividend yield curves (2) • basis curves (2) • basis curves (2) • credit curves (2) • equity volatility (1), (2) • repurchase rates • cross currency basis curves (2) • credit spreads • correlation between model inputs (1) • interest rate volatility (1), (2) • currency correlation • repurchase rates • independent non-binding broker quotations __________________ (1) Option-based only. (2) Extrapolation beyond the observable limits of the curve(s). Embedded Derivatives Embedded derivatives principally include certain direct and assumed variable annuity guarantees, annuity contracts, guarantees on reinsurance, and investment risk within funds withheld related to certain reinsurance agreements. Embedded derivatives are recorded at estimated fair value with changes in estimated fair value reported in net income. The Company issues certain variable annuity products with guaranteed minimum benefits. GMWBs, GMABs and certain GMIBs contain embedded derivatives, which are measured at estimated fair value separately from the host variable annuity contract, with changes in estimated fair value reported in net derivative gains (losses). These embedded derivatives are classified within policyholder account balances on the interim condensed consolidated balance sheets. The Company calculates the fair value of these embedded derivatives, which is estimated as the present value of projected future benefits minus the present value of projected future fees using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the embedded derivative over multiple risk neutral stochastic scenarios using observable risk-free rates. Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. The valuation of these guarantee liabilities includes nonperformance risk adjustments and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc. Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions as annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions including, but not limited to, changes in interest rates, equity indices, market volatility and foreign currency exchange rates; changes in nonperformance risk; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, may result in significant fluctuations in the estimated fair value of the guarantees that could materially affect net income. The estimated fair value of the embedded derivatives within funds withheld related to certain ceded reinsurance is determined based on the change in estimated fair value of the underlying assets held by the Company in a reference portfolio backing the funds withheld liability. The estimated fair value of the underlying assets is determined as described in “— Investments — Securities, Short-term Investments and Other Investments.” The estimated fair value of guarantees related to reinsurance is determined based on multiple stochastic scenarios and includes a nonperformance risk adjustment. The estimated fair value of these embedded derivatives is included, along with their underlying host contracts, in other liabilities on the interim condensed consolidated balance sheets with changes in estimated fair value recorded in net derivative gains (losses). Changes in the credit spreads on the underlying assets, interest rates and market volatility may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income. The Company issues certain annuity contracts which allow the policyholder to participate in returns from equity indices. These equity indexed features are embedded derivatives which are measured at estimated fair value separately from the host fixed annuity contract, with changes in estimated fair value reported in net derivative gains (losses). These embedded derivatives are classified within policyholder account balances on the interim condensed consolidated balance sheets. The estimated fair value of the embedded equity indexed derivatives, based on the present value of future equity returns to the policyholder using actuarial and present value assumptions including expectations concerning policyholder behavior, is calculated by the Company’s actuarial department. The calculation is based on in-force business and uses standard capital market techniques, such as Black-Scholes, to calculate the value of the portion of the embedded derivative for which the terms are set. The portion of the embedded derivative covering the period beyond where terms are set is calculated as the present value of amounts expected to be spent to provide equity indexed returns in those periods. The valuation of these embedded derivatives also includes the establishment of a risk margin, as well as changes in nonperformance risk. Embedded Derivatives Within Asset and Liability Host Contracts Level 3 Valuation Approaches and Key Inputs: Direct and assumed guaranteed minimum benefits These embedded derivatives are principally valued using the income approach. Valuations are based on option pricing techniques, which utilize significant inputs that may include swap yield curves, currency exchange rates and implied volatilities. These embedded derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. Significant unobservable inputs generally include: the extrapolation beyond observable limits of the swap yield curves and implied volatilities, actuarial assumptions for policyholder behavior and mortality and the potential variability in policyholder behavior and mortality, nonperformance risk and cost of capital for purposes of calculating the risk margin. Embedded derivatives within funds withheld related to certain ceded reinsurance These embedded derivatives are principally valued using the income approach. The valuations are based on present value techniques, which utilize significant inputs that may include the swap yield curves and the fair value of assets within the reference portfolio. These embedded derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. Significant unobservable inputs generally include the fair value of certain assets within the reference portfolio which are not observable in the market and cannot be derived principally from, or corroborated by, observable market data. Transfers between Levels Overall, transfers between levels occur when there are changes in the observability of inputs and market activity. Transfers into or out of Level 3: Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable. Assets and Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at: September 30, 2022 December 31, 2021 Impact of Valuation Techniques Significant Range Weighted Range Weighted Fixed maturity securities AFS (3) U.S. corporate and foreign corporate • Matrix pricing • Offered quotes (4) — - 121 87 1 - 165 110 Increase • Market pricing • Quoted prices (4) 5 - 102 95 — - 117 101 Increase RMBS • Market pricing • Quoted prices (4) — - 113 92 — - 121 99 Increase (5) ABS & CLO • Market pricing • Quoted prices (4) 76 - 102 92 91 - 110 102 Increase (5) Derivatives Interest rate • Present value techniques • Swap yield (6) 369 - 379 374 151 - 200 188 Increase (7) • Volatility (8) —% - —% —% 1% - 1% 1% Increase (7) Credit • Present value techniques • Credit spreads (9) 86 - 148 105 96 - 133 109 Decrease (7) • Consensus pricing • Offered quotes (10) Embedded derivatives Direct and assumed guaranteed minimum benefits • Option pricing techniques • Mortality rates: Ages 0 - 40 0.01% - 0.14% 0.05% 0.01% - 0.12% 0.08% Decrease (11) Ages 41 - 60 0.05% - 0.43% 0.21% 0.05% - 0.65% 0.27% Decrease (11) Ages 61 - 115 0.33% - 100% 1.45% 0.32% - 100% 2.08% Decrease (11) • Lapse rates: Durations 1 - 10 0% - 80% 8.84% 0.25% - 100% 6.30% Decrease (12) Durations 11 - 20 0.70% - 80% 6.46% 0.70% - 100% 5.22% Decrease (12) Durations 21 - 116 1.60% - 80% 2.90% 1.60% - 100% 5.22% Decrease (12) • Utilization rates 0% - 22% 0.37% 0% - 22% 0.22% Increase (13) • Withdrawal rates 0% - 10% 4% 0.25% - 10% 3.72% (14) • Long-term equity volatilities 16.46% - 22.01% 18.49% 16.44% - 22.16% 18.60% Increase (15) • Nonperformance risk spread 0.33% - 0.81% 0.75% 0.04% - 0.40% 0.35% Decrease (16) __________________ (1) The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for embedded derivatives is determined based on a combination of account values and experience data. (2) The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For embedded derivatives, changes to direct and assumed guaranteed minimum benefits are based on liability positions. (3) Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations. (4) Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par. (5) Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates. (6) Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation. (7) Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions. (8) Ranges represent the underlying interest rate volatility quoted in percentage points. Since this valuation methodology uses an equivalent of LIBOR for secured overnight financing rate volatility, presenting a range is more representative of the unobservable input used in the valuation. (9) Represents the risk quoted in basis points of a credit default event on the underlying instrument. Credit derivatives with significant unobservable inputs are primarily comprised of written credit default swaps. (10) At both September 30, 2022 and December 31, 2021, independent non-binding broker quotations were used in the determination of less than 1% of the total net derivative estimated fair value. (11) Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (12) Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (13) The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (14) The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. For GMWBs, any increase (decrease) in withdrawal rates results in an incre |
Equity
Equity | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Equity | 8. Equity Accumulated Other Comprehensive Income (Loss) Information regarding changes in the balances of each component of AOCI attributable to Metropolitan Life Insurance Company was as follows: Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Unrealized Gains (Losses) on Derivatives Foreign Currency Translation Adjustments Defined Benefit Plans Adjustment Total (In millions) Balance, beginning of period $ (5,214) $ 1,905 $ (89) $ (379) $ (3,777) OCI before reclassifications (8,845) 284 (88) — (8,649) Deferred income tax benefit (expense) 1,872 (60) 19 — 1,831 AOCI before reclassifications, net of income tax (12,187) 2,129 (158) (379) (10,595) Amounts reclassified from AOCI 186 485 — 10 681 Deferred income tax benefit (expense) (40) (102) — (2) (144) Amounts reclassified from AOCI, net of income tax 146 383 — 8 537 Balance, end of period $ (12,041) $ 2,512 $ (158) $ (371) $ (10,058) Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Unrealized Gains (Losses) on Derivatives Foreign Currency Translation Adjustments Defined Benefit Plans Adjustment Total (In millions) Balance, beginning of period $ 8,938 $ 1,419 $ (33) $ (445) $ 9,879 OCI before reclassifications 38 228 7 3 276 Deferred income tax benefit (expense) 20 (178) (2) — (160) AOCI before reclassifications, net of income tax 8,996 1,469 (28) (442) 9,995 Amounts reclassified from AOCI (13) 233 — 7 227 Deferred income tax benefit (expense) 2 75 — (2) 75 Amounts reclassified from AOCI, net of income tax (11) 308 — 5 302 Balance, end of period $ 8,985 $ 1,777 $ (28) $ (437) $ 10,297 Nine Months Unrealized Unrealized Foreign Defined Total (In millions) Balance, beginning of period $ 8,485 $ 1,872 $ (45) $ (395) $ 9,917 OCI before reclassifications (26,804) (202) (140) — (27,146) Deferred income tax benefit (expense) 5,643 42 27 — 5,712 AOCI before reclassifications, net of income tax (12,676) 1,712 (158) (395) (11,517) Amounts reclassified from AOCI 805 1,013 — 30 1,848 Deferred income tax benefit (expense) (170) (213) — (6) (389) Amounts reclassified from AOCI, net of income tax 635 800 — 24 1,459 Balance, end of period $ (12,041) $ 2,512 $ (158) $ (371) $ (10,058) Nine Months Unrealized Unrealized Foreign Defined Total (In millions) Balance, beginning of period $ 10,384 $ 1,791 $ (53) $ (460) $ 11,662 OCI before reclassifications (1,862) (173) 31 1 (2,003) Deferred income tax benefit (expense) 428 (94) (6) — 328 AOCI before reclassifications, net of income tax 8,950 1,524 (28) (459) 9,987 Amounts reclassified from AOCI 46 164 — 28 238 Deferred income tax benefit (expense) (11) 89 — (6) 72 Amounts reclassified from AOCI, net of income tax 35 253 — 22 310 Balance, end of period $ 8,985 $ 1,777 $ (28) $ (437) $ 10,297 __________________ (1) See Note 5 for information on offsets to investments related to policyholder liabilities, DAC, VOBA and DSI. Information regarding amounts reclassified out of each component of AOCI was as follows: Three Months Nine Months 2022 2021 2022 2021 AOCI Components Amounts Reclassified from AOCI Consolidated Statements of (In millions) Net unrealized investment gains (losses): Net unrealized investment gains (losses) $ (174) $ 17 $ (775) $ (17) Net investment gains (losses) Net unrealized investment gains (losses) 1 (3) 4 (10) Net investment income Net unrealized investment gains (losses) (13) (1) (34) (19) Net derivative gains (losses) Net unrealized investment gains (losses), before income tax (186) 13 (805) (46) Income tax (expense) benefit 40 (2) 170 11 Net unrealized investment gains (losses), net of income tax (146) 11 (635) (35) Unrealized gains (losses) on derivatives - cash flow hedges: Interest rate derivatives 15 14 46 41 Net investment income Interest rate derivatives (16) 8 55 56 Net investment gains (losses) Foreign currency exchange rate derivatives 1 2 3 4 Net investment income Foreign currency exchange rate derivatives (485) (257) (1,117) (265) Net investment gains (losses) Gains (losses) on cash flow hedges, before income tax (485) (233) (1,013) (164) Income tax (expense) benefit 102 (75) 213 (89) Gains (losses) on cash flow hedges, net of income tax (383) (308) (800) (253) Defined benefit plans adjustment: (1) Amortization of net actuarial gains (losses) (10) (10) (31) (33) Amortization of prior service (costs) credit — 3 1 5 Amortization of defined benefit plan items, before income tax (10) (7) (30) (28) Income tax (expense) benefit 2 2 6 6 Amortization of defined benefit plan items, net of income tax (8) (5) (24) (22) Total reclassifications, net of income tax $ (537) $ (302) $ (1,459) $ (310) __________________ (1) These AOCI components are included in the computation of net periodic benefit costs. |
Other Revenues and Other Expens
Other Revenues and Other Expenses | 9 Months Ended |
Sep. 30, 2022 | |
Other Income and Expenses [Abstract] | |
Other Revenues and Other Expenses Disclosure | 9. Other Revenues and Other Expenses Other Revenues Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows: Three Months Nine Months 2022 2021 2022 2021 (In millions) Prepaid legal plans $ 105 $ 99 $ 319 $ 298 Recordkeeping and administrative services (1) 40 53 129 158 Administrative services-only contracts 56 54 168 166 Other revenue from service contracts from customers 8 6 22 26 Total revenues from service contracts from customers 209 212 638 648 Other (2) 292 156 648 577 Total other revenues $ 501 $ 368 $ 1,286 $ 1,225 __________________ (1) Related to products and businesses no longer actively marketed by the Company. (2) Primarily includes reinsurance ceded. See Note 12. Other Expenses Information on other expenses was as follows: Three Months Nine Months 2022 2021 2022 2021 (In millions) General and administrative expenses (1) $ 675 $ 566 $ 2,039 $ 1,660 Pension, postretirement and postemployment benefit costs 30 27 89 85 Premium taxes, other taxes, and licenses & fees 108 77 269 243 Commissions and other variable expenses 755 1,048 1,728 2,030 Capitalization of DAC (58) (16) (120) (45) Amortization of DAC and VOBA (119) 99 55 171 Interest expense on debt 27 24 76 72 Total other expenses $ 1,418 $ 1,825 $ 4,136 $ 4,216 __________________ (1) Includes $21 million and $95 million for the three months and nine months ended September 30, 2022, respectively, and ($14) million and ($71) million for the three months and nine months ended September 30, 2021, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid. Affiliated Expenses See Note 12 for a discussion of affiliated expenses included in the table above. |
Income Tax
Income Tax | 9 Months Ended |
Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Tax | 10. Income Tax For the three months and nine months ended September 30, 2022, the effective tax rate on income (loss) before provision for income tax was 17% and 16%, respectively. The Company’s effective tax rate for the three months ended September 30, 2022 differed from the U.S. statutory rate primarily due to tax benefits related to tax credits. The Company’s effective tax rate for the nine months ended September 30, 2022 differed from the U.S. statutory rate primarily due to tax benefits related to tax credits, the corporate tax deduction for stock compensation and non-taxable investment income. For the three months and nine months ended September 30, 2021, the effective tax rate on income (loss) before provision for income tax was 14% and 15%, respectively. The Company’s effective tax rate for the three months ended September 30, 2021 differed from the U.S. statutory rate primarily due to tax benefits related to tax credits and non-taxable investment income. The Company’s effective tax rate for the nine months ended September 30, 2021 differed from the U.S. statutory rate primarily due to tax benefits related to tax credits, non-taxable investment income and the corporate tax deduction for stock compensation. |
Contingencies, Commitments and
Contingencies, Commitments and Guarantees | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies, Commitments and Guarantees | 11. Contingencies, Commitments and Guarantees Contingencies Litigation The Company is a defendant in a large number of litigation matters. Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed below and those otherwise provided for in the Company’s interim condensed consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lending bank, employer, investor, investment advisor, broker-dealer, and taxpayer. The Company also receives and responds to subpoenas or other inquiries seeking a broad range of information from state regulators, including state insurance commissioners; state attorneys general or other state governmental authorities; federal regulators, including the U.S. Securities and Exchange Commission; federal governmental authorities, including congressional committees; and the Financial Industry Regulatory Authority, as well as from local and national regulators and government authorities in jurisdictions outside the United States where the Company conducts business. The issues involved in information requests and regulatory matters vary widely, but can include inquiries or investigations concerning the Company’s compliance with applicable insurance and other laws and regulations. The Company cooperates in these inquiries. It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. The Company establishes liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Liabilities have been established for a number of the matters noted below. In certain circumstances where liabilities have been established there may be coverage under one or more corporate insurance policies, pursuant to which there may be an insurance recovery. Insurance recoveries are recognized as gains when any contingencies relating to the insurance claim have been resolved, which is the earlier of when the gains are realized or realizable. It is possible that some of the matters could require the Company to pay damages or make other expenditures or establish accruals in amounts that could not be reasonably estimated at September 30, 2022. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known to management, management does not believe any such charges are likely to have a material effect on the Company’s financial position. Given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods. Matters as to Which an Estimate Can Be Made For some matters, the Company is able to estimate a reasonably possible range of loss. For matters where a loss is believed to be reasonably possible, but not probable, the Company has not made an accrual. As of September 30, 2022, the Company estimates the aggregate range of reasonably possible losses in excess of amounts accrued for these matters to be $0 to $125 million. Matters as to Which an Estimate Cannot Be Made For other matters, the Company is not currently able to estimate the reasonably possible loss or range of loss. The Company is often unable to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support an assessment of the range of possible loss, such as quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by the court on motions or appeals, analysis by experts, and the progress of settlement negotiations. On a quarterly and annual basis, the Company reviews relevant information with respect to litigation contingencies and updates its accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews. Asbestos-Related Claims Metropolitan Life Insurance Company is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages. Metropolitan Life Insurance Company has never engaged in the business of manufacturing or selling asbestos-containing products, nor has Metropolitan Life Insurance Company issued liability or workers’ compensation insurance to companies in the business of manufacturing or selling asbestos-containing products. The lawsuits principally have focused on allegations with respect to certain research, publication and other activities of one or more of Metropolitan Life Insurance Company’s employees during the period from the 1920s through approximately the 1950s and allege that Metropolitan Life Insurance Company learned or should have learned of certain health risks posed by asbestos and, among other things, improperly publicized or failed to disclose those health risks. Metropolitan Life Insurance Company believes that it should not have legal liability in these cases. The outcome of most asbestos litigation matters, however, is uncertain and can be impacted by numerous variables, including differences in legal rulings in various jurisdictions, the nature of the alleged injury and factors unrelated to the ultimate legal merit of the claims asserted against Metropolitan Life Insurance Company. Metropolitan Life Insurance Company’s defenses include that: (i) Metropolitan Life Insurance Company owed no duty to the plaintiffs; (ii) plaintiffs did not rely on any actions of Metropolitan Life Insurance Company; (iii) Metropolitan Life Insurance Company’s conduct was not the cause of the plaintiffs’ injuries; and (iv) plaintiffs’ exposure occurred after the dangers of asbestos were known. During the course of the litigation, certain trial courts have granted motions dismissing claims against Metropolitan Life Insurance Company, while other trial courts have denied Metropolitan Life Insurance Company’s motions. There can be no assurance that Metropolitan Life Insurance Company will receive favorable decisions on motions in the future. While most cases brought to date have settled, Metropolitan Life Insurance Company intends to continue to defend aggressively against claims based on asbestos exposure, including defending claims at trials. As reported in the 2021 Annual Report, Metropolitan Life Insurance Company received approximately 2,824 asbestos-related claims in 2021. For the nine months ended September 30, 2022 and 2021, Metropolitan Life Insurance Company received approximately 1,962 and 2,156 new asbestos-related claims, respectively. See Note 16 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for historical information concerning asbestos claims and Metropolitan Life Insurance Company’s update in its recorded liability at December 31, 2021. The number of asbestos cases that may be brought, the aggregate amount of any liability that Metropolitan Life Insurance Company may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year. The ability of Metropolitan Life Insurance Company to estimate its ultimate asbestos exposure is subject to considerable uncertainty, and the conditions impacting its liability can be dynamic and subject to change. The availability of reliable data is limited and it is difficult to predict the numerous variables that can affect liability estimates, including the number of future claims, the cost to resolve claims, the disease mix and severity of disease in pending and future claims, the willingness of courts to allow plaintiffs to pursue claims against Metropolitan Life Insurance Company when exposure to asbestos took place after the dangers of asbestos exposure were well known, and the impact of any possible future adverse verdicts and their amounts. The ability to make estimates regarding ultimate asbestos exposure declines significantly as the estimates relate to years further in the future. In the Company’s judgment, there is a future point after which losses cease to be probable and reasonably estimable. It is reasonably possible that the Company’s total exposure to asbestos claims may be materially greater than the asbestos liability currently accrued and that future charges to income may be necessary, but management does not believe any such charges are likely to have a material effect on the Company’s financial position. The Company believes adequate provision has been made in its interim condensed consolidated financial statements for all probable and reasonably estimable losses for asbestos-related claims. Metropolitan Life Insurance Company’s recorded asbestos liability covers pending claims, claims not yet asserted, and legal defense costs and is based on estimates and includes significant assumptions underlying its analysis. Metropolitan Life Insurance Company reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the United States, assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. Based upon its regular reevaluation of its exposure from asbestos litigation, Metropolitan Life Insurance Company has updated its liability analysis for asbestos-related claims through September 30, 2022. Total Asset Recovery Services, LLC. v. MetLife, Inc., et al. (Supreme Court of the State of New York, County of New York, filed December 27, 2017) Total Asset Recovery Services (the “Relator”) brought an action under the qui tam provision of the New York False Claims Act (the “Act”) on behalf of itself and the State of New York. The Relator originally filed this action under seal in 2010, and the complaint was unsealed on December 19, 2017. The Relator alleges that MetLife, Inc., Metropolitan Life Insurance Company and several other insurance companies violated the Act by filing false unclaimed property reports with the State of New York from 1986 to 2017, to avoid having to escheat the proceeds of more than 25,000 life insurance policies, including policies for which the defendants escheated funds as part of their demutualizations in the late 1990s. The Relator seeks treble damages and other relief. The Appellate Division of the New York State Supreme Court, First Department, reversed the court’s order granting MetLife, Inc. and Metropolitan Life Insurance Company’s motion to dismiss and remanded the case to the trial court where the Relator has filed an amended complaint. The Company intends to defend the action vigorously. Matters Related to Group Annuity Benefits In 2018, the Company announced that it identified a material weakness in its internal control over financial reporting related to the practices and procedures for estimating reserves for certain group annuity benefits. Several regulators have made inquiries into this issue and it is possible that other jurisdictions may pursue similar investigations or inquiries. The Company could be exposed to lawsuits and additional legal actions relating to this issue. These may result in payments, including damages, fines, penalties, interest and other amounts assessed or awarded by courts or regulatory authorities under applicable escheat, tax, securities, Employee Retirement Income Security Act of 1974, or other laws or regulations. The Company could incur significant costs in connection with these actions. Commitments Mortgage Loan Commitments The Company commits to lend funds under mortgage loan commitments. The amounts of these mortgage loan commitments were $2.5 billion and $3.1 billion at September 30, 2022 and December 31, 2021, respectively. Commitments to Fund Partnership Investments, Bank Credit Facilities, Bridge Loans and Private Corporate Bond Investments Guarantees In the normal course of its business, the Company has provided certain indemnities, guarantees and commitments to third parties such that it may be required to make payments now or in the future. In the context of acquisition, disposition, investment and other transactions, the Company has provided indemnities and guarantees, including those related to tax, environmental and other specific liabilities and other indemnities and guarantees that are triggered by, among other things, breaches of representations, warranties or covenants provided by the Company. In addition, in the normal course of business, the Company provides indemnifications to counterparties in contracts with triggers similar to the foregoing, as well as for certain other liabilities, such as third-party lawsuits. These obligations are often subject to time limitations that vary in duration, including contractual limitations and those that arise by operation of law, such as applicable statutes of limitation. In some cases, the maximum potential obligation under the indemnities and guarantees is subject to a contractual limitation ranging from less than $1 million to $263 million, with a cumulative maximum of $365 million, while in other cases such limitations are not specified or applicable. Since certain of these obligations are not subject to limitations, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. Management believes that it is unlikely the Company will have to make any material payments under these indemnities, guarantees, or commitments. In addition, the Company indemnifies its directors and officers as provided in its charters and by-laws. Also, the Company indemnifies its agents for liabilities incurred as a result of their representation of the Company’s interests. Since these indemnities are generally not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these indemnities in the future. The Company’s recorded liabilities were $2 million at both September 30, 2022 and December 31, 2021, for indemnities, guarantees and commitments. |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Sep. 30, 2022 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 12. Related Party TransactionsService Agreements The Company has entered into various agreements with affiliates for services necessary to conduct its activities. Typical services provided under these agreements include personnel, policy administrative functions and distribution services. The bases for such charges are modified and adjusted by management when necessary or appropriate to reflect fairly and equitably the actual cost incurred by the Company and/or its affiliates. Expenses and fees incurred with affiliates related to these agreements, recorded in other expenses, were $686 million and $2.0 billion for the three months and nine months ended September 30, 2022, respectively, and $624 million and $1.8 billion for the three months and nine months ended September 30, 2021, respectively. Total revenues received from affiliates related to these agreements were $13 million and $36 million for the three months and nine months ended September 30, 2022, respectively, and $11 million and $32 million for the three months and nine months ended September 30, 2021, respectively. The Company had net payables to affiliates, related to the items discussed above, of $69 million and $143 million at September 30, 2022 and December 31, 2021, respectively. See Note 5 for additional information on related party transactions. Related Party Reinsurance Transactions The Company has reinsurance agreements with certain of MetLife, Inc.’s subsidiaries, including MetLife Reinsurance Company of Charleston (“MRC”), MetLife Reinsurance Company of Vermont, Metropolitan Tower Life Insurance Company, and MetLife Insurance K.K., all of which are related parties. Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated statements of operations and comprehensive income (loss) was as follows: Three Months Nine Months 2022 2021 2022 2021 (In millions) Premiums Reinsurance assumed $ 2 $ 3 $ 5 $ 845 Reinsurance ceded (29) (26) (97) (86) Net premiums $ (27) $ (23) $ (92) $ 759 Universal life and investment-type product policy fees Reinsurance assumed $ — $ — $ — $ — Reinsurance ceded (4) (13) (11) (14) Net universal life and investment-type product policy fees $ (4) $ (13) $ (11) $ (14) Other revenues Reinsurance assumed $ 23 $ 1 $ 52 $ 3 Reinsurance ceded 106 96 353 379 Net other revenues $ 129 $ 97 $ 405 $ 382 Policyholder benefits and claims Reinsurance assumed $ 17 $ 1 $ 51 $ 833 Reinsurance ceded (36) (43) (117) (115) Net policyholder benefits and claims $ (19) $ (42) $ (66) $ 718 Interest credited to policyholder account balances Reinsurance assumed $ 26 $ 8 $ 47 $ 22 Reinsurance ceded (3) (3) (9) (9) Net interest credited to policyholder account balances $ 23 $ 5 $ 38 $ 13 Other expenses Reinsurance assumed $ 4 $ — $ 14 $ 19 Reinsurance ceded 343 713 533 947 Net other expenses $ 347 $ 713 $ 547 $ 966 Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated balance sheets was as follows at: September 30, 2022 December 31, 2021 Assumed Ceded Assumed Ceded (In millions) Assets Premiums, reinsurance and other receivables $ 538 $ 11,336 $ 25 $ 11,710 Deferred policy acquisition costs and value of business acquired 69 (164) 6 (139) Total assets $ 607 $ 11,172 $ 31 $ 11,571 Liabilities Future policy benefits $ 3,012 $ 10 $ 3,139 $ (10) Policyholder account balances 3,533 — 366 — Other policy-related balances 63 (3) 14 — Other liabilities 908 10,380 894 12,190 Total liabilities $ 7,516 $ 10,387 $ 4,413 $ 12,180 The Company ceded two blocks of business to an affiliate on a 75% coinsurance with funds withheld basis. Certain contractual features of these agreements qualify as embedded derivatives, which are separately accounted for at estimated fair value on the Company’s interim condensed consolidated balance sheets. The embedded derivatives related to the funds withheld associated with these reinsurance agreements are included within other liabilities and were ($31) million and $31 million at September 30, 2022 and December 31, 2021, respectively. Net derivative gains (losses) associated with these embedded derivatives were $15 million and $62 million for the three months and nine months ended September 30, 2022, respectively, and $1 million and $14 million for the three months and nine months ended September 30, 2021, respectively. Certain contractual features of the closed block agreement with MRC create an embedded derivative, which is separately accounted for at estimated fair value on the Company’s interim condensed consolidated balance sheets. The embedded derivative related to the funds withheld associated with this reinsurance agreement was included within other liabilities and was ($464) million and $1.0 billion at September 30, 2022 and December 31, 2021, respectively. Net derivative gains (losses) associated with the embedded derivative were $388 million and $1.5 billion for the three months and nine months ended September 30, 2022, respectively, and $50 million and $279 million for the three months and nine months ended September 30, 2021, respectively. |
Business, Basis of Presentati_2
Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Use of Estimates | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain, including uncertainties associated with the COVID-19 pandemic. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates. |
Consolidation of Subsidiaries | The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2021 consolidated balance sheet data was derived from audited consolidated financial statements included in Metropolitan Life Insurance Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2021 Annual Report. Consolidation The accompanying interim condensed consolidated financial statements include the accounts of MLIC, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated. The Company uses the equity method of accounting or the fair value option (“FVO”) for real estate joint ventures and other limited partnership interests (“investee”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. Since the Company is a member of a controlled group of affiliated companies, its results may not be indicative of those of a stand-alone entity. |
New Accounting Pronouncements | Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following tables provide a description of ASUs recently issued by the FASB and the impact of their adoption on the Company’s interim condensed consolidated financial statements. Adopted Accounting Pronouncements The table below describes the impacts of the ASUs recently adopted by the Company. Standard Description Effective Date and Method of Adoption Impact on Financial Statements ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting; as clarified and amended by ASU 2021-01, Reference Rate Reform (Topic 848):Scope The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, with certain exceptions. ASU 2021-01 amends the scope of the recent reference rate reform guidance. New optional expedients allow derivative instruments impacted by changes in the interest rate used for margining, discounting, or contract price alignment to qualify for certain optional relief. Effective for contract modifications made between March 12, 2020 and December 31, 2022. The guidance has reduced the operational and financial impacts of contract modifications that replace a reference rate, such as London Interbank Offered Rate (“LIBOR”), affected by reference rate reform. Contract modifications for invested assets and derivative instruments occurred during 2021 and have continued into 2022. Based on actions taken to date, the adoption of the guidance has not had a material impact on the Company’s interim condensed consolidated financial statements. The Company does not expect the adoption of this guidance to have a material ongoing impact and will continue to evaluate the impacts of reference rate reform on contract modifications and hedging relationships through December 31, 2022. ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance The guidance requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy and can include tax credits and other forms of government assistance. Entities are required to disclose information about (i) the nature of the transactions and the related accounting policy used to account for the transactions; (ii) the line items on the balance sheet and income statement that are affected by the transactions, including the associated amounts; and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. Effective for annual periods beginning January 1, 2022, to be applied prospectively. The adoption of the guidance will not have a material impact on the Company’s annual consolidated financial statements. |
Investments | Maturities of Fixed Maturity Securities AFSActual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity. Evaluation and Measurement Methodologies Management considers a wide range of factors about the security issuer and uses its best judgment in evaluating the cause of the decline in the estimated fair value of the security and in assessing the prospects for near-term recovery. Inherent in management’s evaluation of the security are assumptions and estimates about the operations of the issuer and its future earnings potential. Considerations used in the credit loss evaluation process include, but are not limited to: (i) the extent to which the estimated fair value has been below amortized cost, (ii) adverse conditions specifically related to a security, an industry sector or sub-sector, or an economically depressed geographic area, adverse change in the financial condition of the issuer of the security, changes in technology, discontinuance of a segment of the business that may affect future earnings, and changes in the quality of credit enhancement, (iii) payment structure of the security and likelihood of the issuer being able to make payments, (iv) failure of the issuer to make scheduled interest and principal payments, (v) whether the issuer, or series of issuers or an industry has suffered a catastrophic loss or has exhausted natural resources, (vi) whether the Company has the intent to sell or will more likely than not be required to sell a particular security before the decline in estimated fair value below amortized cost recovers, (vii) with respect to Structured Products, changes in forecasted cash flows after considering the changes in the financial condition of the underlying loan obligors and quality of underlying collateral, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying assets backing a particular security, and the payment priority within the tranche structure of the security, (viii) changes in the rating of the security by a rating agency, and (ix) other subjective factors, including concentrations and information obtained from regulators. The methodology and significant inputs used to determine the amount of credit loss are as follows: • The Company calculates the recovery value by performing a discounted cash flow analysis based on the present value of future cash flows. The discount rate is generally the effective interest rate of the security at the time of purchase for fixed-rate securities and the spot rate at the date of evaluation of credit loss for floating-rate securities. • When determining collectability and the period over which value is expected to recover, the Company applies considerations utilized in its overall credit loss evaluation process which incorporates information regarding the specific security, fundamentals of the industry and geographic area in which the security issuer operates, and overall macroeconomic conditions. Projected future cash flows are estimated using assumptions derived from management’s single best estimate, the most likely outcome in a range of possible outcomes, after giving consideration to a variety of variables that include, but are not limited to: payment terms of the security; the likelihood that the issuer can service the interest and principal payments; the quality and amount of any credit enhancements; the security’s position within the capital structure of the issuer; possible corporate restructurings or asset sales by the issuer; any private and public sector programs to restructure foreign government securities and municipals; and changes to the rating of the security or the issuer by rating agencies. • Additional considerations are made when assessing the unique features that apply to certain Structured Products including, but not limited to: the quality of underlying collateral, historical performance of the underlying loan obligors, historical rent and vacancy levels, changes in the financial condition of the underlying loan obligors, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying loans or assets backing a particular security, changes in the quality of credit enhancement and the payment priority within the tranche structure of the security. With respect to securities that have attributes of debt and equity (“perpetual hybrid securities”), consideration is given in the credit loss analysis as to whether there has been any deterioration in the credit of the issuer and the likelihood of recovery in value of the securities that are in a severe unrealized loss position. Consideration is also given as to whether any perpetual hybrid securities with an unrealized loss, regardless of credit rating, have deferred any dividend payments. In periods subsequent to the recognition of an initial ACL on a security, the Company reassesses credit loss quarterly. Subsequent increases or decreases in the expected cash flow from the security result in corresponding decreases or increases in the ACL which are recognized in earnings and reported within net investment gains (losses); however, the previously recorded ACL is not reduced to an amount below zero. Full or partial write-offs are deducted from the ACL in the period the security, or a portion thereof, is considered uncollectible. Recoveries of amounts previously written off are recorded to the ACL in the period received. When the Company has the intent-to-sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost, any ACL is written off and the amortized cost is written down to estimated fair value through a charge within net investment gains (losses), which becomes the new amortized cost of the security. Allowance for Credit Loss Methodology The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable) and reasonably expected TDRs (i.e., the Company grants concessions to borrower that is experiencing financial difficulties) are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses). Commercial and Agricultural Mortgage Loan Portfolio Segments Commercial and agricultural mortgage loan ACL are calculated in a similar manner. Within each loan portfolio segment, commercial and agricultural, loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. The Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans. Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans. For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio. For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated. Commitments to lend: After loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that are not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly. Residential Mortgage Loan Portfolio Segment The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and pooled by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company immediately reverts to industry historical loss experience. For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss. Troubled Debt Restructuring The Company may grant concessions to borrowers experiencing financial difficulties and if significant, these concessions are classified as TDRs. Generally, the types of concessions include: reduction of contractual interest rates, extension of the maturity date at an interest rate lower than current market interest rates, and/or a reduction of accrued interest. The amount, timing and extent of the concessions granted are considered in determining any ACL recorded. For the three months and nine months ended September 30, 2022, the Company had one and two commercial mortgage loans modified in a TDR, respectively, with both pre-modification and post-modification carrying value, after ACL, of $31 million and $123 million, respectively. |
Derivatives | The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives.The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities and (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities.The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments. The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements. Derivatives may be exchange-traded or contracted in the over-the-counter (“OTC”) market. Certain of the Company’s OTC derivatives are cleared and settled through central clearinghouses (“OTC-cleared”), while others are bilateral contracts between two counterparties (“OTC-bilateral”). The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s OTC-bilateral derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of Dodd-Frank) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, effective September 1, 2021, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third party custodians. The Company’s OTC-cleared derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives. See Note 7 for a description of the impact of credit risk on the valuation of derivatives. |
Closed Block | On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving Metropolitan Life Insurance Company’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, Metropolitan Life Insurance Company established a closed block for the benefit of holders of certain individual life insurance policies of Metropolitan Life Insurance Company.Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon cumulative actual and expected earnings within the closed block. Accordingly, the Company’s net income continues to be sensitive to the actual performance of the closed block. |
Segment Information (Tables)
Segment Information (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Segment Reporting [Abstract] | |
Segment Reporting Information, by Segment | Three Months Ended September 30, 2022 U.S. MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 13,158 $ 611 $ — $ 13,769 $ — $ 13,769 Universal life and investment-type product policy fees 277 188 — 465 19 484 Net investment income 1,482 990 (62) 2,410 (150) 2,260 Other revenues 356 36 109 501 — 501 Net investment gains (losses) — — — — (82) (82) Net derivative gains (losses) — — — — 454 454 Total revenues 15,273 1,825 47 17,145 241 17,386 Expenses Policyholder benefits and claims and policyholder dividends 13,107 1,397 — 14,504 (207) 14,297 Interest credited to policyholder account balances 445 160 19 624 — 624 Capitalization of DAC (21) 1 (38) (58) — (58) Amortization of DAC and VOBA 14 (24) 1 (9) (110) (119) Interest expense on debt 3 2 22 27 — 27 Other expenses 883 199 483 1,565 3 1,568 Total expenses 14,431 1,735 487 16,653 (314) 16,339 Provision for income tax expense (benefit) 175 15 (133) 57 117 174 Adjusted earnings $ 667 $ 75 $ (307) 435 Adjustments to: Total revenues 241 Total expenses 314 Provision for income tax (expense) benefit (117) Net income (loss) $ 873 $ 873 Three Months Ended September 30, 2021 U.S. MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 5,058 $ 657 $ — $ 5,715 $ — $ 5,715 Universal life and investment-type product policy fees 267 219 — 486 20 506 Net investment income 1,889 1,587 7 3,483 (152) 3,331 Other revenues 217 53 98 368 — 368 Net investment gains (losses) — — — — 190 190 Net derivative gains (losses) — — — — 84 84 Total revenues 7,431 2,516 105 10,052 142 10,194 Expenses Policyholder benefits and claims and policyholder dividends 5,317 1,349 — 6,666 116 6,782 Interest credited to policyholder account balances 346 166 — 512 — 512 Capitalization of DAC (15) 1 (2) (16) — (16) Amortization of DAC and VOBA 25 63 — 88 11 99 Interest expense on debt 2 2 20 24 — 24 Other expenses 768 207 742 1,717 1 1,718 Total expenses 6,443 1,788 760 8,991 128 9,119 Provision for income tax expense (benefit) 207 148 (204) 151 2 153 Adjusted earnings $ 781 $ 580 $ (451) 910 Adjustments to: Total revenues 142 Total expenses (128) Provision for income tax (expense) benefit (2) Net income (loss) $ 922 $ 922 Nine Months Ended September 30, 2022 U.S. MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 23,492 $ 1,855 $ — $ 25,347 $ — $ 25,347 Universal life and investment-type product policy fees 840 626 — 1,466 57 1,523 Net investment income 4,588 3,416 (76) 7,928 (400) 7,528 Other revenues 819 106 361 1,286 — 1,286 Net investment gains (losses) — — — — (391) (391) Net derivative gains (losses) — — — — 980 980 Total revenues 29,739 6,003 285 36,027 246 36,273 Expenses Policyholder benefits and claims and policyholder dividends 23,646 3,911 — 27,557 (450) 27,107 Interest credited to policyholder account balances 1,138 482 25 1,645 — 1,645 Capitalization of DAC (56) 1 (65) (120) — (120) Amortization of DAC and VOBA 40 95 2 137 (82) 55 Interest expense on debt 6 5 65 76 — 76 Other expenses 2,567 590 963 4,120 5 4,125 Total expenses 27,341 5,084 990 33,415 (527) 32,888 Provision for income tax expense (benefit) 499 181 (305) 375 164 539 Adjusted earnings $ 1,899 $ 738 $ (400) 2,237 Adjustments to: Total revenues 246 Total expenses 527 Provision for income tax (expense) benefit (164) Net income (loss) $ 2,846 $ 2,846 Nine Months Ended September 30, 2021 U.S. MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 15,955 $ 2,016 $ — $ 17,971 $ — $ 17,971 Universal life and investment-type product policy fees 828 668 — 1,496 59 1,555 Net investment income 5,540 4,478 (22) 9,996 (444) 9,552 Other revenues 663 177 385 1,225 — 1,225 Net investment gains (losses) — — — — 692 692 Net derivative gains (losses) — — — — (906) (906) Total revenues 22,986 7,339 363 30,688 (599) 30,089 Expenses Policyholder benefits and claims and policyholder dividends 16,685 3,932 — 20,617 278 20,895 Interest credited to policyholder account balances 1,037 500 — 1,537 (2) 1,535 Capitalization of DAC (44) 1 (2) (45) — (45) Amortization of DAC and VOBA 47 132 — 179 (8) 171 Interest expense on debt 5 4 63 72 — 72 Other expenses 2,377 638 1,010 4,025 (7) 4,018 Total expenses 20,107 5,207 1,071 26,385 261 26,646 Provision for income tax expense (benefit) 600 433 (353) 680 (170) 510 Adjusted earnings $ 2,279 $ 1,699 $ (355) 3,623 Adjustments to: Total revenues (599) Total expenses (261) Provision for income tax (expense) benefit 170 Net income (loss) $ 2,933 $ 2,933 The following table presents total assets with respect to the Company’s segments, as well as Corporate & Other, at: September 30, 2022 December 31, 2021 (In millions) U.S. $ 222,531 $ 256,381 MetLife Holdings 133,791 161,614 Corporate & Other 30,526 28,562 Total $ 386,848 $ 446,557 |
Insurance (Tables)
Insurance (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Insurance [Abstract] | |
Guarantees related to Annuity, Universal and Variable Life Contracts | Information regarding the Company’s guarantee exposure, which includes direct business, but excludes offsets from hedging or reinsurance, if any, was as follows at: September 30, 2022 December 31, 2021 In the Event of Death At Annuitization In the Event of Death At Annuitization (Dollars in millions) Annuity Contracts: Variable Annuity Guarantees: Total account value (1), (2) $ 36,100 $ 14,185 $ 48,868 $ 20,140 Separate account value (1) $ 27,465 $ 13,427 $ 39,882 $ 19,347 Net amount at risk $ 5,139 (3) $ 638 (4) $ 1,160 (3) $ 461 (4) Average attained age of contractholders 69 years 69 years 69 years 66 years Other Annuity Guarantees: Total account value (1), (2) N/A $ 135 N/A $ 135 Net amount at risk N/A $ 66 (5) N/A $ 70 (5) Average attained age of contractholders N/A 56 years N/A 55 years September 30, 2022 December 31, 2021 Secondary Guarantees Paid-Up Guarantees Secondary Guarantees Paid-Up Guarantees (Dollars in millions) Universal and Variable Life Contracts: Total account value (1), (2) $ 4,622 $ 798 $ 5,935 $ 826 Net amount at risk (6) $ 37,546 $ 4,929 $ 37,482 $ 5,181 Average attained age of policyholders 59 years 66 years 59 years 65 years __________________ (1) The Company’s annuity and life contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed above may not be mutually exclusive. (2) Includes the contractholders’ investments in the general account and separate account, if applicable. (3) Defined as the death benefit less the total account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date and includes any additional contractual claims associated with riders purchased to assist with covering income taxes payable upon death. (4) Defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. This amount represents the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date, even though the contracts contain terms that allow annuitization of the guaranteed amount only after the 10th anniversary of the contract, which not all contractholders have achieved. (5) Defined as either the excess of the upper tier, adjusted for a profit margin, less the lower tier, as of the balance sheet date or the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. These amounts represent the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date. (6) Defined as the guarantee amount less the account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date. |
Liabilities for Unpaid Claims and Claim Expenses | Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows: Nine Months 2022 2021 (In millions) Balance, beginning of period $ 15,059 $ 13,523 Less: Reinsurance recoverables 2,263 1,639 Net balance, beginning of period 12,796 11,884 Incurred related to: Current period 15,527 15,300 Prior periods (1) 378 511 Total incurred 15,905 15,811 Paid related to: Current period (10,018) (10,249) Prior periods (5,226) (4,785) Total paid (15,244) (15,034) Net balance, end of period 13,457 12,661 Add: Reinsurance recoverables 2,044 2,099 Balance, end of period (included in future policy benefits and other policy-related balances) $ 15,501 $ 14,760 __________________ (1) The nine months ended September 30, 2022 and 2021 include incurred claim activity and claim adjustment expenses associated with prior periods but reported in the respective current period, which contain impacts related to the COVID-19 pandemic, partially offset by additional premiums recorded for experience-rated contracts that are not reflected in the table above. |
Closed Block (Tables)
Closed Block (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Closed Block Disclosure [Abstract] | |
Closed block liabilities and assets | Information regarding the closed block liabilities and assets designated to the closed block was as follows at: September 30, 2022 December 31, 2021 (In millions) Closed Block Liabilities Future policy benefits $ 37,385 $ 38,046 Other policy-related balances 257 290 Policyholder dividends payable 219 253 Policyholder dividend obligation — 1,682 Deferred income tax liability — 210 Other liabilities 444 263 Total closed block liabilities 38,305 40,744 Assets Designated to the Closed Block Investments: Fixed maturity securities available-for-sale, at estimated fair value 19,515 25,669 Mortgage loans 6,624 6,417 Policy loans 4,096 4,191 Real estate and real estate joint ventures 604 565 Other invested assets 924 556 Total investments 31,763 37,398 Cash and cash equivalents 344 126 Accrued investment income 386 384 Premiums, reinsurance and other receivables 38 50 Current income tax recoverable 82 81 Deferred income tax asset 460 — Total assets designated to the closed block 33,073 38,039 Excess of closed block liabilities over assets designated to the closed block 5,232 2,705 AOCI: Unrealized investment gains (losses), net of income tax (1,609) 2,562 Unrealized gains (losses) on derivatives, net of income tax 408 107 Allocated to policyholder dividend obligation, net of income tax — (1,329) Total amounts included in AOCI (1,201) 1,340 Maximum future earnings to be recognized from closed block assets and liabilities $ 4,031 $ 4,045 |
Closed block policyholder dividend obligation | Information regarding the closed block policyholder dividend obligation was as follows: Nine Months Year (In millions) Balance, beginning of period $ 1,682 $ 2,969 Change in unrealized investment and derivative gains (losses) (1,682) (1,287) Balance, end of period $ — $ 1,682 |
Closed block revenues and expenses | Information regarding the closed block revenues and expenses was as follows: Three Months Nine Months 2022 2021 2022 2021 (In millions) Revenues Premiums $ 267 $ 310 $ 816 $ 955 Net investment income 326 390 1,039 1,165 Net investment gains (losses) (4) (7) (52) (12) Net derivative gains (losses) 28 12 39 19 Total revenues 617 705 1,842 2,127 Expenses Policyholder benefits and claims 459 522 1,404 1,588 Policyholder dividends 91 127 352 478 Other expenses 22 24 68 73 Total expenses 572 673 1,824 2,139 Revenues, net of expenses before provision for income tax expense (benefit) 45 32 18 (12) Provision for income tax expense (benefit) 10 6 4 (3) Revenues, net of expenses and provision for income tax expense (benefit) $ 35 $ 26 $ 14 $ (9) |
Investments (Tables)
Investments (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Fixed Maturity Securities Available-for-Sale by Sector | The following table presents fixed maturity securities available-for-sale (“AFS”) by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. Residential mortgage-backed securities (“RMBS”) includes agency, prime, alternative and sub-prime mortgage-backed securities. Asset-backed securities and collateralized loan obligations (“ABS & CLO”), previously disclosed as ABS in the 2021 Annual Report, includes securities collateralized by consumer loans, corporate loans and broadly syndicated bank loans. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.” September 30, 2022 December 31, 2021 Amortized Gross Unrealized Estimated Amortized Gross Unrealized Estimated Sector Allowance for Gains Losses Allowance for Gains Losses (In millions) U.S. corporate $ 55,430 $ (30) $ 432 $ 5,729 $ 50,103 $ 51,328 $ (30) $ 7,257 $ 153 $ 58,402 U.S. government and agency 23,718 — 531 2,209 22,040 26,782 — 4,568 128 31,222 Foreign corporate 28,681 (3) 113 5,929 22,862 27,475 (10) 2,651 431 29,685 RMBS 22,297 — 207 2,414 20,090 22,082 — 1,198 135 23,145 ABS & CLO 12,450 — 11 889 11,572 12,787 — 127 35 12,879 Municipals 7,741 — 217 720 7,238 6,884 — 1,849 5 8,728 CMBS 6,532 (15) 3 582 5,938 6,686 (13) 237 32 6,878 Foreign government 3,965 (69) 136 461 3,571 4,330 — 698 82 4,946 Total fixed maturity securities AFS $ 160,814 $ (117) $ 1,650 $ 18,933 $ 143,414 $ 158,354 $ (53) $ 18,585 $ 1,001 $ 175,885 |
Available-for-sale fixed maturity securities by contractual maturity date | The amortized cost, net of allowance for credit loss (“ACL”), and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at September 30, 2022: Due in One Due After Due After Due After Structured Total Fixed (In millions) Amortized cost, net of ACL $ 3,091 $ 26,418 $ 28,564 $ 61,360 $ 41,264 $ 160,697 Estimated fair value $ 2,878 $ 24,706 $ 25,593 $ 52,637 $ 37,600 $ 143,414 |
Continuous Gross Unrealized Losses for Fixed Maturity Securities Available for Sale | The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position. September 30, 2022 December 31, 2021 Less than 12 Months Equal to or Greater Less than 12 Months Equal to or Greater Sector & Credit Quality Estimated Gross Estimated Gross Estimated Gross Estimated Gross (Dollars in millions) U.S. corporate $ 37,447 $ 5,166 $ 2,031 $ 563 $ 4,503 $ 83 $ 784 $ 70 U.S. government and agency 13,035 1,846 1,560 363 10,063 78 523 49 Foreign corporate 18,150 4,744 2,774 1,185 4,079 199 1,348 232 RMBS 14,946 1,800 2,393 614 7,481 111 314 24 ABS & CLO 9,520 741 1,367 148 5,643 25 593 10 Municipals 3,980 701 49 19 154 4 17 1 CMBS 4,955 460 793 121 1,613 20 355 12 Foreign government 2,005 346 232 114 497 37 148 45 Total fixed maturity securities AFS $ 104,038 $ 15,804 $ 11,199 $ 3,127 $ 34,033 $ 557 $ 4,082 $ 443 Investment grade $ 97,820 $ 14,938 $ 9,742 $ 2,686 $ 31,419 $ 454 $ 3,273 $ 353 Below investment grade 6,218 866 1,457 441 2,614 103 809 90 Total fixed maturity securities AFS $ 104,038 $ 15,804 $ 11,199 $ 3,127 $ 34,033 $ 557 $ 4,082 $ 443 Total number of securities in an 12,614 1,284 2,549 427 |
Debt Securities, Available-for-sale, Allowance for Credit Loss | The rollforward of ACL for fixed maturity securities AFS by sector is as follows: U.S. Foreign Corporate CMBS Foreign Total Three Months Ended September 30, 2022 (In millions) Balance, at beginning of period $ 27 $ 7 $ 13 $ 77 $ 124 Additions: ACL not previously recorded — 1 2 — 3 Reductions: Changes for securities with previously recorded ACL 3 — — (8) (5) Securities sold or exchanged — (5) — — (5) Write-offs — — — — — Balance, at end of period $ 30 $ 3 $ 15 $ 69 $ 117 Three Months Ended September 30, 2021 Balance, at beginning of period $ 39 $ 14 $ 6 $ — $ 59 Additions: ACL not previously recorded 18 — — — 18 Reductions: Changes for securities with previously recorded ACL — (2) 1 — (1) Securities sold or exchanged (26) (2) — — (28) Write-offs (13) — — — (13) Balance, at end of period $ 18 $ 10 $ 7 $ — $ 35 U.S. Foreign Corporate CMBS Foreign Total Nine Months Ended September 30, 2022 (In millions) Balance, at beginning of period $ 30 $ 10 $ 13 $ — $ 53 Additions: ACL not previously recorded 13 12 2 104 131 Changes for securities with previously recorded ACL 17 3 — (15) 5 Reductions: Securities sold or exchanged (8) (22) — (20) (50) Write-offs (22) — — — (22) Balance, at end of period $ 30 $ 3 $ 15 $ 69 $ 117 Nine Months Ended September 30, 2021 Balance, at beginning of period $ 43 $ 8 $ — $ — $ 51 Additions: ACL not previously recorded 18 12 9 — 39 Reductions: Changes for securities with previously recorded ACL 3 (5) (2) — (4) Securities sold or exchanged (33) (5) — — (38) Write-offs (13) — — — (13) Balance, at end of period $ 18 $ 10 $ 7 $ — $ 35 |
Disclosure of Mortgage Loans Net of Valuation Allowance | Mortgage loans are summarized as follows at: September 30, 2022 December 31, 2021 Portfolio Segment Carrying % of Carrying % of (Dollars in millions) Commercial $ 37,038 60.1 % $ 35,772 59.4 % Agricultural 15,668 25.4 15,450 25.7 Residential 9,289 15.1 9,406 15.6 Total amortized cost 61,995 100.6 60,628 100.7 Allowance for credit loss (392) (0.6) (536) (0.9) Subtotal mortgage loans, net 61,603 100.0 60,092 99.8 Residential — FVO — — 127 0.2 Total mortgage loans held-for-investment, net 61,603 100.0 60,219 100.0 Total mortgage loans, net $ 61,603 100.0 % $ 60,219 100.0 % |
Allowance for Loan and Lease Losses, Provision for Loss, Net | The rollforward of ACL for mortgage loans, by portfolio segment, is as follows: Nine Months Ended September 30, 2022 2021 Commercial Agricultural Residential Total Commercial Agricultural Residential Total (In millions) Balance, beginning of period $ 260 $ 79 $ 197 $ 536 $ 199 $ 97 $ 221 $ 517 Provision (release) (8) 48 (77) (37) 18 1 (34) (15) Initial credit losses on PCD loans (1) — — — — — — 3 3 Charge-offs, net of recoveries (83) (22) (2) (107) — (13) (2) (15) Balance, end of period $ 169 $ 105 $ 118 $ 392 $ 217 $ 85 $ 188 $ 490 ________________ (1) Represents the initial credit losses on purchased mortgage loans accounted for as purchased financial assets with credit deterioration (“PCD”). |
Disclosure of the mortgage loans portfolio segment by the recorded investment, prior to valuation allowances, by credit quality indicator categories | The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2022: Credit Quality Indicator 2022 2021 2020 2019 2018 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 2,872 $ 3,309 $ 2,285 $ 3,347 $ 3,551 $ 10,813 $ 2,756 $ 28,933 78.1 % 65% to 75% 1,412 903 612 996 769 1,418 — 6,110 16.5 76% to 80% — — 18 252 223 204 — 697 1.9 Greater than 80% 142 39 — 43 90 984 — 1,298 3.5 Total $ 4,426 $ 4,251 $ 2,915 $ 4,638 $ 4,633 $ 13,419 $ 2,756 $ 37,038 100.0 % DSCR: > 1.20x $ 4,108 $ 3,819 $ 2,709 $ 4,502 $ 4,156 $ 11,526 $ 2,756 $ 33,576 90.6 % 1.00x - 1.20x 285 235 18 9 152 803 — 1,502 4.1 <1.00x 33 197 188 127 325 1,090 — 1,960 5.3 Total $ 4,426 $ 4,251 $ 2,915 $ 4,638 $ 4,633 $ 13,419 $ 2,756 $ 37,038 100.0 % The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2022: Credit Quality Indicator 2022 2021 2020 2019 2018 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 1,603 $ 1,474 $ 1,928 $ 1,516 $ 2,103 $ 4,331 $ 1,133 $ 14,088 89.9 % 65% to 75% 144 228 296 180 51 491 40 1,430 9.1 76% to 80% — — — — — 12 — 12 0.1 Greater than 80% — — 14 76 — 44 4 138 0.9 Total $ 1,747 $ 1,702 $ 2,238 $ 1,772 $ 2,154 $ 4,878 $ 1,177 $ 15,668 100.0 % The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2022: Credit Quality Indicator 2022 2021 2020 2019 2018 Prior Revolving Total % of (Dollars in millions) Performance indicators: Performing $ 740 $ 703 $ 158 $ 619 $ 341 $ 6,282 $ — $ 8,843 95.2 % Nonperforming (1) 2 3 4 37 12 388 — 446 4.8 Total $ 742 $ 706 $ 162 $ 656 $ 353 $ 6,670 $ — $ 9,289 100.0 % __________________ (1) Includes residential mortgage loans in process of foreclosure of $142 million and $69 million at September 30, 2022 and December 31, 2021, respectively. |
Schedule of Past Due and Non Accrual Mortgage Loans | The past due and nonaccrual mortgage loans at amortized cost, prior to ACL, by portfolio segment, were as follows: Past Due Greater than 90 Days Past Due Nonaccrual Portfolio Segment September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 (In millions) Commercial $ — $ — $ — $ — $ 142 $ 146 Agricultural 115 124 27 16 207 225 Residential 446 418 2 — 449 418 Total $ 561 $ 542 $ 29 $ 16 $ 798 $ 789 |
Disclosure Real Estate and Real Estate Joint Ventures | Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated: September 30, 2022 December 31, 2021 Three Months Nine Months 2022 2021 2022 2021 Income Type Carrying Value Income (In millions) Wholly-owned real estate: Leased real estate $ 1,763 $ 1,934 $ 47 $ 53 $ 151 $ 160 Other real estate 478 473 88 53 184 133 Real estate joint ventures 5,977 5,466 49 70 281 107 Total real estate and real estate joint ventures $ 8,218 $ 7,873 $ 184 $ 176 $ 616 $ 400 |
Debt Securities, Trading, and Equity Securities, FV-NI | The following table presents FVO Securities and equity securities by security type. Common stock includes common stock and mutual funds. September 30, 2022 December 31, 2021 Cost Net Unrealized Gains (Losses) (1) Estimated Fair Value Cost Net Unrealized Gains (Losses) (1) Estimated Fair Value Security Type (In millions) FVO Securities $ 704 $ 111 $ 815 $ 598 $ 250 $ 848 Equity securities Common stock $ 83 $ 42 $ 125 $ 88 $ 32 $ 120 Non-redeemable preferred stock 122 (7) 115 107 (1) 106 Total equity securities $ 205 $ 35 $ 240 $ 195 $ 31 $ 226 __________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in other comprehensive income (loss) (“OCI”). |
Components of net unrealized investment gains (losses) included in accumulated other comprehensive income (loss) | The components of net unrealized investment gains (losses), included in AOCI, were as follows: September 30, 2022 December 31, 2021 (In millions) Fixed maturity securities AFS $ (17,233) $ 17,586 Derivatives 3,181 2,370 Other 420 377 Subtotal (13,632) 20,333 Amounts allocated from: Policyholder liabilities 55 (5,962) DAC, VOBA and DSI 1,403 (1,357) Subtotal 1,458 (7,319) Deferred income tax benefit (expense) 2,645 (2,657) Net unrealized investment gains (losses) $ (9,529) $ 10,357 The changes in net unrealized investment gains (losses) were as follows: Nine Months (In millions) Balance, beginning of period $ 10,357 Unrealized investment gains (losses) during the period (33,965) Unrealized investment gains (losses) relating to: Policyholder liabilities 6,017 DAC, VOBA and DSI 2,760 Deferred income tax benefit (expense) 5,302 Balance, end of period $ (9,529) Change in net unrealized investment gains (losses) $ (19,886) |
Securities Lending and Repurchase Agreements | A summary of these transactions and agreements accounted for as secured borrowings was as follows: September 30, 2022 December 31, 2021 Securities (1) Securities (1) Agreement Type Estimated Fair Value Cash Collateral Received from Counterparties (2) Reinvestment Portfolio at Estimated Estimated Fair Value Cash Collateral Received from Counterparties (2) Reinvestment Portfolio at Estimated (In millions) Securities lending $ 7,894 $ 8,095 $ 7,882 $ 14,689 $ 14,977 $ 15,116 Repurchase agreements $ 3,160 $ 3,125 $ 3,043 $ 3,416 $ 3,325 $ 3,357 __________________ (1) These securities were included within fixed maturity securities AFS and short-term investments at September 30, 2022 and within fixed maturity securities AFS at December 31, 2021. (2) The liability for cash collateral is included within payables for collateral under securities loaned and other transactions. Contractual maturities of these transactions and agreements accounted for as secured borrowings were as follows: September 30, 2022 December 31, 2021 Remaining Maturities Remaining Maturities Security Type Open (1) 1 Month Over 1 Over 6 Total Open (1) 1 Month Over 1 Over 6 Months to 1 Year Total (In millions) Cash collateral liability by security type: Securities lending: U.S. government and agency $ 927 $ 4,393 $ 2,775 $ — $ 8,095 $ 3,996 $ 5,279 $ 5,702 $ — $ 14,977 Repurchase agreements: U.S. government and agency $ — $ 3,125 $ — $ — $ 3,125 $ — $ 3,325 $ — $ — $ 3,325 __________________ (1) The related security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral. |
Invested Assets on Deposit and Pledged as Collateral | Invested assets on deposit and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value and were as follows at: September 30, 2022 December 31, 2021 (In millions) Invested assets on deposit (regulatory deposits) $ 97 $ 118 Invested assets pledged as collateral (1) 21,519 20,390 Total invested assets on deposit and pledged as collateral $ 21,616 $ 20,508 __________________ (1) The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements, secured debt (see Notes 3 and 11 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report) and derivative transactions (see Note 6). |
Schedule of Variable Interest Entities | The following table presents the total assets and total liabilities relating to investment related VIEs for which the Company has concluded that it is the primary beneficiary and which are consolidated at: September 30, 2022 December 31, 2021 Asset Type Total Total Total Total (In millions) Real estate joint ventures (1) $ 1,017 $ — $ 1,094 $ — Investment funds (primarily mortgage loans) (2) 151 — 226 — Other (primarily other invested assets) 98 — 101 — Renewable energy partnership (primarily other invested assets) 78 — 79 — Total $ 1,344 $ — $ 1,500 $ — __________________ (1) The Company’s investment in affiliated real estate joint ventures was $907 million and $1.0 billion at September 30, 2022 and December 31, 2021, respectively. Other affiliates’ investments in these affiliated real estate joint ventures were $110 million and $112 million at September 30, 2022 and December 31, 2021, respectively. (2) The Company’s investment in affiliated investment funds was $124 million and $187 million at September 30, 2022 and December 31, 2021, respectively. Other affiliates’ investments in these affiliated investment funds were $27 million and $39 million at September 30, 2022 and December 31, 2021, respectively. Unconsolidated VIEs The carrying amount and maximum exposure to loss relating to VIEs in which the Company holds a significant variable interest but is not the primary beneficiary and which have not been consolidated were as follows at: September 30, 2022 December 31, 2021 Asset Type Carrying Maximum Carrying Maximum (In millions) Fixed maturity securities AFS (2) $ 35,907 $ 35,907 $ 43,653 $ 43,653 Other limited partnership interests 7,410 9,871 8,005 11,057 Other invested assets 1,368 1,589 1,605 1,815 Real estate joint ventures 211 213 97 100 Total $ 44,896 $ 47,580 $ 53,360 $ 56,625 __________________ (1) The maximum exposure to loss relating to fixed maturity securities AFS is equal to their carrying amounts or the carrying amounts of retained interests. The maximum exposure to loss relating to other limited partnership interests and real estate joint ventures is equal to the carrying amounts plus any unfunded commitments. For certain of its investments in other invested assets, the Company’s return is in the form of income tax credits which are guaranteed by creditworthy third parties. For such investments, the maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments, reduced by income tax credits guaranteed by third parties of $6 million and $5 million at September 30, 2022 and December 31, 2021, respectively. Such a maximum loss would be expected to occur only upon bankruptcy of the issuer or investee. (2) For variable interests in Structured Products included within fixed maturity securities AFS, the Company’s involvement is limited to that of a passive investor in mortgage-backed or asset-backed securities issued by trusts that do not have substantial equity. |
Components of Net Investment Income | The composition of net investment income by asset type was as follows: Three Months Nine Months Asset Type 2022 2021 2022 2021 (In millions) Fixed maturity securities AFS $ 1,627 $ 1,520 $ 4,671 $ 4,574 Equity securities 7 2 9 14 Mortgage loans 654 643 1,872 2,015 Policy loans 72 72 216 221 Real estate and real estate joint ventures 184 176 616 400 Other limited partnership interests (153) 992 444 2,569 Cash, cash equivalents and short-term investments 44 2 59 7 FVO Securities (40) 4 (182) 65 Operating joint venture 9 12 51 45 Other 101 73 355 118 Subtotal investment income 2,505 3,496 8,111 10,028 Less: Investment expenses 245 165 583 476 Net investment income $ 2,260 $ 3,331 $ 7,528 $ 9,552 |
Components of Net Investment Gains (Losses) | The composition of net investment gains (losses) by asset type and transaction type was as follows: Three Months Nine Months Asset Type 2022 2021 2022 2021 (In millions) Fixed maturity securities AFS $ (167) $ 43 $ (825) $ 14 Equity securities (1) (11) 3 34 Mortgage loans 15 5 25 21 Real estate and real estate joint ventures (excluding changes in estimated fair value) — 132 163 548 Other limited partnership interests (excluding changes in estimated fair value) (1) — 4 (14) Other gains (losses) (16) 17 50 65 Subtotal (170) 186 (580) 668 Change in estimated fair value of other limited partnership interests and real estate joint ventures (19) 9 (13) 23 Non-investment portfolio gains (losses) 107 (5) 202 1 Subtotal 88 4 189 24 Net investment gains (losses) $ (82) $ 190 $ (391) $ 692 Transaction Type Realized gains (losses) on investments sold or disposed $ (199) $ 154 $ (530) $ 568 Impairments (4) (11) (37) (24) Recognized gains (losses): Change in allowance for credit loss recognized in earnings 34 31 (17) 31 Unrealized net gains (losses) recognized in earnings (20) 21 (9) 116 Total recognized gains (losses) 14 52 (26) 147 Non-investment portfolio gains (losses) 107 (5) 202 1 Net investment gains (losses) $ (82) $ 190 $ (391) $ 692 |
Schedule of Realized Gain (Loss) | The composition of net investment gains (losses) for these securities is as follows: Three Months Nine Months Fixed Maturity Securities AFS 2022 2021 2022 2021 (In millions) Proceeds $ 11,337 $ 7,279 $ 31,325 $ 19,123 Gross investment gains $ 88 $ 91 $ 158 $ 199 Gross investment (losses) (259) (62) (882) (178) Realized gains (losses) on sales and disposals (171) 29 (724) 21 Net credit loss (provision) release (change in ACL recognized in earnings) 8 24 (64) 16 Impairment (loss) (4) (10) (37) (23) Net credit loss (provision) release and impairment (loss) 4 14 (101) (7) Net investment gains (losses) $ (167) $ 43 $ (825) $ 14 Equity Securities Realized gains (losses) on sales and disposals $ 2 $ (21) $ (2) $ (54) Unrealized net gains (losses) recognized in earnings (3) 10 5 88 Net investment gains (losses) $ (1) $ (11) $ 3 $ 34 |
Schedule of Related Party Transactions | The Company transfers invested assets primarily consisting of fixed maturity securities AFS, mortgage loans and real estate and real estate joint ventures to and from affiliates. Invested assets transferred were as follows: Three Months Nine Months 2022 2021 2022 2021 (In millions) Estimated fair value of invested assets transferred to affiliates $ 139 $ 393 $ 328 $ 696 Amortized cost of invested assets transferred to affiliates $ 136 $ 379 $ 327 $ 679 Net investment gains (losses) recognized on transfers $ 3 $ 14 $ 1 $ 17 Estimated fair value of invested assets transferred from affiliates $ 130 $ 584 $ 332 $ 1,228 Estimated fair value of derivative liabilities transferred from affiliates $ — $ — $ 64 $ — Recurring related party investments and related net investment income were as follows at and for the periods ended: September 30, 2022 December 31, 2021 Three Months Nine Months 2022 2021 2022 2021 Investment Type/ Related Party Carrying Value Net Investment Income (In millions) Affiliated investments (1) MetLife, Inc. $ 1,100 $ 1,399 $ 5 $ 8 $ 15 $ 24 Affiliated investments (2) American Life Insurance Company 100 100 — — 1 1 Other invested assets $ 1,200 $ 1,499 $ 5 $ 8 $ 16 $ 25 ________________ (1) Represents an investment in affiliated senior unsecured notes which have maturity dates from July 2023 to December 2031 and bear interest, payable semi-annually, at rates per annum ranging from 1.60% to 1.85%. See Note 7 of the Notes to the Consolidated Financial Statements included in the 2021 Annual Report for further information. (2) Represents an affiliated surplus note which matures in June 2025 and bears interest, payable semi-annually, at a rate per annum of 1.88%. |
Derivatives (Tables)
Derivatives (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Primary Risks Managed by Derivatives | The following table presents the primary underlying risk exposure, gross notional amount, and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at: September 30, 2022 December 31, 2021 Primary Underlying Risk Exposure Gross Notional Amount Estimated Fair Value Gross Notional Amount Estimated Fair Value Assets Liabilities Assets Liabilities (In millions) Derivatives Designated as Hedging Instruments: Fair value hedges: Interest rate swaps Interest rate $ 4,115 $ 1,435 $ 425 $ 3,540 $ 2,163 $ 6 Foreign currency swaps Foreign currency exchange rate 593 123 — 764 8 22 Subtotal 4,708 1,558 425 4,304 2,171 28 Cash flow hedges: Interest rate swaps Interest rate 3,740 6 19 4,079 4 1 Interest rate forwards Interest rate 2,783 — 448 3,058 69 1 Foreign currency swaps Foreign currency exchange rate 27,786 3,319 2,126 28,772 1,317 966 Subtotal 34,309 3,325 2,593 35,909 1,390 968 Total qualifying hedges 39,017 4,883 3,018 40,213 3,561 996 Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate swaps Interest rate 17,596 1,670 685 21,565 3,206 59 Interest rate floors Interest rate 16,170 58 — 7,701 145 — Interest rate caps Interest rate 63,659 1,012 — 64,309 117 — Interest rate futures Interest rate 418 — 2 515 — — Interest rate options Interest rate 20,367 601 — 9,703 364 — Interest rate forwards Interest rate 265 — 102 265 — 20 Interest rate total return swaps Interest rate 1,048 — 99 1,048 9 4 Synthetic GICs Interest rate 11,808 — — 11,307 — — Foreign currency swaps Foreign currency exchange rate 6,336 1,318 — 4,800 340 75 Foreign currency forwards Foreign currency exchange rate 1,222 27 8 1,902 11 13 Credit default swaps — purchased Credit 902 29 — 956 12 8 Credit default swaps — written Credit 10,569 73 77 6,074 111 12 Equity futures Equity market 1,155 14 1 1,751 5 — Equity index options Equity market 20,799 901 144 26,800 714 166 Equity variance swaps Equity market 425 12 10 425 12 10 Equity total return swaps Equity market 2,108 178 — 2,148 11 46 Total non-designated or nonqualifying derivatives 174,847 5,893 1,128 161,269 5,057 413 Total $ 213,864 $ 10,776 $ 4,146 $ 201,482 $ 8,618 $ 1,409 |
The Effects of Derivatives on the Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) | The following table presents the interim condensed consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, nonqualifying hedging relationships and embedded derivatives Three Months Ended September 30, 2022 Net Net Net Policyholder Interest Credited to Policyholder Account Balances OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 2 $ — $ — $ (292) $ (16) N/A Hedged items — — — 264 15 N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 64 — — — — N/A Hedged items (65) — — — — N/A Subtotal 1 — — (28) (1) N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (324) Amount of gains (losses) reclassified from AOCI into income 15 (16) — — — 1 Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 608 Amount of gains (losses) reclassified from AOCI into income 1 (485) — — — 484 Foreign currency transaction gains (losses) on hedged items — 485 — — — — Subtotal 16 (16) — — — 769 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — — (395) — — N/A Foreign currency exchange rate derivatives (1) — — 476 — — N/A Credit derivatives — purchased (1) — — 4 — — N/A Credit derivatives — written (1) — — 1 — — N/A Equity derivatives (1) 8 — 163 62 — N/A Foreign currency transaction gains (losses) on hedged items — — (189) — — N/A Subtotal 8 — 60 62 — N/A Earned income on derivatives 100 — 144 33 (41) — Embedded derivatives (2) N/A N/A 250 — N/A N/A Total $ 125 $ (16) $ 454 $ 67 $ (42) $ 769 Three Months Ended September 30, 2021 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to Policyholder Account Balances OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 1 $ — $ — $ (53) $ — N/A Hedged items (2) — — 48 — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 28 — — — — N/A Hedged items (22) — — — — N/A Subtotal 5 — — (5) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ 27 Amount of gains (losses) reclassified from AOCI into income 14 8 — — — (22) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 201 Amount of gains (losses) reclassified from AOCI into income 2 (257) — — — 255 Foreign currency transaction gains (losses) on hedged items — 254 — — — — Subtotal 16 5 — — — 461 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) (1) — (276) — — N/A Foreign currency exchange rate derivatives (1) — — 181 — — N/A Credit derivatives — purchased (1) — — 2 — — N/A Credit derivatives — written (1) — — (1) — — N/A Equity derivatives (1) — — 34 8 — N/A Foreign currency transaction gains (losses) on hedged items — — (50) — — N/A Subtotal (1) — (110) 8 — N/A Earned income on derivatives 63 — 165 53 (43) — Embedded derivatives (2) N/A N/A 29 — N/A N/A Total $ 83 $ 5 $ 84 $ 56 $ (43) $ 461 Nine Months Ended September 30, 2022 Net Net Net Policyholder Interest Credited to Policyholder Account Balances OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 8 $ — $ — $ (1,137) $ (26) N/A Hedged items (8) — — 1,072 24 N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 154 — — — — N/A Hedged items (152) — — — — N/A Subtotal 2 — — (65) (2) N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (1,434) Amount of gains (losses) reclassified from AOCI into income 46 55 — — — (101) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 1,232 Amount of gains (losses) reclassified from AOCI into income 3 (1,117) — — — 1,114 Foreign currency transaction gains (losses) on hedged items — 1,104 — — — — Subtotal 49 42 — — — 811 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) 3 — (1,998) — — N/A Foreign currency exchange rate derivatives (1) 2 — 985 — — N/A Credit derivatives — purchased (1) — — 62 — — N/A Credit derivatives — written (1) — — (189) — — N/A Equity derivatives (1) 37 — 724 320 — N/A Foreign currency transaction gains (losses) on hedged items — — (431) — — N/A Subtotal 42 — (847) 320 — N/A Earned income on derivatives 325 — 403 130 (113) — Embedded derivatives (2) N/A N/A 1,424 — N/A N/A Total $ 418 $ 42 $ 980 $ 385 $ (115) $ 811 Nine Months Ended September 30, 2021 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to Policyholder Account Balances OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ 4 $ — $ — $ (418) $ — N/A Hedged items (4) — — 379 — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 39 — — — — N/A Hedged items (32) — — — — N/A Subtotal 7 — — (39) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (676) Amount of gains (losses) reclassified from AOCI into income 41 56 — — — (97) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 503 Amount of gains (losses) reclassified from AOCI into income 4 (265) — — — 261 Foreign currency transaction gains (losses) on hedged items — 258 — — — — Subtotal 45 49 — — — (9) Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) 1 — (1,463) — — N/A Foreign currency exchange rate derivatives (1) — — 224 — — N/A Credit derivatives — purchased (1) — — 6 — — N/A Credit derivatives — written (1) — — 20 — — N/A Equity derivatives (1) (2) — (793) (174) — N/A Foreign currency transaction gains (losses) on hedged items — — (62) — — N/A Subtotal (1) — (2,068) (174) — N/A Earned income on derivatives 141 — 499 155 (120) — Embedded derivatives (2) N/A N/A 663 — N/A N/A Total $ 192 $ 49 $ (906) $ (58) $ (120) $ (9) __________________ (1) Excludes earned income on derivatives. (2) The valuation of guaranteed minimum benefits includes a nonperformance risk adjustment. The amounts included in net derivative gains (losses) in connection with this adjustment w ere $42 million and $41 million for the three months and nine months ended September 30, 2022, respectively, and $5 million and ($10) million for the three months and nine months ended September 30, 2021, respectively. |
Fair Value Hedges | The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges: Balance Sheet Line Item Carrying Amount of the Cumulative Amount September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 (In millions) Fixed maturity securities AFS $ 300 $ 366 $ 1 $ (1) Mortgage loans $ 276 $ 617 $ (20) $ 3 Future policy benefits $ (3,626) $ (4,735) $ 215 $ (877) Policyholder account balances $ (1,074) $ — $ 24 $ — __________________ (1) Includes ($142) million and ($161) million of hedging adjustments on discontinued hedging relationships at September 30, 2022 and December 31, 2021, respectively. |
Schedule of estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps | The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at: September 30, 2022 December 31, 2021 Rating Agency Designation of Referenced Estimated Maximum Weighted Estimated Maximum Weighted (Dollars in millions) Aaa/Aa/A Single name credit default swaps (3) $ — $ 10 1.7 $ — $ 10 2.5 Credit default swaps referencing indices 51 4,404 3.5 17 1,191 2.5 Subtotal 51 4,414 3.5 17 1,201 2.5 Baa Single name credit default swaps (3) — 40 2.7 1 60 3.3 Credit default swaps referencing indices (45) 5,977 5.4 90 4,698 5.1 Subtotal (45) 6,017 5.4 91 4,758 5.1 Ba Single name credit default swaps (3) 2 45 0.9 1 65 0.5 Credit default swaps referencing indices 1 25 4.2 (1) 20 5.0 Subtotal 3 70 2.1 — 85 1.5 B Credit default swaps referencing indices (1) 38 4.7 — — — Subtotal (1) 38 4.7 — — — Caa3 Credit default swaps referencing indices (12) 30 3.7 (9) 30 4.5 Subtotal (12) 30 3.7 (9) 30 4.5 Total $ (4) $ 10,569 4.6 $ 99 $ 6,074 4.6 __________________ (1) The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P Global Ratings (“S&P”) and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used. (2) The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts. (3) Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals. |
Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral | The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at: September 30, 2022 December 31, 2021 Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement Assets Liabilities Assets Liabilities (In millions) Gross estimated fair value of derivatives: OTC-bilateral (1) $ 10,871 $ 4,072 $ 8,602 $ 1,379 OTC-cleared (1) 25 94 104 8 Exchange-traded 14 3 5 — Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1) 10,910 4,169 8,711 1,387 Gross amounts not offset on the interim condensed consolidated balance sheets: Gross estimated fair value of derivatives: (2) OTC-bilateral (3,968) (3,968) (1,364) (1,364) OTC-cleared (7) (7) (3) (3) Exchange-traded (1) (1) — — Cash collateral: (3), (4) OTC-bilateral (5,577) — (6,414) — OTC-cleared (1) (41) (91) — Securities collateral: (5) OTC-bilateral (1,274) (102) (767) (14) OTC-cleared — (45) — (5) Exchange-traded — (2) — — Net amount after application of master netting agreements and collateral $ 82 $ 3 $ 72 $ 1 __________________ (1) At September 30, 2022 and December 31, 2021, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $134 million and $93 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of $23 million and ($22) million, respectively. (2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals. (3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the centralized clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. (4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At September 30, 2022 and December 31, 2021, the Company received excess cash collateral of $797 million and $60 million, respectively, and provided excess cash collateral of $3 million and $0, respectively, which is not included in the table above due to the foregoing limitation. (5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at September 30, 2022, none of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At September 30, 2022 and December 31, 2021, the Company received excess securities collateral with an estimated fair value of $261 million and $47 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At September 30, 2022 and December 31, 2021, the Company provided excess securities collateral with an estimated fair value of $951 million and $95 million, respectively, for its OTC-bilateral derivatives, $493 million and $584 million, respectively, for its OTC-cleared derivatives, and $80 million and $106 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation. |
Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral | The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at: September 30, 2022 December 31, 2021 Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement Assets Liabilities Assets Liabilities (In millions) Gross estimated fair value of derivatives: OTC-bilateral (1) $ 10,871 $ 4,072 $ 8,602 $ 1,379 OTC-cleared (1) 25 94 104 8 Exchange-traded 14 3 5 — Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1) 10,910 4,169 8,711 1,387 Gross amounts not offset on the interim condensed consolidated balance sheets: Gross estimated fair value of derivatives: (2) OTC-bilateral (3,968) (3,968) (1,364) (1,364) OTC-cleared (7) (7) (3) (3) Exchange-traded (1) (1) — — Cash collateral: (3), (4) OTC-bilateral (5,577) — (6,414) — OTC-cleared (1) (41) (91) — Securities collateral: (5) OTC-bilateral (1,274) (102) (767) (14) OTC-cleared — (45) — (5) Exchange-traded — (2) — — Net amount after application of master netting agreements and collateral $ 82 $ 3 $ 72 $ 1 __________________ (1) At September 30, 2022 and December 31, 2021, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $134 million and $93 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of $23 million and ($22) million, respectively. (2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals. (3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the centralized clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. (4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At September 30, 2022 and December 31, 2021, the Company received excess cash collateral of $797 million and $60 million, respectively, and provided excess cash collateral of $3 million and $0, respectively, which is not included in the table above due to the foregoing limitation. (5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at September 30, 2022, none of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At September 30, 2022 and December 31, 2021, the Company received excess securities collateral with an estimated fair value of $261 million and $47 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At September 30, 2022 and December 31, 2021, the Company provided excess securities collateral with an estimated fair value of $951 million and $95 million, respectively, for its OTC-bilateral derivatives, $493 million and $584 million, respectively, for its OTC-cleared derivatives, and $80 million and $106 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation. |
Estimated Fair Value of OTC-bilateral derivatives after considering effect of netting agreements | The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged. Derivatives Subject to Financial September 30, 2022 December 31, 2021 (In millions) Estimated fair value of derivatives in a net liability position (1) $ 105 $ 15 Estimated fair value of collateral provided: Fixed maturity securities AFS $ 107 $ 17 __________________ (1) After taking into consideration the existence of netting agreements. The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at: Balance Sheet Location September 30, 2022 December 31, 2021 (In millions) Embedded derivatives within asset host contracts: Assumed on affiliated reinsurance Other invested assets $ 174 $ — Embedded derivatives within liability host contracts: Direct guaranteed minimum benefits Policyholder account balances $ 536 $ 257 Assumed guaranteed minimum benefits Policyholder account balances 5 5 Funds withheld and guarantees on reinsurance (including affiliated) Other liabilities (401) 1,072 Fixed annuities with equity indexed returns Policyholder account balances 126 165 Embedded derivatives within liability host contracts $ 266 $ 1,499 |
Embedded Derivatives | The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged. Derivatives Subject to Financial September 30, 2022 December 31, 2021 (In millions) Estimated fair value of derivatives in a net liability position (1) $ 105 $ 15 Estimated fair value of collateral provided: Fixed maturity securities AFS $ 107 $ 17 __________________ (1) After taking into consideration the existence of netting agreements. The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at: Balance Sheet Location September 30, 2022 December 31, 2021 (In millions) Embedded derivatives within asset host contracts: Assumed on affiliated reinsurance Other invested assets $ 174 $ — Embedded derivatives within liability host contracts: Direct guaranteed minimum benefits Policyholder account balances $ 536 $ 257 Assumed guaranteed minimum benefits Policyholder account balances 5 5 Funds withheld and guarantees on reinsurance (including affiliated) Other liabilities (401) 1,072 Fixed annuities with equity indexed returns Policyholder account balances 126 165 Embedded derivatives within liability host contracts $ 266 $ 1,499 |
Fair Value (Tables)
Fair Value (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Recurring Fair Value Measurements | The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at: September 30, 2022 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 43,788 $ 6,315 $ 50,103 U.S. government and agency 9,078 12,962 — 22,040 Foreign corporate — 17,328 5,534 22,862 RMBS 94 17,860 2,136 20,090 ABS & CLO — 10,048 1,524 11,572 Municipals — 7,238 — 7,238 CMBS — 5,637 301 5,938 Foreign government — 3,546 25 3,571 Total fixed maturity securities AFS 9,172 118,407 15,835 143,414 Short-term investments 3,302 224 5 3,531 Residential mortgage loans — FVO — — — — Other investments 252 280 936 1,468 Derivative assets: (1) Interest rate — 4,782 — 4,782 Foreign currency exchange rate — 4,787 — 4,787 Credit — 33 69 102 Equity market 14 1,084 7 1,105 Total derivative assets 14 10,686 76 10,776 Embedded derivatives within asset host contracts (4) — — 174 174 Separate account assets (2) 16,081 70,602 1,026 87,709 Total assets (3) $ 28,821 $ 200,199 $ 18,052 $ 247,072 Liabilities Derivative liabilities: (1) Interest rate $ 2 $ 1,252 $ 526 $ 1,780 Foreign currency exchange rate — 2,134 — 2,134 Credit — 41 36 77 Equity market 1 154 — 155 Total derivative liabilities 3 3,581 562 4,146 Embedded derivatives within liability host contracts (4) — — 266 266 Separate account liabilities (2) 12 17 21 50 Total liabilities $ 15 $ 3,598 $ 849 $ 4,462 December 31, 2021 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 51,290 $ 7,112 $ 58,402 U.S. government and agency 15,041 16,181 — 31,222 Foreign corporate — 21,862 7,823 29,685 RMBS 7 20,333 2,805 23,145 ABS & CLO — 11,455 1,424 12,879 Municipals — 8,728 — 8,728 CMBS — 6,507 371 6,878 Foreign government — 4,934 12 4,946 Total fixed maturity securities AFS 15,048 141,290 19,547 175,885 Short-term investments 4,187 677 2 4,866 Residential mortgage loans — FVO — — 127 127 Other investments 328 192 894 1,414 Derivative assets: (1) Interest rate — 5,982 95 6,077 Foreign currency exchange rate — 1,676 — 1,676 Credit — 106 17 123 Equity market 5 730 7 742 Total derivative assets 5 8,494 119 8,618 Embedded derivatives within asset host contracts (4) — — — — Separate account assets (2) 28,231 93,656 1,964 123,851 Total assets (3) $ 47,799 $ 244,309 $ 22,653 $ 314,761 Liabilities Derivative liabilities: (1) Interest rate $ — $ 70 $ 21 $ 91 Foreign currency exchange rate — 1,076 — 1,076 Credit — 8 12 20 Equity market — 222 — 222 Total derivative liabilities — 1,376 33 1,409 Embedded derivatives within liability host contracts (4) — — 1,499 1,499 Separate account liabilities (2) 7 12 6 25 Total liabilities $ 7 $ 1,388 $ 1,538 $ 2,933 __________________ (1) Derivative assets are presented within other invested assets on the interim condensed consolidated balance sheets and derivative liabilities are presented within other liabilities on the interim condensed consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the interim condensed consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables. (2) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities. (3) Total assets included in the fair value hierarchy exclude other limited partnership interests that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. At September 30, 2022 and December 31, 2021, the estimated fair value of such investments was $68 million and $95 million, respectively. (4) Embedded derivatives within asset host contracts are presented within other invested assets on the interim condensed consolidated balance sheets. Embedded derivatives within liability host contracts are presented within policyholder account balances and other liabilities on the interim condensed consolidated balance sheets. |
Fair Value Inputs, Quantitative Information | The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at: September 30, 2022 December 31, 2021 Impact of Valuation Techniques Significant Range Weighted Range Weighted Fixed maturity securities AFS (3) U.S. corporate and foreign corporate • Matrix pricing • Offered quotes (4) — - 121 87 1 - 165 110 Increase • Market pricing • Quoted prices (4) 5 - 102 95 — - 117 101 Increase RMBS • Market pricing • Quoted prices (4) — - 113 92 — - 121 99 Increase (5) ABS & CLO • Market pricing • Quoted prices (4) 76 - 102 92 91 - 110 102 Increase (5) Derivatives Interest rate • Present value techniques • Swap yield (6) 369 - 379 374 151 - 200 188 Increase (7) • Volatility (8) —% - —% —% 1% - 1% 1% Increase (7) Credit • Present value techniques • Credit spreads (9) 86 - 148 105 96 - 133 109 Decrease (7) • Consensus pricing • Offered quotes (10) Embedded derivatives Direct and assumed guaranteed minimum benefits • Option pricing techniques • Mortality rates: Ages 0 - 40 0.01% - 0.14% 0.05% 0.01% - 0.12% 0.08% Decrease (11) Ages 41 - 60 0.05% - 0.43% 0.21% 0.05% - 0.65% 0.27% Decrease (11) Ages 61 - 115 0.33% - 100% 1.45% 0.32% - 100% 2.08% Decrease (11) • Lapse rates: Durations 1 - 10 0% - 80% 8.84% 0.25% - 100% 6.30% Decrease (12) Durations 11 - 20 0.70% - 80% 6.46% 0.70% - 100% 5.22% Decrease (12) Durations 21 - 116 1.60% - 80% 2.90% 1.60% - 100% 5.22% Decrease (12) • Utilization rates 0% - 22% 0.37% 0% - 22% 0.22% Increase (13) • Withdrawal rates 0% - 10% 4% 0.25% - 10% 3.72% (14) • Long-term equity volatilities 16.46% - 22.01% 18.49% 16.44% - 22.16% 18.60% Increase (15) • Nonperformance risk spread 0.33% - 0.81% 0.75% 0.04% - 0.40% 0.35% Decrease (16) __________________ (1) The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for embedded derivatives is determined based on a combination of account values and experience data. (2) The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For embedded derivatives, changes to direct and assumed guaranteed minimum benefits are based on liability positions. (3) Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations. (4) Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par. (5) Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates. (6) Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation. (7) Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions. (8) Ranges represent the underlying interest rate volatility quoted in percentage points. Since this valuation methodology uses an equivalent of LIBOR for secured overnight financing rate volatility, presenting a range is more representative of the unobservable input used in the valuation. (9) Represents the risk quoted in basis points of a credit default event on the underlying instrument. Credit derivatives with significant unobservable inputs are primarily comprised of written credit default swaps. (10) At both September 30, 2022 and December 31, 2021, independent non-binding broker quotations were used in the determination of less than 1% of the total net derivative estimated fair value. (11) Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (12) Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (13) The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (14) The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value. (15) Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. (16) Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the embedded derivative. |
Fair Value, Measured on Recurring Basis, Unobservable Input Reconciliation | The following tables summarize the change of all assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS Corporate (6) Structured Municipals Foreign Short-term (In millions) Three Months Ended September 30, 2022 Balance, beginning of period $ 13,004 $ 4,090 $ — $ 21 $ 100 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (4) 10 — 4 — Total realized/unrealized gains (losses) included in AOCI (1,179) (110) — — — Purchases (3) 622 216 — — 5 Sales (3) (293) (181) — — — Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 186 30 — — — Transfers out of Level 3 (4) (487) (94) — — (100) Balance, end of period $ 11,849 $ 3,961 $ — $ 25 $ 5 Three Months Ended September 30, 2021 Balance, beginning of period $ 14,105 $ 4,831 $ — $ 11 $ 77 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (27) 10 — — — Total realized/unrealized gains (losses) included in AOCI (198) 31 — — — Purchases (3) 914 316 9 10 1 Sales (3) (329) (377) — — (2) Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 237 — — 10 — Transfers out of Level 3 (4) (116) (250) — (6) (24) Balance, end of period $ 14,586 $ 4,561 $ 9 $ 25 $ 52 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2022 (5) $ (3) $ 5 $ — $ 5 $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2021 (5) $ (20) $ 9 $ — $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2022 (5) $ (1,180) $ (105) $ — $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2021 (5) $ (199) $ 32 $ — $ — $ — Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Residential Other Investments Net Net Embedded Separate (In millions) Three Months Ended September 30, 2022 Balance, beginning of period $ 109 $ 961 $ (103) $ (341) $ 1,029 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) 1 (20) (176) 250 2 Total realized/unrealized gains (losses) included in AOCI — — (124) — — Purchases (3) — 4 54 — 61 Sales (3) (108) (9) — — (75) Issuances (3) — — (1) — (1) Settlements (3) (2) — 25 (1) — Transfers into Level 3 (4) — — — — — Transfers out of Level 3 (4) — — (161) — (11) Balance, end of period $ — $ 936 $ (486) $ (92) $ 1,005 Three Months Ended September 30, 2021 Balance, beginning of period $ 140 $ 724 $ 39 $ (1,511) $ 1,105 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) — 45 2 29 5 Total realized/unrealized gains (losses) included in AOCI — — 45 — — Purchases (3) — 109 7 — 150 Sales (3) — (9) — — (18) Issuances (3) — — (1) — — Settlements (3) (6) — (47) (46) — Transfers into Level 3 (4) — — — — — Transfers out of Level 3 (4) — (25) — — (5) Balance, end of period $ 134 $ 844 $ 45 $ (1,528) $ 1,237 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2022 (5) $ — $ (21) $ (31) $ 250 $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2021 (5) $ (1) $ 44 $ 2 $ 27 $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2022 (5) $ — $ — $ (145) $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2021 (5) $ — $ — $ 25 $ — $ — Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS Corporate (6) Structured Municipals Foreign Short-term (In millions) Nine Months Ended September 30, 2022 Balance, beginning of period $ 14,935 $ 4,600 $ — $ 12 $ 2 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (32) 33 — (37) — Total realized/unrealized gains (losses) included in AOCI (3,774) (418) — 6 — Purchases (3) 1,848 580 — — 5 Sales (3) (843) (737) — (1) (2) Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 119 183 — 45 — Transfers out of Level 3 (4) (404) (280) — — — Balance, end of period $ 11,849 $ 3,961 $ — $ 25 $ 5 Nine Months Ended September 30, 2021 Balance, beginning of period $ 14,873 $ 4,465 $ — $ 5 $ 1 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (37) 35 — — — Total realized/unrealized gains (losses) included in AOCI (618) 29 — (1) — Purchases (3) 1,434 1,023 9 12 51 Sales (3) (724) (988) — (1) — Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 128 255 — 10 — Transfers out of Level 3 (4) (470) (258) — — — Balance, end of period $ 14,586 $ 4,561 $ 9 $ 25 $ 52 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2022 (5) $ (34) $ 27 $ — $ (37) $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2021 (5) $ (26) $ 32 $ — $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2022 (5) $ (3,777) $ (400) $ — $ 6 $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2021 (5) $ (616) $ 30 $ — $ (1) $ — Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Residential Other Investments Net Net Embedded Separate Accounts (9) (In millions) Nine Months Ended September 30, 2022 Balance, beginning of period $ 127 $ 894 $ 86 $ (1,499) $ 1,958 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (8) (39) (172) 1,424 19 Total realized/unrealized gains (losses) included in AOCI — — (541) — — Purchases (3) — 199 82 — 146 Sales (3) (108) (19) — — (1,107) Issuances (3) — — (3) — 3 Settlements (3) (11) — 62 (17) 4 Transfers into Level 3 (4) — 3 — — — Transfers out of Level 3 (4) — (102) — — (18) Balance, end of period $ — $ 936 $ (486) $ (92) $ 1,005 Nine Months Ended September 30, 2021 Balance, beginning of period $ 165 $ 565 $ 452 $ (2,061) $ 939 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (3) 120 (112) 663 4 Total realized/unrealized gains (losses) included in AOCI — — (373) — — Purchases (3) — 137 13 — 324 Sales (3) (11) (23) — — (43) Issuances (3) — — (5) — (1) Settlements (3) (17) — 68 (130) 6 Transfers into Level 3 (4) — 74 1 — 10 Transfers out of Level 3 (4) — (29) 1 — (2) Balance, end of period $ 134 $ 844 $ 45 $ (1,528) $ 1,237 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2022 (5) $ — $ (44) $ (133) $ 1,426 $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2021 (5) $ (7) $ 117 $ (26) $ 663 $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2022 (5) $ — $ — $ (478) $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2021 (5) $ — $ — $ (206) $ — $ — __________________ (1) Amortization of premium/accretion of discount is included within net investment income. Impairments and changes in ACL charged to net income (loss) on certain securities are included in net investment gains (losses), while changes in estimated fair value of residential mortgage loans — FVO are included in net investment income. Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses). (2) Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward. (3) Items purchased/issued and then sold/settled in the same period are excluded from the rollforward. Fees attributed to embedded derivatives are included in settlements. (4) Items transferred into and then out of Level 3 in the same period are excluded from the rollforward. (5) Changes in unrealized gains (losses) included in net income (loss) and included in AOCI relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses). (6) Comprised of U.S. and foreign corporate securities. (7) Freestanding derivative assets and liabilities are presented net for purposes of the rollforward. (8) Embedded derivative assets and liabilities are presented net for purposes of the rollforward. (9) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net income (loss). Separate account assets and liabilities are presented net for the purposes of the rollforward. |
Fair Value Option | The following table presents information for residential mortgage loans which are accounted for under the FVO and were initially measured at fair value. September 30, 2022 December 31, 2021 (In millions) Unpaid principal balance $ — $ 130 Difference between estimated fair value and unpaid principal balance — (3) Carrying value at estimated fair value $ — $ 127 Loans in nonaccrual status $ — $ 32 Loans more than 90 days past due $ — $ 14 Loans in nonaccrual status or more than 90 days past due, or both — difference between aggregate estimated fair value and unpaid principal balance $ — $ (7) |
Fair Value of Financial Instruments Carried at Other Than Fair Value | The carrying values and estimated fair values for such financial instruments, and their corresponding placement in the fair value hierarchy, are summarized as follows at: September 30, 2022 Fair Value Hierarchy Carrying Level 1 Level 2 Level 3 Total (In millions) Assets Mortgage loans (1) $ 61,603 $ — $ — $ 58,419 $ 58,419 Policy loans $ 5,732 $ — $ — $ 6,148 $ 6,148 Other invested assets $ 1,910 $ — $ 1,933 $ — $ 1,933 Premiums, reinsurance and other receivables $ 11,833 $ — $ 302 $ 11,772 $ 12,074 Liabilities Policyholder account balances $ 78,941 $ — $ — $ 75,910 $ 75,910 Long-term debt $ 1,615 $ — $ 1,693 $ — $ 1,693 Other liabilities $ 12,313 $ — $ 314 $ 11,970 $ 12,284 Separate account liabilities $ 38,509 $ — $ 38,509 $ — $ 38,509 December 31, 2021 Fair Value Hierarchy Carrying Level 1 Level 2 Level 3 Total (In millions) Assets Mortgage loans (1) $ 60,092 $ — $ — $ 63,094 $ 63,094 Policy loans $ 5,816 $ — $ — $ 6,710 $ 6,710 Other invested assets $ 2,230 $ — $ 1,932 $ 356 $ 2,288 Premiums, reinsurance and other receivables $ 12,101 $ — $ 156 $ 12,375 $ 12,531 Liabilities Policyholder account balances $ 76,387 $ — $ — $ 79,182 $ 79,182 Long-term debt $ 1,659 $ — $ 2,000 $ — $ 2,000 Other liabilities $ 12,357 $ — $ 159 $ 12,412 $ 12,571 Separate account liabilities $ 54,254 $ — $ 54,254 $ — $ 54,254 _________________ (1) Includes mortgage loans measured at estimated fair value on a nonrecurring basis and excludes mortgage loans measured at estimated fair value on a recurring basis. |
Equity (Tables)
Equity (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Components of Accumulated Other Comprehensive Income (Loss) | Information regarding changes in the balances of each component of AOCI attributable to Metropolitan Life Insurance Company was as follows: Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Unrealized Gains (Losses) on Derivatives Foreign Currency Translation Adjustments Defined Benefit Plans Adjustment Total (In millions) Balance, beginning of period $ (5,214) $ 1,905 $ (89) $ (379) $ (3,777) OCI before reclassifications (8,845) 284 (88) — (8,649) Deferred income tax benefit (expense) 1,872 (60) 19 — 1,831 AOCI before reclassifications, net of income tax (12,187) 2,129 (158) (379) (10,595) Amounts reclassified from AOCI 186 485 — 10 681 Deferred income tax benefit (expense) (40) (102) — (2) (144) Amounts reclassified from AOCI, net of income tax 146 383 — 8 537 Balance, end of period $ (12,041) $ 2,512 $ (158) $ (371) $ (10,058) Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Unrealized Gains (Losses) on Derivatives Foreign Currency Translation Adjustments Defined Benefit Plans Adjustment Total (In millions) Balance, beginning of period $ 8,938 $ 1,419 $ (33) $ (445) $ 9,879 OCI before reclassifications 38 228 7 3 276 Deferred income tax benefit (expense) 20 (178) (2) — (160) AOCI before reclassifications, net of income tax 8,996 1,469 (28) (442) 9,995 Amounts reclassified from AOCI (13) 233 — 7 227 Deferred income tax benefit (expense) 2 75 — (2) 75 Amounts reclassified from AOCI, net of income tax (11) 308 — 5 302 Balance, end of period $ 8,985 $ 1,777 $ (28) $ (437) $ 10,297 Nine Months Unrealized Unrealized Foreign Defined Total (In millions) Balance, beginning of period $ 8,485 $ 1,872 $ (45) $ (395) $ 9,917 OCI before reclassifications (26,804) (202) (140) — (27,146) Deferred income tax benefit (expense) 5,643 42 27 — 5,712 AOCI before reclassifications, net of income tax (12,676) 1,712 (158) (395) (11,517) Amounts reclassified from AOCI 805 1,013 — 30 1,848 Deferred income tax benefit (expense) (170) (213) — (6) (389) Amounts reclassified from AOCI, net of income tax 635 800 — 24 1,459 Balance, end of period $ (12,041) $ 2,512 $ (158) $ (371) $ (10,058) Nine Months Unrealized Unrealized Foreign Defined Total (In millions) Balance, beginning of period $ 10,384 $ 1,791 $ (53) $ (460) $ 11,662 OCI before reclassifications (1,862) (173) 31 1 (2,003) Deferred income tax benefit (expense) 428 (94) (6) — 328 AOCI before reclassifications, net of income tax 8,950 1,524 (28) (459) 9,987 Amounts reclassified from AOCI 46 164 — 28 238 Deferred income tax benefit (expense) (11) 89 — (6) 72 Amounts reclassified from AOCI, net of income tax 35 253 — 22 310 Balance, end of period $ 8,985 $ 1,777 $ (28) $ (437) $ 10,297 __________________ (1) See Note 5 for information on offsets to investments related to policyholder liabilities, DAC, VOBA and DSI. |
Reclassification out of Accumulated Other Comprehensive Income (Loss) | Information regarding amounts reclassified out of each component of AOCI was as follows: Three Months Nine Months 2022 2021 2022 2021 AOCI Components Amounts Reclassified from AOCI Consolidated Statements of (In millions) Net unrealized investment gains (losses): Net unrealized investment gains (losses) $ (174) $ 17 $ (775) $ (17) Net investment gains (losses) Net unrealized investment gains (losses) 1 (3) 4 (10) Net investment income Net unrealized investment gains (losses) (13) (1) (34) (19) Net derivative gains (losses) Net unrealized investment gains (losses), before income tax (186) 13 (805) (46) Income tax (expense) benefit 40 (2) 170 11 Net unrealized investment gains (losses), net of income tax (146) 11 (635) (35) Unrealized gains (losses) on derivatives - cash flow hedges: Interest rate derivatives 15 14 46 41 Net investment income Interest rate derivatives (16) 8 55 56 Net investment gains (losses) Foreign currency exchange rate derivatives 1 2 3 4 Net investment income Foreign currency exchange rate derivatives (485) (257) (1,117) (265) Net investment gains (losses) Gains (losses) on cash flow hedges, before income tax (485) (233) (1,013) (164) Income tax (expense) benefit 102 (75) 213 (89) Gains (losses) on cash flow hedges, net of income tax (383) (308) (800) (253) Defined benefit plans adjustment: (1) Amortization of net actuarial gains (losses) (10) (10) (31) (33) Amortization of prior service (costs) credit — 3 1 5 Amortization of defined benefit plan items, before income tax (10) (7) (30) (28) Income tax (expense) benefit 2 2 6 6 Amortization of defined benefit plan items, net of income tax (8) (5) (24) (22) Total reclassifications, net of income tax $ (537) $ (302) $ (1,459) $ (310) __________________ (1) These AOCI components are included in the computation of net periodic benefit costs. |
Other Revenues and Other Expe_2
Other Revenues and Other Expenses (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Other Income and Expenses [Abstract] | |
Disaggregation of Revenue | Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows: Three Months Nine Months 2022 2021 2022 2021 (In millions) Prepaid legal plans $ 105 $ 99 $ 319 $ 298 Recordkeeping and administrative services (1) 40 53 129 158 Administrative services-only contracts 56 54 168 166 Other revenue from service contracts from customers 8 6 22 26 Total revenues from service contracts from customers 209 212 638 648 Other (2) 292 156 648 577 Total other revenues $ 501 $ 368 $ 1,286 $ 1,225 __________________ (1) Related to products and businesses no longer actively marketed by the Company. (2) Primarily includes reinsurance ceded. See Note 12. |
Other Expenses | Information on other expenses was as follows: Three Months Nine Months 2022 2021 2022 2021 (In millions) General and administrative expenses (1) $ 675 $ 566 $ 2,039 $ 1,660 Pension, postretirement and postemployment benefit costs 30 27 89 85 Premium taxes, other taxes, and licenses & fees 108 77 269 243 Commissions and other variable expenses 755 1,048 1,728 2,030 Capitalization of DAC (58) (16) (120) (45) Amortization of DAC and VOBA (119) 99 55 171 Interest expense on debt 27 24 76 72 Total other expenses $ 1,418 $ 1,825 $ 4,136 $ 4,216 __________________ (1) Includes $21 million and $95 million for the three months and nine months ended September 30, 2022, respectively, and ($14) million and ($71) million for the three months and nine months ended September 30, 2021, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid. |
Related Party Transactions (Tab
Related Party Transactions (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Related Party Transactions [Abstract] | |
Effects of reinsurance | Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated statements of operations and comprehensive income (loss) was as follows: Three Months Nine Months 2022 2021 2022 2021 (In millions) Premiums Reinsurance assumed $ 2 $ 3 $ 5 $ 845 Reinsurance ceded (29) (26) (97) (86) Net premiums $ (27) $ (23) $ (92) $ 759 Universal life and investment-type product policy fees Reinsurance assumed $ — $ — $ — $ — Reinsurance ceded (4) (13) (11) (14) Net universal life and investment-type product policy fees $ (4) $ (13) $ (11) $ (14) Other revenues Reinsurance assumed $ 23 $ 1 $ 52 $ 3 Reinsurance ceded 106 96 353 379 Net other revenues $ 129 $ 97 $ 405 $ 382 Policyholder benefits and claims Reinsurance assumed $ 17 $ 1 $ 51 $ 833 Reinsurance ceded (36) (43) (117) (115) Net policyholder benefits and claims $ (19) $ (42) $ (66) $ 718 Interest credited to policyholder account balances Reinsurance assumed $ 26 $ 8 $ 47 $ 22 Reinsurance ceded (3) (3) (9) (9) Net interest credited to policyholder account balances $ 23 $ 5 $ 38 $ 13 Other expenses Reinsurance assumed $ 4 $ — $ 14 $ 19 Reinsurance ceded 343 713 533 947 Net other expenses $ 347 $ 713 $ 547 $ 966 Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated balance sheets was as follows at: September 30, 2022 December 31, 2021 Assumed Ceded Assumed Ceded (In millions) Assets Premiums, reinsurance and other receivables $ 538 $ 11,336 $ 25 $ 11,710 Deferred policy acquisition costs and value of business acquired 69 (164) 6 (139) Total assets $ 607 $ 11,172 $ 31 $ 11,571 Liabilities Future policy benefits $ 3,012 $ 10 $ 3,139 $ (10) Policyholder account balances 3,533 — 366 — Other policy-related balances 63 (3) 14 — Other liabilities 908 10,380 894 12,190 Total liabilities $ 7,516 $ 10,387 $ 4,413 $ 12,180 |
Business, Basis of Presentati_3
Business, Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) | 9 Months Ended |
Sep. 30, 2022 Segment | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Number of segments | 2 |
Business, Basis of Presentati_4
Business, Basis of Presentation and Summary of Significant Accounting Policies - Future Adoption - (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Jan. 01, 2021 | Dec. 31, 2020 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | $ 13,751 | $ 20,135 | $ 33,428 | $ 34,236 | $ 33,660 | $ 34,858 | |
Accumulated Other Comprehensive Income (Loss), Net of Tax | (10,058) | $ (3,777) | 9,917 | $ 10,297 | $ 9,879 | $ 11,662 | |
Retained Earnings (Accumulated Deficit) | $ 11,171 | $ 10,868 | |||||
Cumulative Effect, Period of Adoption, Adjustment | Pro Forma | Accounting Standards Update 2018-12 | Minimum | |||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | $ (16,000) | ||||||
Accumulated Other Comprehensive Income (Loss), Net of Tax | (12,500) | ||||||
Retained Earnings (Accumulated Deficit) | (3,500) | ||||||
Cumulative Effect, Period of Adoption, Adjustment | Pro Forma | Accounting Standards Update 2018-12 | Maximum | |||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | (18,500) | ||||||
Accumulated Other Comprehensive Income (Loss), Net of Tax | (14,000) | ||||||
Retained Earnings (Accumulated Deficit) | $ (4,500) |
Segment Information (Earnings)
Segment Information (Earnings) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues | ||||||
Premiums | $ 13,769 | $ 5,715 | $ 25,347 | $ 17,971 | ||
Universal life and investment-type product policy fees | 484 | 506 | 1,523 | 1,555 | ||
Net investment income | 2,260 | 3,331 | 7,528 | 9,552 | ||
Other revenues | 501 | 368 | 1,286 | 1,225 | ||
Net investment gains (losses) | (82) | 190 | (391) | 692 | ||
Net derivative gains (losses) | 454 | 84 | 980 | (906) | ||
Total revenues | 17,386 | 10,194 | 36,273 | 30,089 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 14,297 | 6,782 | 27,107 | 20,895 | ||
Interest credited to policyholder account balances | 624 | 512 | 1,645 | 1,535 | ||
Capitalization of DAC | (58) | (16) | (120) | (45) | ||
Amortization of DAC and VOBA | (119) | 99 | 55 | 171 | ||
Interest expense on debt | 27 | 24 | 76 | 72 | ||
Other expenses | 1,568 | 1,718 | 4,125 | 4,018 | ||
Total expenses | 16,339 | 9,119 | 32,888 | 26,646 | ||
Provision for income tax expense (benefit) | 174 | 153 | 539 | 510 | ||
Net income (loss) | 873 | 922 | $ 1,973 | $ 2,011 | 2,846 | 2,933 |
Operating Segments | ||||||
Revenues | ||||||
Premiums | 13,769 | 5,715 | 25,347 | 17,971 | ||
Universal life and investment-type product policy fees | 465 | 486 | 1,466 | 1,496 | ||
Net investment income | 2,410 | 3,483 | 7,928 | 9,996 | ||
Other revenues | 501 | 368 | 1,286 | 1,225 | ||
Net investment gains (losses) | 0 | 0 | 0 | 0 | ||
Net derivative gains (losses) | 0 | 0 | 0 | 0 | ||
Total revenues | 17,145 | 10,052 | 36,027 | 30,688 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 14,504 | 6,666 | 27,557 | 20,617 | ||
Interest credited to policyholder account balances | 624 | 512 | 1,645 | 1,537 | ||
Capitalization of DAC | (58) | (16) | (120) | (45) | ||
Amortization of DAC and VOBA | (9) | 88 | 137 | 179 | ||
Interest expense on debt | 27 | 24 | 76 | 72 | ||
Other expenses | 1,565 | 1,717 | 4,120 | 4,025 | ||
Total expenses | 16,653 | 8,991 | 33,415 | 26,385 | ||
Provision for income tax expense (benefit) | 57 | 151 | 375 | 680 | ||
Adjusted earnings | 435 | 910 | 2,237 | 3,623 | ||
Segment Reconciling Items | ||||||
Revenues | ||||||
Premiums | 0 | 0 | 0 | 0 | ||
Universal life and investment-type product policy fees | 19 | 20 | 57 | 59 | ||
Net investment income | (150) | (152) | (400) | (444) | ||
Other revenues | 0 | 0 | 0 | 0 | ||
Net investment gains (losses) | (82) | 190 | (391) | 692 | ||
Net derivative gains (losses) | 454 | 84 | 980 | (906) | ||
Total revenues | 241 | 142 | 246 | (599) | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | (207) | 116 | (450) | 278 | ||
Interest credited to policyholder account balances | 0 | 0 | 0 | (2) | ||
Capitalization of DAC | 0 | 0 | 0 | 0 | ||
Amortization of DAC and VOBA | (110) | 11 | (82) | (8) | ||
Interest expense on debt | 0 | 0 | 0 | 0 | ||
Other expenses | 3 | 1 | 5 | (7) | ||
Total expenses | (314) | 128 | (527) | 261 | ||
Provision for income tax expense (benefit) | 117 | 2 | 164 | (170) | ||
U.S. | Operating Segments | ||||||
Revenues | ||||||
Premiums | 13,158 | 5,058 | 23,492 | 15,955 | ||
Universal life and investment-type product policy fees | 277 | 267 | 840 | 828 | ||
Net investment income | 1,482 | 1,889 | 4,588 | 5,540 | ||
Other revenues | 356 | 217 | 819 | 663 | ||
Net investment gains (losses) | 0 | 0 | 0 | 0 | ||
Net derivative gains (losses) | 0 | 0 | 0 | 0 | ||
Total revenues | 15,273 | 7,431 | 29,739 | 22,986 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 13,107 | 5,317 | 23,646 | 16,685 | ||
Interest credited to policyholder account balances | 445 | 346 | 1,138 | 1,037 | ||
Capitalization of DAC | (21) | (15) | (56) | (44) | ||
Amortization of DAC and VOBA | 14 | 25 | 40 | 47 | ||
Interest expense on debt | 3 | 2 | 6 | 5 | ||
Other expenses | 883 | 768 | 2,567 | 2,377 | ||
Total expenses | 14,431 | 6,443 | 27,341 | 20,107 | ||
Provision for income tax expense (benefit) | 175 | 207 | 499 | 600 | ||
Adjusted earnings | 667 | 781 | 1,899 | 2,279 | ||
MetLife Holdings | Operating Segments | ||||||
Revenues | ||||||
Premiums | 611 | 657 | 1,855 | 2,016 | ||
Universal life and investment-type product policy fees | 188 | 219 | 626 | 668 | ||
Net investment income | 990 | 1,587 | 3,416 | 4,478 | ||
Other revenues | 36 | 53 | 106 | 177 | ||
Net investment gains (losses) | 0 | 0 | 0 | 0 | ||
Net derivative gains (losses) | 0 | 0 | 0 | 0 | ||
Total revenues | 1,825 | 2,516 | 6,003 | 7,339 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 1,397 | 1,349 | 3,911 | 3,932 | ||
Interest credited to policyholder account balances | 160 | 166 | 482 | 500 | ||
Capitalization of DAC | 1 | 1 | 1 | 1 | ||
Amortization of DAC and VOBA | (24) | 63 | 95 | 132 | ||
Interest expense on debt | 2 | 2 | 5 | 4 | ||
Other expenses | 199 | 207 | 590 | 638 | ||
Total expenses | 1,735 | 1,788 | 5,084 | 5,207 | ||
Provision for income tax expense (benefit) | 15 | 148 | 181 | 433 | ||
Adjusted earnings | 75 | 580 | 738 | 1,699 | ||
Corporate & Other | Operating Segments | ||||||
Revenues | ||||||
Premiums | 0 | 0 | 0 | 0 | ||
Universal life and investment-type product policy fees | 0 | 0 | 0 | 0 | ||
Net investment income | (62) | 7 | (76) | (22) | ||
Other revenues | 109 | 98 | 361 | 385 | ||
Net investment gains (losses) | 0 | 0 | 0 | 0 | ||
Net derivative gains (losses) | 0 | 0 | 0 | 0 | ||
Total revenues | 47 | 105 | 285 | 363 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 0 | 0 | 0 | 0 | ||
Interest credited to policyholder account balances | 19 | 0 | 25 | 0 | ||
Capitalization of DAC | (38) | (2) | (65) | (2) | ||
Amortization of DAC and VOBA | 1 | 0 | 2 | 0 | ||
Interest expense on debt | 22 | 20 | 65 | 63 | ||
Other expenses | 483 | 742 | 963 | 1,010 | ||
Total expenses | 487 | 760 | 990 | 1,071 | ||
Provision for income tax expense (benefit) | (133) | (204) | (305) | (353) | ||
Adjusted earnings | $ (307) | $ (451) | $ (400) | $ (355) |
Segment Information (Total Asse
Segment Information (Total Assets) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Segment Reporting Information [Line Items] | ||
Total assets | $ 386,848 | $ 446,557 |
U.S. | ||
Segment Reporting Information [Line Items] | ||
Total assets | 222,531 | 256,381 |
MetLife Holdings | ||
Segment Reporting Information [Line Items] | ||
Total assets | 133,791 | 161,614 |
Corporate & Other | ||
Segment Reporting Information [Line Items] | ||
Total assets | $ 30,526 | $ 28,562 |
Segment Information (Narrative)
Segment Information (Narrative) (Details) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) Segment | Sep. 30, 2021 USD ($) | |
Segment Reporting [Abstract] | ||||
Number of segments | Segment | 2 | |||
Segment Reporting Information [Line Items] | ||||
Total revenues | $ 17,386 | $ 10,194 | $ 36,273 | $ 30,089 |
Revenue Benchmark | ||||
Segment Reporting Information [Line Items] | ||||
Concentration Risk, Benchmark Description | 10 | 10 | 10 | 10 |
U.S. | One.U.S.Customer | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | $ 8,100 | $ 896 | $ 8,100 | $ 2,900 |
U.S. | One.U.S.Customer | Revenue Benchmark | Customer Concentration Risk | ||||
Segment Reporting Information [Line Items] | ||||
Concentration Risk, Percentage | 55% | 14% | 29% | 14% |
Insurance (Guarantees Related t
Insurance (Guarantees Related to Annuity Contracts) (Details) - USD ($) $ in Millions | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Variable Annuity Guarantees: | Guaranteed Death Benefits | ||
Net Amount at Risk by Product and Guarantee [Line Items] | ||
Total account value (1), (2) | $ 36,100 | $ 48,868 |
Separate account value (1) | 27,465 | 39,882 |
Net amount at risk | $ 5,139 | $ 1,160 |
Average attained age of contractholders | 69 years | 69 years |
Variable Annuity Guarantees: | Guaranteed Annuitization Benefits | ||
Net Amount at Risk by Product and Guarantee [Line Items] | ||
Total account value (1), (2) | $ 14,185 | $ 20,140 |
Separate account value (1) | 13,427 | 19,347 |
Net amount at risk | $ 638 | $ 461 |
Average attained age of contractholders | 69 years | 66 years |
Other Annuity Guarantees: | Guaranteed Annuitization Benefits | ||
Net Amount at Risk by Product and Guarantee [Line Items] | ||
Total account value (1), (2) | $ 135 | $ 135 |
Net amount at risk | $ 66 | $ 70 |
Average attained age of contractholders | 56 years | 55 years |
Insurance (Guarantees Related_2
Insurance (Guarantees Related to Universal and Variable Life Contracts) (Details) - Universal and Variable Life Contracts - USD ($) $ in Millions | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Secondary Guarantees | ||
Net Amount at Risk by Product and Guarantee [Line Items] | ||
Total account value (1), (2) | $ 4,622 | $ 5,935 |
Net amount at risk (6) | $ 37,546 | $ 37,482 |
Average attained age of policyholders | 59 years | 59 years |
Paid-Up Guarantees | ||
Net Amount at Risk by Product and Guarantee [Line Items] | ||
Total account value (1), (2) | $ 798 | $ 826 |
Net amount at risk (6) | $ 4,929 | $ 5,181 |
Average attained age of policyholders | 66 years | 65 years |
Insurance (Rollforward of Unpai
Insurance (Rollforward of Unpaid Claims) (Details) - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] | ||
Balance, beginning of period | $ 15,059 | $ 13,523 |
Less: Reinsurance recoverables | 2,263 | 1,639 |
Net balance, beginning of period | 12,796 | 11,884 |
Incurred related to: | ||
Current period | 15,527 | 15,300 |
Prior periods (1) | 378 | 511 |
Total incurred | 15,905 | 15,811 |
Paid related to: | ||
Current period | (10,018) | (10,249) |
Prior periods | (5,226) | (4,785) |
Total paid | (15,244) | (15,034) |
Net balance, end of period | 13,457 | 12,661 |
Add: Reinsurance recoverables | 2,044 | 2,099 |
Balance, end of period (included in future policy benefits and other policy-related balances) | $ 15,501 | $ 14,760 |
Closed Block (Liabilities and A
Closed Block (Liabilities and Assets) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Closed Block Liabilities | |||
Future policy benefits | $ 37,385 | $ 38,046 | |
Other policy-related balances | 257 | 290 | |
Policyholder dividends payable | 219 | 253 | |
Policyholder dividend obligation | 0 | 1,682 | $ 2,969 |
Deferred income tax liability | 0 | 210 | |
Other liabilities | 444 | 263 | |
Total closed block liabilities | 38,305 | 40,744 | |
Assets Designated to the Closed Block | |||
Fixed maturity securities available-for-sale, at estimated fair value | 19,515 | 25,669 | |
Mortgage loans | 6,624 | 6,417 | |
Policy loans | 4,096 | 4,191 | |
Real estate and real estate joint ventures | 604 | 565 | |
Other invested assets | 924 | 556 | |
Total investments | 31,763 | 37,398 | |
Cash and cash equivalents | 344 | 126 | |
Accrued investment income | 386 | 384 | |
Premiums, reinsurance and other receivables | 38 | 50 | |
Current income tax recoverable | 82 | 81 | |
Deferred income tax asset | 460 | 0 | |
Total assets designated to the closed block | 33,073 | 38,039 | |
Excess of closed block liabilities over assets designated to the closed block | 5,232 | 2,705 | |
AOCI: | |||
Unrealized investment gains (losses), net of income tax | (1,609) | 2,562 | |
Unrealized gains (losses) on derivatives, net of income tax | 408 | 107 | |
Allocated to policyholder dividend obligation, net of income tax | 0 | (1,329) | |
Total amounts included in AOCI | (1,201) | 1,340 | |
Maximum future earnings to be recognized from closed block assets and liabilities | $ 4,031 | $ 4,045 |
Closed Block (Policyholder Divi
Closed Block (Policyholder Dividend Obligation) (Details) - USD ($) $ in Millions | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Closed block policyholder dividend obligation | ||
Balance, beginning of period | $ 1,682 | $ 2,969 |
Change in unrealized investment and derivative gains (losses) | (1,682) | (1,287) |
Balance, end of period | $ 0 | $ 1,682 |
Closed Block (Revenues and Expe
Closed Block (Revenues and Expenses) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues | ||||
Premiums | $ 267 | $ 310 | $ 816 | $ 955 |
Net investment income | 326 | 390 | 1,039 | 1,165 |
Net investment gains (losses) | (4) | (7) | (52) | (12) |
Net derivative gains (losses) | 28 | 12 | 39 | 19 |
Total revenues | 617 | 705 | 1,842 | 2,127 |
Expenses | ||||
Policyholder benefits and claims | 459 | 522 | 1,404 | 1,588 |
Policyholder dividends | 91 | 127 | 352 | 478 |
Other expenses | 22 | 24 | 68 | 73 |
Total expenses | 572 | 673 | 1,824 | 2,139 |
Revenues, net of expenses before provision for income tax expense (benefit) | 45 | 32 | 18 | (12) |
Provision for income tax expense (benefit) | 10 | 6 | 4 | (3) |
Revenues, net of expenses and provision for income tax expense (benefit) | $ 35 | $ 26 | $ 14 | $ (9) |
Investments (Fixed Maturity Sec
Investments (Fixed Maturity Securities Available-For-Sale by Sector) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Dec. 31, 2020 |
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | $ 160,814 | $ 158,354 | ||||
Allowance for Credit Loss for Debt Securities | (117) | $ (124) | (53) | $ (35) | $ (59) | $ (51) |
Gross Unrealized Gains | 1,650 | 18,585 | ||||
Gross Unrealized Losses | 18,933 | 1,001 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 143,414 | 175,885 | ||||
U.S. corporate | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 55,430 | 51,328 | ||||
Allowance for Credit Loss for Debt Securities | (30) | (27) | (30) | (18) | (39) | (43) |
Gross Unrealized Gains | 432 | 7,257 | ||||
Gross Unrealized Losses | 5,729 | 153 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 50,103 | 58,402 | ||||
U.S. government and agency | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 23,718 | 26,782 | ||||
Allowance for Credit Loss for Debt Securities | 0 | 0 | ||||
Gross Unrealized Gains | 531 | 4,568 | ||||
Gross Unrealized Losses | 2,209 | 128 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 22,040 | 31,222 | ||||
Foreign corporate | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 28,681 | 27,475 | ||||
Allowance for Credit Loss for Debt Securities | (3) | (7) | (10) | (10) | (14) | (8) |
Gross Unrealized Gains | 113 | 2,651 | ||||
Gross Unrealized Losses | 5,929 | 431 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 22,862 | 29,685 | ||||
RMBS | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 22,297 | 22,082 | ||||
Allowance for Credit Loss for Debt Securities | 0 | 0 | ||||
Gross Unrealized Gains | 207 | 1,198 | ||||
Gross Unrealized Losses | 2,414 | 135 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 20,090 | 23,145 | ||||
ABS & CLO | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 12,450 | 12,787 | ||||
Allowance for Credit Loss for Debt Securities | 0 | 0 | ||||
Gross Unrealized Gains | 11 | 127 | ||||
Gross Unrealized Losses | 889 | 35 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 11,572 | 12,879 | ||||
Municipals | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 7,741 | 6,884 | ||||
Allowance for Credit Loss for Debt Securities | 0 | 0 | ||||
Gross Unrealized Gains | 217 | 1,849 | ||||
Gross Unrealized Losses | 720 | 5 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 7,238 | 8,728 | ||||
CMBS | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 6,532 | 6,686 | ||||
Allowance for Credit Loss for Debt Securities | (15) | (13) | (13) | (7) | (6) | 0 |
Gross Unrealized Gains | 3 | 237 | ||||
Gross Unrealized Losses | 582 | 32 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 5,938 | 6,878 | ||||
Foreign government | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 3,965 | 4,330 | ||||
Allowance for Credit Loss for Debt Securities | (69) | $ (77) | 0 | $ 0 | $ 0 | $ 0 |
Gross Unrealized Gains | 136 | 698 | ||||
Gross Unrealized Losses | 461 | 82 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | $ 3,571 | $ 4,946 |
Investments (Maturities of Fixe
Investments (Maturities of Fixed Maturity Securities) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Available-for-sale Securities, Debt Maturities [Abstract] | ||
Amortized Cost, Due in one year or less | $ 3,091 | |
Amortized Cost, Due after one year through five years | 26,418 | |
Amortized Cost, Due after five years through ten years | 28,564 | |
Amortized Cost, Due after ten years | 61,360 | |
Amortized Cost, Structured Securities | 41,264 | |
Amortized Cost net of ACL | 160,697 | |
Estimated Fair Value, Due in one year or less | 2,878 | |
Estimated Fair Value, Due after one year through five years | 24,706 | |
Estimated Fair Value, Due after five years through ten years | 25,593 | |
Estimated Fair Value, Due after ten years | 52,637 | |
Estimated Fair Value, Structured Securities | 37,600 | |
Estimated Fair Value of Fixed Maturity Securities AFS | $ 143,414 | $ 175,885 |
Investments (Continuous Gross U
Investments (Continuous Gross Unrealized Losses for Fixed Maturity Securities Available For Sale) Details (Details) $ in Millions | Sep. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) |
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | $ 104,038 | $ 34,033 |
Less than 12 months Gross Unrealized Loss | $ 15,804 | $ 557 |
Total number of securities in an unrealized loss position less than 12 months | 12,614 | 2,549 |
Equal to or Greater than 12 Months Estimated Fair Value | $ 11,199 | $ 4,082 |
Equal to or Greater than 12 Months Gross Unrealized Loss | $ 3,127 | $ 443 |
Total number of securities in an unrealized loss position equal or greater than 12 months | 1,284 | 427 |
U.S. corporate | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | $ 37,447 | $ 4,503 |
Less than 12 months Gross Unrealized Loss | 5,166 | 83 |
Equal to or Greater than 12 Months Estimated Fair Value | 2,031 | 784 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 563 | 70 |
U.S. government and agency | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 13,035 | 10,063 |
Less than 12 months Gross Unrealized Loss | 1,846 | 78 |
Equal to or Greater than 12 Months Estimated Fair Value | 1,560 | 523 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 363 | 49 |
Foreign corporate | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 18,150 | 4,079 |
Less than 12 months Gross Unrealized Loss | 4,744 | 199 |
Equal to or Greater than 12 Months Estimated Fair Value | 2,774 | 1,348 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 1,185 | 232 |
RMBS | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 14,946 | 7,481 |
Less than 12 months Gross Unrealized Loss | 1,800 | 111 |
Equal to or Greater than 12 Months Estimated Fair Value | 2,393 | 314 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 614 | 24 |
ABS & CLO | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 9,520 | 5,643 |
Less than 12 months Gross Unrealized Loss | 741 | 25 |
Equal to or Greater than 12 Months Estimated Fair Value | 1,367 | 593 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 148 | 10 |
Municipals | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 3,980 | 154 |
Less than 12 months Gross Unrealized Loss | 701 | 4 |
Equal to or Greater than 12 Months Estimated Fair Value | 49 | 17 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 19 | 1 |
CMBS | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 4,955 | 1,613 |
Less than 12 months Gross Unrealized Loss | 460 | 20 |
Equal to or Greater than 12 Months Estimated Fair Value | 793 | 355 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 121 | 12 |
Foreign government | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 2,005 | 497 |
Less than 12 months Gross Unrealized Loss | 346 | 37 |
Equal to or Greater than 12 Months Estimated Fair Value | 232 | 148 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 114 | 45 |
Investment Grade | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 97,820 | 31,419 |
Less than 12 months Gross Unrealized Loss | 14,938 | 454 |
Equal to or Greater than 12 Months Estimated Fair Value | 9,742 | 3,273 |
Equal to or Greater than 12 Months Gross Unrealized Loss | $ 2,686 | 353 |
Total number of securities in an unrealized loss position equal or greater than 12 months | 1,052 | |
Below Investment Grade | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | $ 6,218 | 2,614 |
Less than 12 months Gross Unrealized Loss | 866 | 103 |
Equal to or Greater than 12 Months Estimated Fair Value | 1,457 | 809 |
Equal to or Greater than 12 Months Gross Unrealized Loss | $ 441 | $ 90 |
Total number of securities in an unrealized loss position equal or greater than 12 months | 232 |
Investments (ACL for Fixed Matu
Investments (ACL for Fixed Maturity Securities AFS By Sector) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | $ 124 | $ 59 | $ 53 | $ 51 |
ACL not previously recorded | 3 | 18 | 131 | 39 |
Changes for securities with previously recorded ACL | (5) | (1) | 5 | (4) |
Securities sold or exchanged | (5) | (28) | (50) | (38) |
Write-offs | 0 | (13) | (22) | (13) |
Allowance, end of period | 117 | 35 | 117 | 35 |
U.S. corporate | ||||
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | 27 | 39 | 30 | 43 |
ACL not previously recorded | 0 | 18 | 13 | 18 |
Changes for securities with previously recorded ACL | 3 | 0 | 17 | 3 |
Securities sold or exchanged | 0 | (26) | (8) | (33) |
Write-offs | 0 | (13) | (22) | (13) |
Allowance, end of period | 30 | 18 | 30 | 18 |
Foreign corporate | ||||
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | 7 | 14 | 10 | 8 |
ACL not previously recorded | 1 | 0 | 12 | 12 |
Changes for securities with previously recorded ACL | 0 | (2) | 3 | (5) |
Securities sold or exchanged | (5) | (2) | (22) | (5) |
Write-offs | 0 | 0 | 0 | 0 |
Allowance, end of period | 3 | 10 | 3 | 10 |
CMBS | ||||
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | 13 | 6 | 13 | 0 |
ACL not previously recorded | 2 | 0 | 2 | 9 |
Changes for securities with previously recorded ACL | 0 | 1 | 0 | (2) |
Securities sold or exchanged | 0 | 0 | 0 | 0 |
Write-offs | 0 | 0 | 0 | 0 |
Allowance, end of period | 15 | 7 | 15 | 7 |
Foreign government | ||||
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | 77 | 0 | 0 | 0 |
ACL not previously recorded | 0 | 0 | 104 | 0 |
Changes for securities with previously recorded ACL | (8) | 0 | (15) | 0 |
Securities sold or exchanged | 0 | 0 | (20) | 0 |
Write-offs | 0 | 0 | 0 | 0 |
Allowance, end of period | $ 69 | $ 0 | $ 69 | $ 0 |
Investments (Mortgage Loans by
Investments (Mortgage Loans by Portfolio Segment) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Dec. 31, 2020 |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Mortgage Loans, Gross | $ 61,995 | $ 60,628 | ||
Allowance for Credit Loss | (392) | (536) | $ (490) | $ (517) |
Subtotal mortgage loans, net | 61,603 | 60,092 | ||
Total mortgage loans held-for-investment, net | 61,603 | 60,219 | ||
Mortgage loans (net of allowance for credit loss of $392 and $536, respectively; includes $143 and $224, respectively, relating to variable interest entities; $0 and $127, respectively, under the fair value option) | $ 61,603 | $ 60,219 | ||
Percentage Of mortgage total recorded investment To Mortgage Loans On Real Estate Commercial And Consumer Net | 100.60% | 100.70% | ||
Percentage of Allowance for Credit Losses for Financing Receivables | (0.60%) | (0.90%) | ||
Percentage Of Mortgage Loans Held For Investment Net To Mortgage Loans On Real Estate Commercial And Consumer Net | 100% | 99.80% | ||
Percentage Of Loans And Leases Receivable Consumer Other To Mortgage Loans On Real Estate Commercial And Consumer Net | 0% | 0.20% | ||
Percentage of total mortgage loans held-for-investments | 100% | 100% | ||
Percentage Of Mortgage Loans On Real Estate To Mortgage Loans On Real Estate Commercial And Consumer Net | 100% | 100% | ||
Residential mortgage loans — FVO | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Total mortgage loans held-for-investment, net | $ 0 | $ 127 | ||
Mortgage loans (net of allowance for credit loss of $392 and $536, respectively; includes $143 and $224, respectively, relating to variable interest entities; $0 and $127, respectively, under the fair value option) | 0 | 127 | ||
Commercial Mortgage Loans | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Mortgage Loans, Gross | 37,038 | 35,772 | ||
Allowance for Credit Loss | $ (169) | $ (260) | (217) | (199) |
Percentage Of Mortgage Loans, Gross | 60.10% | 59.40% | ||
Residential Mortgage Loans | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Mortgage Loans, Gross | $ 9,289 | $ 9,406 | ||
Allowance for Credit Loss | $ (118) | $ (197) | (188) | (221) |
Percentage Of Mortgage Loans, Gross | 15.10% | 15.60% | ||
Agricultural Mortgage Loans | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Mortgage Loans, Gross | $ 15,668 | $ 15,450 | ||
Allowance for Credit Loss | $ (105) | $ (79) | $ (85) | $ (97) |
Percentage Of Mortgage Loans, Gross | 25.40% | 25.70% |
Investments (Mortgage Loans All
Investments (Mortgage Loans Allowance for Credit Loss Rollforward by Portfolio Segment) (Details) - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Balance, beginning of period | $ 536 | $ 517 |
Provision (release) | (37) | (15) |
Initial credit losses on PCD loans (1) | 0 | 3 |
Charge-offs, net of recoveries | (107) | (15) |
Balance, end of period | 392 | 490 |
Commercial Mortgage Loans | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Balance, beginning of period | 260 | 199 |
Provision (release) | (8) | 18 |
Initial credit losses on PCD loans (1) | 0 | 0 |
Charge-offs, net of recoveries | (83) | 0 |
Balance, end of period | 169 | 217 |
Residential Mortgage Loans | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Balance, beginning of period | 197 | 221 |
Provision (release) | (77) | (34) |
Initial credit losses on PCD loans (1) | 0 | 3 |
Charge-offs, net of recoveries | (2) | (2) |
Balance, end of period | 118 | 188 |
Agricultural Mortgage Loans | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Balance, beginning of period | 79 | 97 |
Provision (release) | 48 | 1 |
Initial credit losses on PCD loans (1) | 0 | 0 |
Charge-offs, net of recoveries | (22) | (13) |
Balance, end of period | $ 105 | $ 85 |
Investments (Credit Quality of
Investments (Credit Quality of Commercial Mortgage Loans) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Mortgage Loans, Gross | $ 61,995 | $ 60,628 |
Commercial Mortgage Loans | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | 4,426 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 4,251 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 2,915 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 4,638 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 4,633 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 13,419 | |
Financing Receivable, Revolving | 2,756 | |
Mortgage Loans, Gross | $ 37,038 | $ 35,772 |
Loans Receivable Commercial Mortgage Percentage | 100% | |
Commercial Mortgage Loans | Greater than 1.20x | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 4,108 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 3,819 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 2,709 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 4,502 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 4,156 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 11,526 | |
Financing Receivable, Revolving | 2,756 | |
Mortgage Loans, Gross | $ 33,576 | |
Loans Receivable Commercial Mortgage Percentage | 90.60% | |
Commercial Mortgage Loans | 1.00x - 1.20x | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 285 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 235 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 18 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 9 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 152 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 803 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 1,502 | |
Loans Receivable Commercial Mortgage Percentage | 4.10% | |
Commercial Mortgage Loans | Less than 1.00x | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 33 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 197 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 188 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 127 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 325 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 1,090 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 1,960 | |
Loans Receivable Commercial Mortgage Percentage | 5.30% | |
Commercial Mortgage Loans | Less than 65% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 2,872 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 3,309 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 2,285 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 3,347 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 3,551 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 10,813 | |
Financing Receivable, Revolving | 2,756 | |
Mortgage Loans, Gross | $ 28,933 | |
Loans Receivable Commercial Mortgage Percentage | 78.10% | |
Commercial Mortgage Loans | 65% to 75% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 1,412 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 903 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 612 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 996 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 769 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 1,418 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 6,110 | |
Loans Receivable Commercial Mortgage Percentage | 16.50% | |
Commercial Mortgage Loans | 76% to 80% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 0 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 0 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 18 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 252 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 223 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 204 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 697 | |
Loans Receivable Commercial Mortgage Percentage | 1.90% | |
Commercial Mortgage Loans | Greater than 80% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 142 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 39 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 0 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 43 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 90 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 984 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 1,298 | |
Loans Receivable Commercial Mortgage Percentage | 3.50% |
Investments (Credit Quality o_2
Investments (Credit Quality of Agricultural and Residential Mortgage Loans) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Mortgage Loans, Gross | $ 61,995 | $ 60,628 |
Mortgage Loans in Process of Foreclosure, Amount | 142 | 69 |
Residential Mortgage Loans | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | 742 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 706 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 162 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 656 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 353 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 6,670 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 9,289 | 9,406 |
Loans Receivable Residential Mortgage Percentage | 100% | |
Residential Mortgage Loans | Performing | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 740 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 703 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 158 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 619 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 341 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 6,282 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 8,843 | |
Loans Receivable Residential Mortgage Percentage | 95.20% | |
Residential Mortgage Loans | Nonperforming | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 2 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 3 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 4 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 37 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 12 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 388 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 446 | |
Loans Receivable Residential Mortgage Percentage | 4.80% | |
Agricultural Mortgage Loans | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 1,747 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 1,702 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 2,238 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 1,772 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 2,154 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 4,878 | |
Financing Receivable, Revolving | 1,177 | |
Mortgage Loans, Gross | $ 15,668 | $ 15,450 |
Loans Receivable Agricultural Mortgage Percentage | 100% | |
Agricultural Mortgage Loans | Less than 65% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 1,603 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 1,474 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 1,928 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 1,516 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 2,103 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 4,331 | |
Financing Receivable, Revolving | 1,133 | |
Mortgage Loans, Gross | $ 14,088 | |
Loans Receivable Agricultural Mortgage Percentage | 89.90% | |
Agricultural Mortgage Loans | 65% to 75% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 144 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 228 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 296 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 180 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 51 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 491 | |
Financing Receivable, Revolving | 40 | |
Mortgage Loans, Gross | $ 1,430 | |
Loans Receivable Agricultural Mortgage Percentage | 9.10% | |
Agricultural Mortgage Loans | 76% to 80% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 0 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 0 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 0 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 0 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 0 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 12 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 12 | |
Loans Receivable Agricultural Mortgage Percentage | 0.10% | |
Agricultural Mortgage Loans | Greater than 80% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 0 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 0 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 14 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 76 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 0 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 44 | |
Financing Receivable, Revolving | 4 | |
Mortgage Loans, Gross | $ 138 | |
Loans Receivable Agricultural Mortgage Percentage | 0.90% |
Investments (Past Due and Inter
Investments (Past Due and Interest Accrual Status of Mortgage Loans) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Financing Receivable, Nonaccrual [Line Items] | |||
Mortgage Loans, Gross | $ 61,995 | $ 60,628 | |
Greater than 90 Days Past Due and Still Accruing Interest | 29 | 16 | |
Financing Receivable, Nonaccrual | 798 | 789 | |
Financial Asset, Past Due | |||
Financing Receivable, Nonaccrual [Line Items] | |||
Mortgage Loans, Gross | 561 | 542 | |
Commercial Mortgage Loans | |||
Financing Receivable, Nonaccrual [Line Items] | |||
Mortgage Loans, Gross | 37,038 | 35,772 | |
Greater than 90 Days Past Due and Still Accruing Interest | 0 | 0 | |
Financing Receivable, Nonaccrual | 142 | 146 | $ 293 |
Commercial Mortgage Loans | Financial Asset, Past Due | |||
Financing Receivable, Nonaccrual [Line Items] | |||
Mortgage Loans, Gross | 0 | 0 | |
Residential Mortgage Loans | |||
Financing Receivable, Nonaccrual [Line Items] | |||
Mortgage Loans, Gross | 9,289 | 9,406 | |
Greater than 90 Days Past Due and Still Accruing Interest | 2 | 0 | |
Financing Receivable, Nonaccrual | 449 | 418 | 503 |
Residential Mortgage Loans | Financial Asset, Past Due | |||
Financing Receivable, Nonaccrual [Line Items] | |||
Mortgage Loans, Gross | 446 | 418 | |
Agricultural Mortgage Loans | |||
Financing Receivable, Nonaccrual [Line Items] | |||
Mortgage Loans, Gross | 15,668 | 15,450 | |
Greater than 90 Days Past Due and Still Accruing Interest | 27 | 16 | |
Financing Receivable, Nonaccrual | 207 | 225 | $ 261 |
Agricultural Mortgage Loans | Financial Asset, Past Due | |||
Financing Receivable, Nonaccrual [Line Items] | |||
Mortgage Loans, Gross | $ 115 | $ 124 |
Investments (Real Estate and Re
Investments (Real Estate and Real Estate Joint Ventures) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Real Estate [Line Items] | |||||
Leased real estate investments, Carrying Value | $ 1,763 | $ 1,763 | $ 1,934 | ||
Other real estate investments, Carrying Value | 478 | 478 | 473 | ||
Real estate joint ventures, Carrying Value | 5,977 | 5,977 | 5,466 | ||
Real Estate Investments, Net | 8,218 | 8,218 | $ 7,873 | ||
Income (Loss) from Equity Method Investments | (145) | $ 1,100 | 660 | $ 2,600 | |
Gross Investment Income, Operating | 2,505 | 3,496 | 8,111 | 10,028 | |
Real Estate and Real Estate Joint Ventures | |||||
Real Estate [Line Items] | |||||
Gross Investment Income, Operating | 184 | 176 | 616 | 400 | |
Leased real estate | |||||
Real Estate [Line Items] | |||||
Operating Lease, Lease Income | 47 | 53 | 151 | 160 | |
Other real estate | |||||
Real Estate [Line Items] | |||||
Operating Lease, Lease Income | 88 | 53 | 184 | 133 | |
Real estate joint ventures | |||||
Real Estate [Line Items] | |||||
Income (Loss) from Equity Method Investments | $ 49 | $ 70 | $ 281 | $ 107 |
Investments (FVO Securities and
Investments (FVO Securities and Equity Securities) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
FVO Securities | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Debt Securities, Trading, and Equity Securities, FV-NI, Cost | $ 704 | $ 598 |
Equity and Trading Securities, FV-NI, Unrealized Gains (Losses) | 111 | 250 |
Debt Securities, Trading, and Equity Securities, FV-NI | 815 | 848 |
Common Stock | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Equity Securities, FV-NI, Cost | 83 | 88 |
Equity and Trading Securities, FV-NI, Unrealized Gains (Losses) | 42 | 32 |
Equity Securities, FV-NI | 125 | 120 |
Non-redeemable preferred stock | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Equity Securities, FV-NI, Cost | 122 | 107 |
Equity and Trading Securities, FV-NI, Unrealized Gains (Losses) | (7) | (1) |
Equity Securities, FV-NI | 115 | 106 |
Equity securities | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Equity Securities, FV-NI, Cost | 205 | 195 |
Equity and Trading Securities, FV-NI, Unrealized Gains (Losses) | 35 | 31 |
Equity Securities, FV-NI | $ 240 | $ 226 |
Investments (Net Unrealized Inv
Investments (Net Unrealized Investment Gains Losses) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Components of net unrealized investment gains (losses) included in accumulated other comprehensive income | ||
Fixed maturity securities AFS | $ (17,233) | $ 17,586 |
Derivatives | 3,181 | 2,370 |
Other | 420 | 377 |
Subtotal | (13,632) | 20,333 |
Policyholder liabilities | 55 | (5,962) |
DAC, VOBA and DSI | 1,403 | (1,357) |
Subtotal | 1,458 | (7,319) |
Deferred income tax benefit (expense) | 2,645 | (2,657) |
Net unrealized investment gains (losses) | $ (9,529) | $ 10,357 |
Investments (Changes in Net Unr
Investments (Changes in Net Unrealized Investment Gains Losses) (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2022 USD ($) | |
Changes In Net Unrealized Investment Gains Losses Included In Accumulated Other Comprehensive Loss [Abstract] | |
Balance, beginning of period | $ 10,357 |
Unrealized investment gains (losses) during the period | (33,965) |
Unrealized investment gains (losses) relating to: | |
Policyholder liabilities | 6,017 |
DAC, VOBA and DSI | 2,760 |
Deferred income tax benefit (expense) | 5,302 |
Balance, end of period | (9,529) |
Change in net unrealized investment gains (losses) | $ (19,886) |
Investments (Securities Lending
Investments (Securities Lending and Repurchase Agreements) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | $ 8,095 | $ 14,977 |
Securities Lending Reinvestment Portfolio Estimated Fair Value | 7,882 | 15,116 |
Estimated fair value | ||
Securities Financing Transaction [Line Items] | ||
Securities loaned | 7,894 | 14,689 |
Repurchase Agreements | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 3,125 | 3,325 |
Securities Lending Reinvestment Portfolio Estimated Fair Value | 3,043 | 3,357 |
Repurchase Agreements | Estimated fair value | ||
Securities Financing Transaction [Line Items] | ||
Securities Sold under Agreements to Repurchase | $ 3,160 | $ 3,416 |
Investments (Securities Lendi_2
Investments (Securities Lending and Repurchase Agreements Remaining Tenor) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | $ 8,095 | $ 14,977 |
Repurchase Agreements | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 3,125 | 3,325 |
U.S. government and agency | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 8,095 | 14,977 |
U.S. government and agency | Open (1) | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 927 | 3,996 |
U.S. government and agency | 1 Month or Less | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 4,393 | 5,279 |
U.S. government and agency | Over 1 Month to 6 Months | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 2,775 | 5,702 |
U.S. government and agency | Over 6 Months to 1 Year | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 0 | 0 |
U.S. government and agency | Repurchase Agreements | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 3,125 | 3,325 |
U.S. government and agency | Repurchase Agreements | Open (1) | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 0 | 0 |
U.S. government and agency | Repurchase Agreements | 1 Month or Less | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 3,125 | 3,325 |
U.S. government and agency | Repurchase Agreements | Over 1 Month to 6 Months | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 0 | 0 |
U.S. government and agency | Repurchase Agreements | Over 6 Months to 1 Year | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | $ 0 | $ 0 |
Investments (Invested Assets on
Investments (Invested Assets on Deposit and Pledged as Collateral) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Investments, Debt and Equity Securities [Abstract] | ||
Invested assets on deposit (regulatory deposits) | $ 97 | $ 118 |
Invested assets pledged as collateral (1) | 21,519 | 20,390 |
Total invested assets on deposit and pledged as collateral | $ 21,616 | $ 20,508 |
Investments (Consolidated Varia
Investments (Consolidated Variable Interest Entities) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Variable Interest Entity [Line Items] | ||
Assets | $ 386,848 | $ 446,557 |
Liabilities | 373,097 | 413,129 |
Consolidated Entities [Member] | Variable Interest Entity, Primary Beneficiary | ||
Variable Interest Entity [Line Items] | ||
Assets | 1,344 | 1,500 |
Liabilities | 0 | 0 |
Real estate joint ventures | Variable Interest Entity, Primary Beneficiary | Affiliated Entity [Member] | ||
Variable Interest Entity [Line Items] | ||
Assets | 110 | 112 |
Real estate joint ventures | Variable Interest Entity, Primary Beneficiary | Parent [Member] | ||
Variable Interest Entity [Line Items] | ||
Assets | 907 | 1,000 |
Real estate joint ventures | Consolidated Entities [Member] | Variable Interest Entity, Primary Beneficiary | ||
Variable Interest Entity [Line Items] | ||
Assets | 1,017 | 1,094 |
Liabilities | 0 | 0 |
Mortgage loans | Variable Interest Entity, Primary Beneficiary | Affiliated Entity [Member] | ||
Variable Interest Entity [Line Items] | ||
Assets | 27 | 39 |
Mortgage loans | Variable Interest Entity, Primary Beneficiary | Parent [Member] | ||
Variable Interest Entity [Line Items] | ||
Assets | 124 | 187 |
Mortgage loans | Consolidated Entities [Member] | Variable Interest Entity, Primary Beneficiary | ||
Variable Interest Entity [Line Items] | ||
Assets | 151 | 226 |
Liabilities | 0 | 0 |
Other Investments | Consolidated Entities [Member] | Variable Interest Entity, Primary Beneficiary | ||
Variable Interest Entity [Line Items] | ||
Assets | 98 | 101 |
Liabilities | 0 | 0 |
Renewable energy partnership | Consolidated Entities [Member] | Variable Interest Entity, Primary Beneficiary | ||
Variable Interest Entity [Line Items] | ||
Assets | 78 | 79 |
Liabilities | $ 0 | $ 0 |
Investments (Unconsolidated Var
Investments (Unconsolidated Variable Interest Entities) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Variable Interest Entity [Line Items] | ||
Assets | $ 386,848 | $ 446,557 |
Tax Credits Guaranteed By Third Parties Amount That Reduces Maximum Exposure To Loss Related To Other Invested Assets | 6 | 5 |
Variable Interest Entity, Not Primary Beneficiary | ||
Variable Interest Entity [Line Items] | ||
Assets | 44,896 | 53,360 |
Maximum Exposure to Loss | 47,580 | 56,625 |
Variable Interest Entity, Not Primary Beneficiary | Fixed Maturity Securities | ||
Variable Interest Entity [Line Items] | ||
Assets | 35,907 | 43,653 |
Maximum Exposure to Loss | 35,907 | 43,653 |
Variable Interest Entity, Not Primary Beneficiary | Other limited partnership interests | ||
Variable Interest Entity [Line Items] | ||
Assets | 7,410 | 8,005 |
Maximum Exposure to Loss | 9,871 | 11,057 |
Variable Interest Entity, Not Primary Beneficiary | Other invested assets | ||
Variable Interest Entity [Line Items] | ||
Assets | 1,368 | 1,605 |
Maximum Exposure to Loss | 1,589 | 1,815 |
Variable Interest Entity, Not Primary Beneficiary | Real estate joint ventures | ||
Variable Interest Entity [Line Items] | ||
Assets | 211 | 97 |
Maximum Exposure to Loss | $ 213 | $ 100 |
Investments (Net Investment Inc
Investments (Net Investment Income) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | $ 2,505 | $ 3,496 | $ 8,111 | $ 10,028 |
Less: Investment expenses | 245 | 165 | 583 | 476 |
Net investment income | 2,260 | 3,331 | 7,528 | 9,552 |
Fixed Maturity Securities | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 1,627 | 1,520 | 4,671 | 4,574 |
Equity securities | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 7 | 2 | 9 | 14 |
Mortgage loans | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 654 | 643 | 1,872 | 2,015 |
Policy loans | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 72 | 72 | 216 | 221 |
Real Estate and Real Estate Joint Ventures | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 184 | 176 | 616 | 400 |
Other limited partnership interests | ||||
Net Investment Income [Line Items] | ||||
Net investment income | (153) | 992 | 444 | 2,569 |
Cash, cash equivalents and short-term investments | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 44 | 2 | 59 | 7 |
FVO Securities | ||||
Net Investment Income [Line Items] | ||||
Net investment income | (40) | 4 | (182) | 65 |
Operating joint venture | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 9 | 12 | 51 | 45 |
Other Investments | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | $ 101 | $ 73 | $ 355 | $ 118 |
Investments (Components of Net
Investments (Components of Net Investment Gains Losses - Asset Type) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Marketable Securities, Gain (Loss) [Abstract] | ||||
Fixed maturity securities AFS | $ (167) | $ 43 | $ (825) | $ 14 |
Equity securities | (1) | (11) | 3 | 34 |
Other net investment gains (losses): | ||||
Mortgage loans | 15 | 5 | 25 | 21 |
Real estate and real estate joint ventures (excluding changes in estimated fair value) | 0 | 132 | 163 | 548 |
Other limited partnership interests (excluding changes in estimated fair value) | (1) | 0 | 4 | (14) |
Other gains (losses) | (16) | 17 | 50 | 65 |
Subtotal - investment portfolio gains (losses) | (170) | 186 | (580) | 668 |
Change In Estimated Fair Value Of Other Limited Partnership Interests And Real Estate Joint Ventures | (19) | 9 | (13) | 23 |
Non-investment portfolio gains (losses) | 107 | (5) | 202 | 1 |
Subtotal | 88 | 4 | 189 | 24 |
Net investment gains (losses) | $ (82) | $ 190 | $ (391) | $ 692 |
Investments (Components of Ne_2
Investments (Components of Net Investment Gains Losses - Transaction Type) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Investments, Debt and Equity Securities [Abstract] | ||||
Realized gains (losses) on investments sold or disposed | $ (199) | $ 154 | $ (530) | $ 568 |
Impairments | (4) | (11) | (37) | (24) |
Change in allowance for credit loss recognized in earnings | 34 | 31 | (17) | 31 |
Unrealized net gains (losses) recognized in earnings | (20) | 21 | (9) | 116 |
Total recognized gains (losses) | 14 | 52 | (26) | 147 |
Non-investment portfolio gains (losses) | 107 | (5) | 202 | 1 |
Net investment gains (losses) | $ (82) | $ 190 | $ (391) | $ 692 |
Investments (Fixed Maturity S_2
Investments (Fixed Maturity Securities AFS - Sales and Disposals and Credit Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Debt Securities, Available-for-sale [Line Items] | ||||
Proceeds | $ 11,337 | $ 7,279 | $ 31,325 | $ 19,123 |
Gross investment gains | 88 | 91 | 158 | 199 |
Gross investment (losses) | (259) | (62) | (882) | (178) |
Realized gains (losses) on sales and disposals | (171) | 29 | (724) | 21 |
Net credit loss (provision) release (change in ACL recognized in earnings) | 8 | 24 | (64) | 16 |
Impairment (loss) | (4) | (10) | (37) | (23) |
Net credit loss (provision) release and impairment (loss) | 4 | 14 | (101) | (7) |
Net investment gains (losses) | (199) | 154 | (530) | 568 |
Equity securities, Realized gains(losses) on sales and disposals | 2 | (21) | (2) | (54) |
Equity Securities, FV-NI, Unrealized Gain (Loss) | (3) | 10 | 5 | 88 |
Equity Securities, FV-NI, Gain (Loss) | (1) | (11) | 3 | 34 |
Fixed Maturity Securities | ||||
Debt Securities, Available-for-sale [Line Items] | ||||
Net investment gains (losses) | $ (167) | $ 43 | $ (825) | $ 14 |
Investments (Recurring Related
Investments (Recurring Related Party Investments Transactions) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Related Party Transaction [Line Items] | |||||
Other Investments | $ 21,532 | $ 21,532 | $ 19,860 | ||
Minimum | |||||
Related Party Transaction [Line Items] | |||||
Debt Instrument, Interest Rate, Stated Percentage | 1.60% | 1.60% | |||
Maximum | |||||
Related Party Transaction [Line Items] | |||||
Debt Instrument, Interest Rate, Stated Percentage | 1.85% | 1.85% | |||
Metlife Inc | |||||
Related Party Transaction [Line Items] | |||||
Other Investments | $ 1,100 | $ 1,100 | 1,399 | ||
Related Party Transaction, Other Revenues from Transactions with Related Party | 5 | $ 8 | 15 | $ 24 | |
American Life Insurance Company | |||||
Related Party Transaction [Line Items] | |||||
Other Investments | 100 | 100 | 100 | ||
Related Party Transaction, Other Revenues from Transactions with Related Party | $ 0 | 0 | $ 1 | 1 | |
Debt Instrument, Interest Rate, Stated Percentage | 1.88% | 1.88% | |||
Affiliated Entity | |||||
Related Party Transaction [Line Items] | |||||
Assets Transferred To Affiliates, Estimated Fair Value | $ 139 | 393 | $ 328 | 696 | |
Transfers of Financial Assets Accounted for as Sale, Amortized Cost of Assets Obtained as Proceeds | 136 | 379 | 327 | 679 | |
Securitization or Asset-backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale, Gain (Loss) on Sale | 3 | 14 | 1 | 17 | |
Assets Transferred From Affiliates Estimated Fair Value | 130 | 584 | 332 | 1,228 | |
Derivative Liabilities Transferred From Affiliates, Estimated Fair derivative liabilities transferred from affiliates, Estimated Fair Value | 0 | 0 | 64 | 0 | |
Other Investments | 1,200 | 1,200 | $ 1,499 | ||
Affiliated Entity | Other Investments | |||||
Related Party Transaction [Line Items] | |||||
Related Party Transaction, Other Revenues from Transactions with Related Party | $ 5 | $ 8 | $ 16 | $ 25 |
Investments (Fixed Maturity S_3
Investments (Fixed Maturity Securities AFS - Narrative) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Debt Securities, Available-for-sale [Line Items] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | $ 143,414 | $ 175,885 |
Gross Unrealized Gains | 1,650 | 18,585 |
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax | (18,933) | (1,001) |
Nonperforming | ||
Debt Securities, Available-for-sale [Line Items] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 107 | 19 |
Gross Unrealized Gains | $ 10 | |
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax | $ (13) |
Investments (Evaluation of Fixe
Investments (Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position - Narrative) (Details) $ in Millions | 9 Months Ended | |
Sep. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Debt Securities, Available-for-sale [Line Items] | ||
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | $ 18,900 | |
Equal to or Greater than 12 Months Gross Unrealized Loss | $ 3,127 | $ 443 |
Percentage Of Gross Unrealized Loss for 12 months or greater | 17% | |
Total number of securities in an unrealized loss position equal or greater than 12 months | 1,284 | 427 |
Investment Grade | ||
Debt Securities, Available-for-sale [Line Items] | ||
Equal to or Greater than 12 Months Gross Unrealized Loss | $ 2,686 | $ 353 |
Percentage Of Gross Unrealized Loss for 12 months or greater | 86% | |
Total number of securities in an unrealized loss position equal or greater than 12 months | 1,052 | |
Below Investment Grade | ||
Debt Securities, Available-for-sale [Line Items] | ||
Equal to or Greater than 12 Months Gross Unrealized Loss | $ 441 | $ 90 |
Percentage Of Gross Unrealized Loss for 12 months or greater | 14% | |
Total number of securities in an unrealized loss position equal or greater than 12 months | 232 | |
Fixed maturity securities without an allowance for credit loss | ||
Debt Securities, Available-for-sale [Line Items] | ||
Change in Gross Unrealized Temporary Loss | $ 17,900 |
Investments (Mortgage Loans - N
Investments (Mortgage Loans - Narrative) (Details) $ in Millions | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2022 USD ($) Contracts | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) Contracts | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||||
Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums | $ (656) | $ (656) | $ (736) | |||
Financing Receivable, Purchase | 182 | $ 262 | 1,300 | $ 1,100 | ||
Mortgage Loans, Gross | $ 61,995 | $ 61,995 | $ 60,628 | |||
Percentage of Mortgage Loans Classified as Performing | 99% | 99% | 99% | |||
Financing Receivable, Nonaccrual | $ 798 | $ 798 | $ 789 | |||
Commercial Mortgage Loans | ||||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||||
Interest Receivable | 161 | 161 | 140 | |||
Mortgage Loans, Gross | 37,038 | 37,038 | 35,772 | |||
Financing Receivable, Nonaccrual | 142 | 142 | 146 | $ 293 | ||
Financing Receivable, Nonaccrual, No Allowance | $ 0 | $ 0 | 0 | |||
Financing Receivable, Modifications, Number of Contracts | Contracts | 1 | 2 | ||||
Financing Receivable, Troubled Debt Restructuring, Premodification | $ 31 | $ 123 | ||||
Financing Receivable, Troubled Debt Restructuring, Postmodification | 31 | 123 | ||||
Residential Mortgage Loans | ||||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||||
Interest Receivable | 68 | 68 | 77 | |||
Mortgage Loans, Gross | 9,289 | 9,289 | 9,406 | |||
Financing Receivable, Nonaccrual | 449 | 449 | 418 | 503 | ||
Financing Receivable, Nonaccrual, No Allowance | 0 | 0 | 0 | |||
Agricultural Mortgage Loans | ||||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||||
Interest Receivable | 127 | 127 | 136 | |||
Mortgage Loans, Gross | 15,668 | 15,668 | 15,450 | |||
Financing Receivable, Nonaccrual | 207 | 207 | 225 | $ 261 | ||
Financing Receivable, Nonaccrual, No Allowance | $ 88 | $ 88 | $ 134 | |||
Maximum | ||||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||||
Percentage of mortgage loans with LTV ratio in excess of 100% | 1% | 1% | ||||
Mortgage Loans with LTV ratio in excess of 100% [Member] | ||||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||||
Mortgage Loans, Gross | $ 565 | $ 565 |
Investments (Real Estate and _2
Investments (Real Estate and Real Estate Joint Ventures - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Real Estate [Line Items] | |||||
Real Estate Acquired Through Foreclosure | $ 173 | $ 173 | $ 180 | ||
Real Estate Investment Property, Net | 634 | 634 | $ 581 | ||
Real Estate and Real Estate Joint Ventures | |||||
Real Estate [Line Items] | |||||
Depreciation | $ 22 | $ 22 | $ 64 | $ 65 |
Investments (Leveraged and Dire
Investments (Leveraged and Direct Financing Leases - Narrative) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Investments, All Other Investments [Abstract] | ||
Leveraged Leases, Net Investment in Leveraged Leases Disclosure, Investment in Leveraged Leases, Net | $ 795 | $ 787 |
Direct Financing Lease, Net Investment in Lease, after Allowance for Credit Loss | 128 | 137 |
Net Investment in Lease, Allowance for Credit Loss | $ 26 | $ 32 |
Investments (Cash Equivalents -
Investments (Cash Equivalents - Narrative) (Details) - USD ($) $ in Billions | Sep. 30, 2022 | Dec. 31, 2021 |
Investments, Debt and Equity Securities [Abstract] | ||
Cash equivalents | $ 5.9 | $ 4.7 |
Investments (Concentrations of
Investments (Concentrations of Credit Risk - Narrative) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Investments, Debt and Equity Securities [Abstract] | ||
Fair Value, Concentration of Risk, Investments | $ 0 | $ 0 |
Investments (Invested Assets _2
Investments (Invested Assets on Deposits and Pledged as Collateral - Narrative) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Investments, Debt and Equity Securities [Abstract] | ||
Federal Home Loan Bank Stock | $ 698 | $ 718 |
Investments (Net Investment I_2
Investments (Net Investment Income - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Net Investment Income [Line Items] | ||||
Debt and Equity Securities, Realized Gain (Loss) | $ (202) | $ 154 | $ (537) | $ 590 |
Equity Securities, FV-NI, Unrealized Gain (Loss) | (3) | 10 | 5 | 88 |
Income (Loss) from Equity Method Investments | (145) | 1,100 | 660 | 2,600 |
Net investment Income | ||||
Net Investment Income [Line Items] | ||||
Debt and Equity Securities, Gain (Loss) | (24) | 43 | (85) | 134 |
Debt and Equity Securities, Realized Gain (Loss) | (3) | 0 | (7) | 22 |
Debt and Equity Securities, Unrealized Gain (Loss) | (21) | 43 | (78) | 112 |
Unit-linked investments | ||||
Net Investment Income [Line Items] | ||||
Equity Securities, FV-NI, Unrealized Gain (Loss) | $ (40) | $ 1 | $ (187) | $ 41 |
Investments (Net Investment Gai
Investments (Net Investment Gains Losses - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Debt Securities, Available-for-sale [Line Items] | ||||
Debt and Equity Securities, Realized Gain (Loss) | $ (202) | $ 154 | $ (537) | $ 590 |
Equity Securities, FV-NI, Unrealized Gain (Loss) | (3) | 10 | 5 | 88 |
Net investment gains (losses) | (82) | 190 | (391) | 692 |
Foreign Currency Transaction Gain (Loss), Realized | 95 | 14 | 161 | 33 |
Equity securities | ||||
Debt Securities, Available-for-sale [Line Items] | ||||
Equity Securities, FV-NI, Unrealized Gain (Loss) | (2) | 1 | 2 | 23 |
Cash Flow Hedging [Member] | ||||
Debt Securities, Available-for-sale [Line Items] | ||||
Net investment gains (losses) | (16) | 5 | 42 | 49 |
Foreign Currency Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income | Cash Flow Hedging [Member] | ||||
Debt Securities, Available-for-sale [Line Items] | ||||
Net investment gains (losses) | $ (15) | $ 8 | $ 55 | $ 56 |
Investments (Related Party Inve
Investments (Related Party Investment Transactions - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Investments, Debt and Equity Securities [Abstract] | ||||
Costs and Expenses, Related Party | $ 68 | $ 75 | $ 204 | $ 219 |
Derivatives (Primary Risks) (De
Derivatives (Primary Risks) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | $ 10,776 | $ 8,618 |
Estimated Fair Value Liabilities | 4,146 | 1,409 |
Derivative, Notional Amount | 213,864 | 201,482 |
Derivatives Designated as Hedging Instruments: | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 4,883 | 3,561 |
Estimated Fair Value Liabilities | 3,018 | 996 |
Derivative, Notional Amount | 39,017 | 40,213 |
Derivatives Designated as Hedging Instruments: | Fair Value Hedges [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 1,558 | 2,171 |
Estimated Fair Value Liabilities | 425 | 28 |
Derivative, Notional Amount | 4,708 | 4,304 |
Derivatives Designated as Hedging Instruments: | Fair Value Hedges [Member] | Interest rate swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 1,435 | 2,163 |
Estimated Fair Value Liabilities | 425 | 6 |
Derivative, Notional Amount | 4,115 | 3,540 |
Derivatives Designated as Hedging Instruments: | Fair Value Hedges [Member] | Foreign currency swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 123 | 8 |
Estimated Fair Value Liabilities | 0 | 22 |
Derivative, Notional Amount | 593 | 764 |
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 3,325 | 1,390 |
Estimated Fair Value Liabilities | 2,593 | 968 |
Derivative, Notional Amount | 34,309 | 35,909 |
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | Interest rate swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 6 | 4 |
Estimated Fair Value Liabilities | 19 | 1 |
Derivative, Notional Amount | 3,740 | 4,079 |
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | Interest rate forwards | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 0 | 69 |
Estimated Fair Value Liabilities | 448 | 1 |
Derivative, Notional Amount | 2,783 | 3,058 |
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | Foreign currency swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 3,319 | 1,317 |
Estimated Fair Value Liabilities | 2,126 | 966 |
Derivative, Notional Amount | 27,786 | 28,772 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 5,893 | 5,057 |
Estimated Fair Value Liabilities | 1,128 | 413 |
Derivative, Notional Amount | 174,847 | 161,269 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 1,670 | 3,206 |
Estimated Fair Value Liabilities | 685 | 59 |
Derivative, Notional Amount | 17,596 | 21,565 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate forwards | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 0 | 0 |
Estimated Fair Value Liabilities | 102 | 20 |
Derivative, Notional Amount | 265 | 265 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate floors | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 58 | 145 |
Estimated Fair Value Liabilities | 0 | 0 |
Derivative, Notional Amount | 16,170 | 7,701 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate caps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 1,012 | 117 |
Estimated Fair Value Liabilities | 0 | 0 |
Derivative, Notional Amount | 63,659 | 64,309 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate futures | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 0 | 0 |
Estimated Fair Value Liabilities | 2 | 0 |
Derivative, Notional Amount | 418 | 515 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate options | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 601 | 364 |
Estimated Fair Value Liabilities | 0 | 0 |
Derivative, Notional Amount | 20,367 | 9,703 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Synthetic GICs | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 0 | 0 |
Estimated Fair Value Liabilities | 0 | 0 |
Derivative, Notional Amount | 11,808 | 11,307 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Foreign currency swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 1,318 | 340 |
Estimated Fair Value Liabilities | 0 | 75 |
Derivative, Notional Amount | 6,336 | 4,800 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Foreign currency forwards | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 27 | 11 |
Estimated Fair Value Liabilities | 8 | 13 |
Derivative, Notional Amount | 1,222 | 1,902 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Credit default swaps — purchased | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 29 | 12 |
Estimated Fair Value Liabilities | 0 | 8 |
Derivative, Notional Amount | 902 | 956 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Credit default swaps — written | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 73 | 111 |
Estimated Fair Value Liabilities | 77 | 12 |
Derivative, Notional Amount | 10,569 | 6,074 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity futures | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 14 | 5 |
Estimated Fair Value Liabilities | 1 | 0 |
Derivative, Notional Amount | 1,155 | 1,751 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity index options | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 901 | 714 |
Estimated Fair Value Liabilities | 144 | 166 |
Derivative, Notional Amount | 20,799 | 26,800 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity variance swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 12 | 12 |
Estimated Fair Value Liabilities | 10 | 10 |
Derivative, Notional Amount | 425 | 425 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity Total Return Swaps [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 178 | 11 |
Estimated Fair Value Liabilities | 0 | 46 |
Derivative, Notional Amount | 2,108 | 2,148 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity total return swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 0 | 9 |
Estimated Fair Value Liabilities | 99 | 4 |
Derivative, Notional Amount | $ 1,048 | $ 1,048 |
Derivatives Derivatives (Effect
Derivatives Derivatives (Effects on the Consolidated Statement of Operations and Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | $ 454 | $ 84 | $ 980 | $ (906) | |
Net Investment Income | (2,260) | (3,331) | (7,528) | (9,552) | |
Net policyholder benefits and claims | (14,178) | (6,628) | (26,675) | (20,336) | |
Interest credited to policyholder account balances | (624) | (512) | (1,645) | (1,535) | |
Net investment gains (losses) | (82) | 190 | (391) | 692 | |
Net Embedded Derivatives | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Derivative [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Net Investment Income | (125) | (83) | (418) | (192) | |
Net policyholder benefits and claims | (67) | (56) | (385) | 58 | |
Interest credited to policyholder account balances | (42) | (43) | (115) | (120) | |
Net investment gains (losses) | (16) | 5 | 42 | 49 | |
Other Comprehensive Income (Loss), before Tax | 769 | 461 | 811 | (9) | |
Nonperformance Risk [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Net derivatives gains (losses) | 42 | 5 | 41 | (10) | |
Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | (16) | (16) | (49) | (45) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | (16) | 5 | 42 | 49 | |
Other Comprehensive Income (Loss), before Tax | 769 | 461 | 811 | (9) | |
Fair Value Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | (1) | (5) | (2) | (7) | |
Net policyholder benefits and claims | (28) | (5) | (65) | (39) | |
Interest credited to policyholder account balances | (1) | 0 | (2) | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Net Embedded Derivatives | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 250 | 29 | 1,424 | 663 | |
Fixed Maturities [Member] | Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Hedged Asset, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) | (142) | (142) | $ (161) | ||
Interest rate contracts | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | (15) | (14) | (46) | (41) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | (16) | 8 | 55 | 56 | |
Other Comprehensive Income (Loss), before Tax | 1 | (22) | (101) | (97) | |
Currency Swap [Member] | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | (1) | (2) | (3) | (4) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | (485) | (257) | (1,117) | (265) | |
Other Comprehensive Income (Loss), before Tax | 484 | 255 | 1,114 | 261 | |
Foreign Currency Gain (Loss) [Member] | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 485 | 254 | 1,104 | 258 | |
Other Comprehensive Income (Loss), before Tax | 0 | 0 | 0 | 0 | |
Derivative [Member] | Currency Swap [Member] | Fair Value Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | (64) | (28) | (154) | (39) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Derivative [Member] | Interest Rate Swap [Member] | Fair Value Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | (2) | (1) | (8) | (4) | |
Net policyholder benefits and claims | 292 | 53 | 1,137 | 418 | |
Interest credited to policyholder account balances | (16) | 0 | (26) | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Fixed Maturity Securities | Currency Swap [Member] | Fair Value Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | (65) | (22) | 152 | (32) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Fixed Maturity Securities | Interest Rate Swap [Member] | Fair Value Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | 0 | (2) | 8 | (4) | |
Net policyholder benefits and claims | 264 | 48 | 1,072 | 379 | |
Interest credited to policyholder account balances | (15) | 0 | (24) | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Accumulated Other Comprehensive Income (Loss) | Currency Swap [Member] | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Other Comprehensive Income (Loss), before Tax | 608 | 201 | 1,232 | 503 | |
Accumulated Other Comprehensive Income (Loss) | Interest Rate Swap [Member] | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Other Comprehensive Income (Loss), before Tax | (324) | 27 | (1,434) | (676) | |
Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 60 | (110) | (847) | (2,068) | |
Net Investment Income | (8) | (1) | (42) | (1) | |
Net policyholder benefits and claims | 62 | 8 | 320 | (174) | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Not Designated as Hedging Instrument [Member] | Nonoperating Income (Expense) [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Net Investment Income | (100) | (63) | (325) | (141) | |
Net policyholder benefits and claims | (33) | (53) | (130) | (155) | |
Interest credited to policyholder account balances | (41) | (43) | (113) | (120) | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Other Comprehensive Income (Loss), before Tax | 0 | 0 | 0 | 0 | |
Not Designated as Hedging Instrument [Member] | Nonoperating Income (Expense) [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 144 | 165 | 403 | 499 | |
Equity Market Risk [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 163 | 34 | 724 | (793) | |
Net Investment Income | (8) | 0 | (37) | (2) | |
Net policyholder benefits and claims | 62 | 8 | 320 | (174) | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Foreign Currency Gain (Loss) [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | (189) | (50) | (431) | (62) | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Interest Rate Risk [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | (395) | (276) | (1,998) | (1,463) | |
Net Investment Income | 0 | (1) | (3) | (1) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Foreign Exchange [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 476 | 181 | 985 | 224 | |
Net Investment Income | 0 | 0 | (2) | 0 | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Credit Default Swap, Buying Protection [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 4 | 2 | 62 | 6 | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Credit Default Swap, Selling Protection [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 1 | (1) | (189) | 20 | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | $ 0 | $ 0 | $ 0 | $ 0 |
Derivatives (Fair Value Hedges)
Derivatives (Fair Value Hedges) (Details) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Mortgage loans | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Debt Instruments, Carrying Amount | $ 276 | $ 617 |
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease) | (20) | 3 |
Future policy benefits [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Debt Instruments, Carrying Amount | (3,626) | (4,735) |
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease) | 215 | (877) |
Policyholder Account Balances [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Debt Instruments, Carrying Amount | (1,074) | 0 |
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease) | 24 | 0 |
Fixed Maturities [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Hedged Asset, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) | (142) | (161) |
Debt Instruments, Carrying Amount | 300 | 366 |
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease) | $ 1 | $ (1) |
Derivatives (Credit Derivatives
Derivatives (Credit Derivatives) (Details) - USD ($) $ in Millions | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ (4) | $ 99 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 10,569 | $ 6,074 |
Weighted Average Years to Maturity | 4 years 7 months 6 days | 4 years 7 months 6 days |
Aaa/Aa/A | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 51 | $ 17 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 4,414 | $ 1,201 |
Weighted Average Years to Maturity | 3 years 6 months | 2 years 6 months |
Aaa/Aa/A | Single name credit default swaps (3) | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 0 | $ 0 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 10 | $ 10 |
Weighted Average Years to Maturity | 1 year 8 months 12 days | 2 years 6 months |
Aaa/Aa/A | Credit default swaps referencing indices | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 51 | $ 17 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 4,404 | $ 1,191 |
Weighted Average Years to Maturity | 3 years 6 months | 2 years 6 months |
Baa [Member] | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ (45) | $ 91 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 6,017 | $ 4,758 |
Weighted Average Years to Maturity | 5 years 4 months 24 days | 5 years 1 month 6 days |
Baa [Member] | Single name credit default swaps (3) | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 0 | $ 1 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 40 | $ 60 |
Weighted Average Years to Maturity | 2 years 8 months 12 days | 3 years 3 months 18 days |
Baa [Member] | Credit default swaps referencing indices | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ (45) | $ 90 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 5,977 | $ 4,698 |
Weighted Average Years to Maturity | 5 years 4 months 24 days | 5 years 1 month 6 days |
Ba | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 3 | $ 0 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 70 | $ 85 |
Weighted Average Years to Maturity | 2 years 1 month 6 days | 1 year 6 months |
Ba | Single name credit default swaps (3) | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 2 | $ 1 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 45 | $ 65 |
Weighted Average Years to Maturity | 10 months 24 days | 6 months |
Ba | Credit default swaps referencing indices | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 1 | $ (1) |
Maximum Amount of Future Payments under Credit Default Swaps | $ 25 | $ 20 |
Weighted Average Years to Maturity | 4 years 2 months 12 days | 5 years |
B | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ (1) | $ 0 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 38 | 0 |
Weighted Average Years to Maturity | 4 years 8 months 12 days | |
B | Credit default swaps referencing indices | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ (1) | 0 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 38 | 0 |
Weighted Average Years to Maturity | 4 years 8 months 12 days | |
Caa3 | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ (12) | (9) |
Maximum Amount of Future Payments under Credit Default Swaps | $ 30 | $ 30 |
Weighted Average Years to Maturity | 3 years 8 months 12 days | 4 years 6 months |
Caa3 | Credit default swaps referencing indices | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ (12) | $ (9) |
Maximum Amount of Future Payments under Credit Default Swaps | $ 30 | $ 30 |
Weighted Average Years to Maturity | 3 years 8 months 12 days | 4 years 6 months |
Derivatives (Estimated Fair Val
Derivatives (Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Offsetting Assets [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Excluding Accruals | $ 10,910 | $ 8,711 |
Derivative Liability, Fair Value, Gross Liability Excluding Accruals | 4,169 | 1,387 |
Net amount of derivative assets after application of master netting agreements and cash collateral | 82 | 72 |
Net amount of derivative liabilities after application of master netting agreements and cash collateral | 3 | 1 |
Over the Counter [Member] | ||
Offsetting Assets [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Excluding Accruals | 10,871 | 8,602 |
Derivative Liability, Fair Value, Gross Liability Excluding Accruals | 4,072 | 1,379 |
Gross estimated fair value of derivative assets | (3,968) | (1,364) |
Gross estimated fair value of derivative liabilities | (3,968) | (1,364) |
Cash collateral on derivative assets | (5,577) | (6,414) |
Cash collateral on derivative liabilities | 0 | 0 |
Securities collateral on derivative assets | (1,274) | (767) |
Securities collateral on derivative liabilities | (102) | (14) |
Exchange Traded [Member] | ||
Offsetting Assets [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Excluding Accruals | 14 | 5 |
Derivative Liability, Fair Value, Gross Liability Excluding Accruals | 3 | 0 |
Gross estimated fair value of derivative assets | (1) | 0 |
Gross estimated fair value of derivative liabilities | (1) | 0 |
Securities collateral on derivative assets | 0 | 0 |
Securities collateral on derivative liabilities | (2) | 0 |
Cleared [Member] | ||
Offsetting Assets [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Excluding Accruals | 25 | 104 |
Derivative Liability, Fair Value, Gross Liability Excluding Accruals | 94 | 8 |
Gross estimated fair value of derivative assets | (7) | (3) |
Gross estimated fair value of derivative liabilities | (7) | (3) |
Cash collateral on derivative assets | (1) | (91) |
Cash collateral on derivative liabilities | (41) | 0 |
Securities collateral on derivative assets | 0 | 0 |
Securities collateral on derivative liabilities | $ (45) | $ (5) |
Derivatives (Credit Risk on Fre
Derivatives (Credit Risk on Freestanding Derivatives) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Credit Derivatives [Line Items] | ||
Derivative, Collateral, Right to Reclaim Cash | $ 3 | $ 0 |
Customer Securities for which Entity has Right to Sell or Repledge, Fair Value of Securities Sold or Repledged | 0 | |
Exchange Traded [Member] | ||
Credit Derivatives [Line Items] | ||
Derivative Asset, Not Offset, Policy Election Deduction | (1) | 0 |
Derivative Liability, Not Offset, Policy Election Deduction | (1) | 0 |
Estimated fair value of derivatives in a net liability position (1) | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Derivatives in Net Liability Position | 105 | 15 |
Estimated fair value of derivatives in a net liability position (1) | Fixed maturity securities AFS | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Collateral Provided | $ 107 | $ 17 |
Derivatives (Embedded Derivativ
Derivatives (Embedded Derivatives) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within liability host contracts | $ 266 | $ 1,499 |
Assumed affiliated reinsurance | Other invested assets | ||
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within asset host contracts (4) | 174 | 0 |
Direct guaranteed minimum benefits | Policyholder account balances | ||
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within liability host contracts | 536 | 257 |
Assumed guaranteed minimum benefits | Policyholder account balances | ||
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within liability host contracts | 5 | 5 |
Fixed annuities with equity indexed returns [Member] | Policyholder account balances | ||
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within liability host contracts | 126 | 165 |
Funds withheld and guarantees on reinsurance (including affiliated) | Other liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within liability host contracts | $ (401) | $ 1,072 |
Derivatives (Narrative) (Detail
Derivatives (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Derivatives, Fair Value [Line Items] | |||||
Estimated Fair Value Assets | $ 10,776 | $ 10,776 | $ 8,618 | ||
Estimated Fair Value Liabilities | 4,146 | 4,146 | 1,409 | ||
Maximum Amount of Future Payments under Credit Default Swaps | 10,569 | $ 10,569 | $ 6,074 | ||
Derivative Instrument Detail [Abstract] | |||||
Hedging exposure to variability in future cash flows for specific length of time | 7 years | 7 years | |||
Accumulated Other Comprehensive Income Loss | 3,200 | $ 3,200 | $ 2,400 | ||
Deferred net gains (losses) expected to be reclassified to earnings | 301 | ||||
Excess cash collateral received on derivatives | 797 | 797 | 60 | ||
Securities collateral received which the company is permitted to sell or repledge, amount that has been sold or repledged | 0 | 0 | |||
Over the Counter [Member] | |||||
Derivatives, Fair Value [Line Items] | |||||
Cash collateral on derivative assets | (5,577) | (5,577) | (6,414) | ||
Excess securities collateral received on derivatives | 261 | 261 | 47 | ||
Excess securities collateral provided on derivatives | 951 | 951 | 95 | ||
Exchange Traded [Member] | |||||
Derivatives, Fair Value [Line Items] | |||||
Excess securities collateral provided on derivatives | 80 | 80 | 106 | ||
Exchange Cleared [Member] | |||||
Derivatives, Fair Value [Line Items] | |||||
Cash collateral on derivative assets | (1) | (1) | (91) | ||
Excess securities collateral received on derivatives | 493 | 493 | 584 | ||
Nonperformance Risk [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Embedded derivative gains (losses) | 42 | $ 5 | 41 | $ (10) | |
Accrued Liabilities [Member] | |||||
Derivatives, Fair Value [Line Items] | |||||
Estimated Fair Value Assets | 134 | 134 | 93 | ||
Estimated Fair Value Liabilities | $ 23 | $ 23 | $ (22) |
Derivatives Cash Flow Hedges (D
Derivatives Cash Flow Hedges (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Maximum Length of Time Hedged in Cash Flow Hedge | 7 years | 7 years | |||
Accumulated Other Comprehensive Income Loss | $ 3,200 | $ 3,200 | $ 2,400 | ||
Gain (Loss) on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net | $ 18 | $ 0 | $ 22 | $ 6 |
Fair Value (Recurring Fair Valu
Fair Value (Recurring Fair Value Measurements) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | $ 143,414 | $ 175,885 |
Short-term investments | 3,531 | 4,866 |
Residential mortgage loans — FVO | 61,603 | 60,219 |
Derivative assets | 10,776 | 8,618 |
Separate account assets | 87,709 | 123,851 |
Liabilities [Abstract] | ||
Derivative liabilities | 4,146 | 1,409 |
Embedded derivatives within liability host contracts | 266 | 1,499 |
Separate account liabilities (2) | 87,709 | 123,851 |
Residential mortgage loans — FVO | ||
Assets [Abstract] | ||
Residential mortgage loans — FVO | 0 | 127 |
Recurring | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 143,414 | 175,885 |
Short-term investments | 3,531 | 4,866 |
Other investments | 1,468 | 1,414 |
Derivative assets | 10,776 | 8,618 |
Embedded derivatives within asset host contracts (4) | 174 | 0 |
Separate account assets | 87,709 | 123,851 |
Total assets | 247,072 | 314,761 |
Liabilities [Abstract] | ||
Derivative liabilities | 4,146 | 1,409 |
Embedded derivatives within liability host contracts | 266 | 1,499 |
Total liabilities | 4,462 | 2,933 |
Recurring | Interest rate | ||
Assets [Abstract] | ||
Derivative assets | 4,782 | 6,077 |
Liabilities [Abstract] | ||
Derivative liabilities | 1,780 | 91 |
Recurring | Foreign currency exchange rate | ||
Assets [Abstract] | ||
Derivative assets | 4,787 | 1,676 |
Liabilities [Abstract] | ||
Derivative liabilities | 2,134 | 1,076 |
Recurring | Credit | ||
Assets [Abstract] | ||
Derivative assets | 102 | 123 |
Liabilities [Abstract] | ||
Derivative liabilities | 77 | 20 |
Recurring | Equity market | ||
Assets [Abstract] | ||
Derivative assets | 1,105 | 742 |
Liabilities [Abstract] | ||
Derivative liabilities | 155 | 222 |
Recurring | Separate account liabilities (2) | ||
Liabilities [Abstract] | ||
Separate account liabilities (2) | 50 | 25 |
Recurring | Residential mortgage loans — FVO | ||
Assets [Abstract] | ||
Residential mortgage loans — FVO | 0 | 127 |
Recurring | U.S. corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 50,103 | 58,402 |
Recurring | U.S. government and agency | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 22,040 | 31,222 |
Recurring | Foreign corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 22,862 | 29,685 |
Recurring | RMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 20,090 | 23,145 |
Recurring | ABS & CLO | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 11,572 | 12,879 |
Recurring | Municipals | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 7,238 | 8,728 |
Recurring | CMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 5,938 | 6,878 |
Recurring | Foreign government | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 3,571 | 4,946 |
Recurring | Level 1 | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 9,172 | 15,048 |
Short-term investments | 3,302 | 4,187 |
Other investments | 252 | 328 |
Derivative assets | 14 | 5 |
Embedded derivatives within asset host contracts (4) | 0 | 0 |
Separate account assets | 16,081 | 28,231 |
Total assets | 28,821 | 47,799 |
Liabilities [Abstract] | ||
Derivative liabilities | 3 | 0 |
Embedded derivatives within liability host contracts | 0 | 0 |
Total liabilities | 15 | 7 |
Recurring | Level 1 | Interest rate | ||
Assets [Abstract] | ||
Derivative assets | 0 | 0 |
Liabilities [Abstract] | ||
Derivative liabilities | 2 | 0 |
Recurring | Level 1 | Foreign currency exchange rate | ||
Assets [Abstract] | ||
Derivative assets | 0 | 0 |
Liabilities [Abstract] | ||
Derivative liabilities | 0 | 0 |
Recurring | Level 1 | Credit | ||
Assets [Abstract] | ||
Derivative assets | 0 | 0 |
Liabilities [Abstract] | ||
Derivative liabilities | 0 | 0 |
Recurring | Level 1 | Equity market | ||
Assets [Abstract] | ||
Derivative assets | 14 | 5 |
Liabilities [Abstract] | ||
Derivative liabilities | 1 | 0 |
Recurring | Level 1 | Separate account liabilities (2) | ||
Liabilities [Abstract] | ||
Separate account liabilities (2) | 12 | 7 |
Recurring | Level 1 | Residential mortgage loans — FVO | ||
Assets [Abstract] | ||
Residential mortgage loans — FVO | 0 | 0 |
Recurring | Level 1 | U.S. corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 1 | U.S. government and agency | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 9,078 | 15,041 |
Recurring | Level 1 | Foreign corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 1 | RMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 94 | 7 |
Recurring | Level 1 | ABS & CLO | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 1 | Municipals | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 1 | CMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 1 | Foreign government | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 2 | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 118,407 | 141,290 |
Short-term investments | 224 | 677 |
Other investments | 280 | 192 |
Derivative assets | 10,686 | 8,494 |
Embedded derivatives within asset host contracts (4) | 0 | 0 |
Separate account assets | 70,602 | 93,656 |
Total assets | 200,199 | 244,309 |
Liabilities [Abstract] | ||
Derivative liabilities | 3,581 | 1,376 |
Embedded derivatives within liability host contracts | 0 | 0 |
Total liabilities | 3,598 | 1,388 |
Recurring | Level 2 | Interest rate | ||
Assets [Abstract] | ||
Derivative assets | 4,782 | 5,982 |
Liabilities [Abstract] | ||
Derivative liabilities | 1,252 | 70 |
Recurring | Level 2 | Foreign currency exchange rate | ||
Assets [Abstract] | ||
Derivative assets | 4,787 | 1,676 |
Liabilities [Abstract] | ||
Derivative liabilities | 2,134 | 1,076 |
Recurring | Level 2 | Credit | ||
Assets [Abstract] | ||
Derivative assets | 33 | 106 |
Liabilities [Abstract] | ||
Derivative liabilities | 41 | 8 |
Recurring | Level 2 | Equity market | ||
Assets [Abstract] | ||
Derivative assets | 1,084 | 730 |
Liabilities [Abstract] | ||
Derivative liabilities | 154 | 222 |
Recurring | Level 2 | Separate account liabilities (2) | ||
Liabilities [Abstract] | ||
Separate account liabilities (2) | 17 | 12 |
Recurring | Level 2 | Residential mortgage loans — FVO | ||
Assets [Abstract] | ||
Residential mortgage loans — FVO | 0 | 0 |
Recurring | Level 2 | U.S. corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 43,788 | 51,290 |
Recurring | Level 2 | U.S. government and agency | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 12,962 | 16,181 |
Recurring | Level 2 | Foreign corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 17,328 | 21,862 |
Recurring | Level 2 | RMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 17,860 | 20,333 |
Recurring | Level 2 | ABS & CLO | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 10,048 | 11,455 |
Recurring | Level 2 | Municipals | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 7,238 | 8,728 |
Recurring | Level 2 | CMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 5,637 | 6,507 |
Recurring | Level 2 | Foreign government | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 3,546 | 4,934 |
Recurring | Level 3 | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 15,835 | 19,547 |
Short-term investments | 5 | 2 |
Other investments | 936 | 894 |
Derivative assets | 76 | 119 |
Embedded derivatives within asset host contracts (4) | 174 | 0 |
Separate account assets | 1,026 | 1,964 |
Total assets | 18,052 | 22,653 |
Liabilities [Abstract] | ||
Derivative liabilities | 562 | 33 |
Embedded derivatives within liability host contracts | 266 | 1,499 |
Total liabilities | 849 | 1,538 |
Recurring | Level 3 | Interest rate | ||
Assets [Abstract] | ||
Derivative assets | 0 | 95 |
Liabilities [Abstract] | ||
Derivative liabilities | 526 | 21 |
Recurring | Level 3 | Foreign currency exchange rate | ||
Assets [Abstract] | ||
Derivative assets | 0 | 0 |
Liabilities [Abstract] | ||
Derivative liabilities | 0 | 0 |
Recurring | Level 3 | Credit | ||
Assets [Abstract] | ||
Derivative assets | 69 | 17 |
Liabilities [Abstract] | ||
Derivative liabilities | 36 | 12 |
Recurring | Level 3 | Equity market | ||
Assets [Abstract] | ||
Derivative assets | 7 | 7 |
Liabilities [Abstract] | ||
Derivative liabilities | 0 | 0 |
Recurring | Level 3 | Separate account liabilities (2) | ||
Liabilities [Abstract] | ||
Separate account liabilities (2) | 21 | 6 |
Recurring | Level 3 | Residential mortgage loans — FVO | ||
Assets [Abstract] | ||
Residential mortgage loans — FVO | 0 | 127 |
Recurring | Level 3 | U.S. corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 6,315 | 7,112 |
Recurring | Level 3 | U.S. government and agency | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 3 | Foreign corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 5,534 | 7,823 |
Recurring | Level 3 | RMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 2,136 | 2,805 |
Recurring | Level 3 | ABS & CLO | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 1,524 | 1,424 |
Recurring | Level 3 | Municipals | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 3 | CMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 301 | 371 |
Recurring | Level 3 | Foreign government | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 25 | 12 |
Other limited partnership interests | Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, Fair Value Disclosure | $ 68 | $ 95 |
Fair Value (Quantitative Inform
Fair Value (Quantitative Information) (Details) | Sep. 30, 2022 | Dec. 31, 2021 |
Minimum | Interest rate | Measurement Input, Swap Yield | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 369 | 151 |
Minimum | Interest rate | Measurement Input, Price Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 0 | 0.01 |
Minimum | Credit | Measurement Input, Credit Spread | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 86 | 96 |
Minimum | Embedded derivatives direct and assumed guaranteed minimum benefits | Mortality rates: Ages 0 - 40 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0001 | 0.0001 |
Minimum | Embedded derivatives direct and assumed guaranteed minimum benefits | Mortality rates: Ages 41 - 60 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0005 | 0.0005 |
Minimum | Embedded derivatives direct and assumed guaranteed minimum benefits | Mortality rates: Ages 61 - 115 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0033 | 0.0032 |
Minimum | Embedded derivatives direct and assumed guaranteed minimum benefits | Lapse rates: Durations 1 - 10 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0 | 0.0025 |
Minimum | Embedded derivatives direct and assumed guaranteed minimum benefits | Lapse rates: Durations 11 - 20 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0070 | 0.0070 |
Minimum | Embedded derivatives direct and assumed guaranteed minimum benefits | Lapse rates: Durations 21 - 116 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0160 | 0.0160 |
Minimum | Embedded derivatives direct and assumed guaranteed minimum benefits | Measurement Input, Utilization Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0 | 0 |
Minimum | Embedded derivatives direct and assumed guaranteed minimum benefits | Measurement Input, Withdrawal Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0 | 0.0025 |
Minimum | Embedded derivatives direct and assumed guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.1646 | 0.1644 |
Minimum | Embedded derivatives direct and assumed guaranteed minimum benefits | Nonperformance risk spread | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0033 | 0.0004 |
Minimum | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 0 | 1 |
Minimum | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 5 | 0 |
Minimum | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 0 | 0 |
Minimum | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 76 | 91 |
Maximum | Interest rate | Measurement Input, Swap Yield | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 379 | 200 |
Maximum | Interest rate | Measurement Input, Price Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 0 | 0.01 |
Maximum | Credit | Measurement Input, Credit Spread | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 148 | 133 |
Maximum | Embedded derivatives direct and assumed guaranteed minimum benefits | Mortality rates: Ages 0 - 40 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0014 | 0.0012 |
Maximum | Embedded derivatives direct and assumed guaranteed minimum benefits | Mortality rates: Ages 41 - 60 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0043 | 0.0065 |
Maximum | Embedded derivatives direct and assumed guaranteed minimum benefits | Mortality rates: Ages 61 - 115 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 1 | 1 |
Maximum | Embedded derivatives direct and assumed guaranteed minimum benefits | Lapse rates: Durations 1 - 10 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.80 | 1 |
Maximum | Embedded derivatives direct and assumed guaranteed minimum benefits | Lapse rates: Durations 11 - 20 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.80 | 1 |
Maximum | Embedded derivatives direct and assumed guaranteed minimum benefits | Lapse rates: Durations 21 - 116 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.80 | 1 |
Maximum | Embedded derivatives direct and assumed guaranteed minimum benefits | Measurement Input, Utilization Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.22 | 0.22 |
Maximum | Embedded derivatives direct and assumed guaranteed minimum benefits | Measurement Input, Withdrawal Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.10 | 0.10 |
Maximum | Embedded derivatives direct and assumed guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.2201 | 0.2216 |
Maximum | Embedded derivatives direct and assumed guaranteed minimum benefits | Nonperformance risk spread | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0081 | 0.0040 |
Maximum | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 121 | 165 |
Maximum | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 102 | 117 |
Maximum | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 113 | 121 |
Maximum | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 102 | 110 |
Weighted Average | Interest rate | Measurement Input, Swap Yield | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 374 | 188 |
Weighted Average | Interest rate | Measurement Input, Price Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 0 | 0.01 |
Weighted Average | Credit | Measurement Input, Credit Spread | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 105 | 109 |
Weighted Average | Embedded derivatives direct and assumed guaranteed minimum benefits | Mortality rates: Ages 0 - 40 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0005 | 0.0008 |
Weighted Average | Embedded derivatives direct and assumed guaranteed minimum benefits | Mortality rates: Ages 41 - 60 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0021 | 0.0027 |
Weighted Average | Embedded derivatives direct and assumed guaranteed minimum benefits | Mortality rates: Ages 61 - 115 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0145 | 0.0208 |
Weighted Average | Embedded derivatives direct and assumed guaranteed minimum benefits | Lapse rates: Durations 1 - 10 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0884 | 0.0630 |
Weighted Average | Embedded derivatives direct and assumed guaranteed minimum benefits | Lapse rates: Durations 11 - 20 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0646 | 0.0522 |
Weighted Average | Embedded derivatives direct and assumed guaranteed minimum benefits | Lapse rates: Durations 21 - 116 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0290 | 0.0522 |
Weighted Average | Embedded derivatives direct and assumed guaranteed minimum benefits | Measurement Input, Utilization Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0037 | 0.0022 |
Weighted Average | Embedded derivatives direct and assumed guaranteed minimum benefits | Measurement Input, Withdrawal Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.04 | 0.0372 |
Weighted Average | Embedded derivatives direct and assumed guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.1849 | 0.1860 |
Weighted Average | Embedded derivatives direct and assumed guaranteed minimum benefits | Nonperformance risk spread | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivatives direct and assumed guaranteed minimum benefits | 0.0075 | 0.0035 |
Weighted Average | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 87 | 110 |
Weighted Average | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 95 | 101 |
Weighted Average | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 92 | 99 |
Weighted Average | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 92 | 102 |
Fair Value (Unobservable Input
Fair Value (Unobservable Input Reconciliation) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Residential mortgage loans — FVO | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | $ 109 | $ 140 | $ 127 | $ 165 |
Total realized/unrealized gains (losses) included in net income (loss) | 1 | 0 | (8) | (3) |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 0 | 0 |
Purchases | 0 | 0 | 0 | 0 |
Sales | (108) | 0 | (108) | (11) |
Issuances | 0 | 0 | 0 | 0 |
Settlements | (2) | (6) | (11) | (17) |
Transfers into Level 3 | 0 | 0 | 0 | 0 |
Transfers out of Level 3 | 0 | 0 | 0 | 0 |
Balance, end of period | 0 | 134 | 0 | 134 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | (1) | 0 | (7) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | (1) | 0 | (7) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Net Derivatives | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | (31) | 2 | (133) | (26) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (145) | 25 | (478) | (206) |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Balance, beginning of period | (103) | 39 | 86 | 452 |
Total realized/unrealized gains (losses) included in net income (loss) | (176) | 2 | (172) | (112) |
Total realized/unrealized gains (losses) included in AOCI | (124) | 45 | (541) | (373) |
Purchases | 54 | 7 | 82 | 13 |
Sales | 0 | 0 | 0 | 0 |
Issuances | (1) | (1) | (3) | (5) |
Settlements | 25 | (47) | 62 | 68 |
Transfers into Level 3 | 0 | 0 | 0 | 1 |
Transfers out of Level 3 | (161) | 0 | 0 | 1 |
Balance, end of period | (486) | 45 | (486) | 45 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | (31) | 2 | (133) | (26) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (145) | 25 | (478) | (206) |
Net Embedded Derivatives | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 250 | 27 | 1,426 | 663 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Balance, beginning of period | (341) | (1,511) | (1,499) | (2,061) |
Total realized/unrealized gains (losses) included in net income (loss) | 250 | 29 | 1,424 | 663 |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 0 | 0 |
Purchases | 0 | 0 | 0 | 0 |
Sales | 0 | 0 | 0 | 0 |
Issuances | 0 | 0 | 0 | 0 |
Settlements | (1) | (46) | (17) | (130) |
Transfers into Level 3 | 0 | 0 | 0 | 0 |
Transfers out of Level 3 | 0 | 0 | 0 | 0 |
Balance, end of period | (92) | (1,528) | (92) | (1,528) |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 250 | 27 | 1,426 | 663 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Corporate fixed maturity securities | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 13,004 | 14,105 | 14,935 | 14,873 |
Total realized/unrealized gains (losses) included in net income (loss) | (4) | (27) | (32) | (37) |
Total realized/unrealized gains (losses) included in AOCI | (1,179) | (198) | (3,774) | (618) |
Purchases | 622 | 914 | 1,848 | 1,434 |
Sales | (293) | (329) | (843) | (724) |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 186 | 237 | 119 | 128 |
Transfers out of Level 3 | (487) | (116) | (404) | (470) |
Balance, end of period | 11,849 | 14,586 | 11,849 | 14,586 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | (3) | (20) | (34) | (26) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (1,180) | (199) | (3,777) | (616) |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | (3) | (20) | (34) | (26) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (1,180) | (199) | (3,777) | (616) |
Structured Securities | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 4,090 | 4,831 | 4,600 | 4,465 |
Total realized/unrealized gains (losses) included in net income (loss) | 10 | 10 | 33 | 35 |
Total realized/unrealized gains (losses) included in AOCI | (110) | 31 | (418) | 29 |
Purchases | 216 | 316 | 580 | 1,023 |
Sales | (181) | (377) | (737) | (988) |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 30 | 0 | 183 | 255 |
Transfers out of Level 3 | (94) | (250) | (280) | (258) |
Balance, end of period | 3,961 | 4,561 | 3,961 | 4,561 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 5 | 9 | 27 | 32 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (105) | 32 | (400) | 30 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 5 | 9 | 27 | 32 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (105) | 32 | (400) | 30 |
Municipals | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 0 | 0 | 0 | 0 |
Total realized/unrealized gains (losses) included in net income (loss) | 0 | 0 | 0 | 0 |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 0 | 0 |
Purchases | 0 | 9 | 0 | 9 |
Sales | 0 | 0 | 0 | 0 |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 0 | 0 | 0 | 0 |
Transfers out of Level 3 | 0 | 0 | 0 | 0 |
Balance, end of period | 0 | 9 | 0 | 9 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Foreign government | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 21 | 11 | 12 | 5 |
Total realized/unrealized gains (losses) included in net income (loss) | 4 | 0 | (37) | 0 |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 6 | (1) |
Purchases | 0 | 10 | 0 | 12 |
Sales | 0 | 0 | (1) | (1) |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 0 | 10 | 45 | 10 |
Transfers out of Level 3 | 0 | (6) | 0 | 0 |
Balance, end of period | 25 | 25 | 25 | 25 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 5 | 0 | (37) | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 6 | (1) |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 5 | 0 | (37) | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 6 | (1) |
Short-term Investments | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 100 | 77 | 2 | 1 |
Total realized/unrealized gains (losses) included in net income (loss) | 0 | 0 | 0 | 0 |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 0 | 0 |
Purchases | 5 | 1 | 5 | 51 |
Sales | 0 | (2) | (2) | 0 |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 0 | 0 | 0 | 0 |
Transfers out of Level 3 | (100) | (24) | 0 | 0 |
Balance, end of period | 5 | 52 | 5 | 52 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Other Investments | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 961 | 724 | 894 | 565 |
Total realized/unrealized gains (losses) included in net income (loss) | (20) | 45 | (39) | 120 |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 0 | 0 |
Purchases | 4 | 109 | 199 | 137 |
Sales | (9) | (9) | (19) | (23) |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 0 | 0 | 3 | 74 |
Transfers out of Level 3 | 0 | (25) | (102) | (29) |
Balance, end of period | 936 | 844 | 936 | 844 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | (21) | 44 | (44) | 117 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | (21) | 44 | (44) | 117 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Separate Accounts | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 1,029 | 1,105 | 1,958 | 939 |
Total realized/unrealized gains (losses) included in net income (loss) | 2 | 5 | 19 | 4 |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 0 | 0 |
Purchases | 61 | 150 | 146 | 324 |
Sales | (75) | (18) | (1,107) | (43) |
Issuances | (1) | 0 | 3 | (1) |
Settlements | 0 | 0 | 4 | 6 |
Transfers into Level 3 | 0 | 0 | 0 | 10 |
Transfers out of Level 3 | (11) | (5) | (18) | (2) |
Balance, end of period | 1,005 | 1,237 | 1,005 | 1,237 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | $ 0 | $ 0 | $ 0 | $ 0 |
Fair Value (Fair Value Option f
Fair Value (Fair Value Option for Residential Mortgage Loans) (Details) - Residential mortgage loans — FVO - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Fair Value, Option, Quantitative Disclosures [Line Items] | ||
Unpaid principal balance | $ 0 | $ 130 |
Difference between estimated fair value and unpaid principal balance | 0 | (3) |
Carrying value at estimated fair value | 0 | 127 |
Loans in nonaccrual status | 0 | 32 |
Loans more than 90 days past due | 0 | 14 |
Loans in nonaccrual status or more than 90 days past due, or both — difference between aggregate estimated fair value and unpaid principal balance | $ 0 | $ (7) |
Fair Value (Financial Instrumen
Fair Value (Financial Instruments Carried at Other Than Fair Value) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Assets | ||
Policy loans | $ 5,732 | $ 5,816 |
Liabilities | ||
Separate account liabilities | 87,709 | 123,851 |
Carrying Value | ||
Assets | ||
Mortgage loans (1) | 61,603 | 60,092 |
Policy loans | 5,732 | 5,816 |
Other invested assets | 1,910 | 2,230 |
Premiums, reinsurance and other receivables | 11,833 | 12,101 |
Liabilities | ||
Policyholder account balances | 78,941 | 76,387 |
Long-term debt | 1,615 | 1,659 |
Other liabilities | 12,313 | 12,357 |
Separate account liabilities | 38,509 | 54,254 |
Estimated Fair Value | ||
Assets | ||
Mortgage loans (1) | 58,419 | 63,094 |
Policy loans | 6,148 | 6,710 |
Other invested assets | 1,933 | 2,288 |
Premiums, reinsurance and other receivables | 12,074 | 12,531 |
Liabilities | ||
Policyholder account balances | 75,910 | 79,182 |
Long-term debt | 1,693 | 2,000 |
Other liabilities | 12,284 | 12,571 |
Separate account liabilities | 38,509 | 54,254 |
Estimated Fair Value | Level 1 | ||
Assets | ||
Mortgage loans (1) | 0 | 0 |
Policy loans | 0 | 0 |
Other invested assets | 0 | 0 |
Premiums, reinsurance and other receivables | 0 | 0 |
Liabilities | ||
Policyholder account balances | 0 | 0 |
Long-term debt | 0 | 0 |
Other liabilities | 0 | 0 |
Separate account liabilities | 0 | 0 |
Estimated Fair Value | Level 2 | ||
Assets | ||
Mortgage loans (1) | 0 | 0 |
Policy loans | 0 | 0 |
Other invested assets | 1,933 | 1,932 |
Premiums, reinsurance and other receivables | 302 | 156 |
Liabilities | ||
Policyholder account balances | 0 | 0 |
Long-term debt | 1,693 | 2,000 |
Other liabilities | 314 | 159 |
Separate account liabilities | 38,509 | 54,254 |
Estimated Fair Value | Level 3 | ||
Assets | ||
Mortgage loans (1) | 58,419 | 63,094 |
Policy loans | 6,148 | 6,710 |
Other invested assets | 0 | 356 |
Premiums, reinsurance and other receivables | 11,772 | 12,375 |
Liabilities | ||
Policyholder account balances | 75,910 | 79,182 |
Long-term debt | 0 | 0 |
Other liabilities | 11,970 | 12,412 |
Separate account liabilities | $ 0 | $ 0 |
Equity (Components of Accumulat
Equity (Components of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Balance, beginning of period | $ (3,777) | $ 9,879 | $ 9,917 | $ 11,662 |
OCI before reclassifications | (8,649) | 276 | (27,146) | (2,003) |
Deferred income tax benefit (expense) | 1,831 | (160) | 5,712 | 328 |
AOCI before reclassifications, net of income tax | (10,595) | 9,995 | (11,517) | 9,987 |
Amounts reclassified from AOCI | 681 | 227 | 1,848 | 238 |
Deferred income tax benefit (expense) | (144) | 75 | (389) | 72 |
Amounts reclassified from AOCI, net of income tax | 537 | 302 | 1,459 | 310 |
Balance, end of period | (10,058) | 10,297 | (10,058) | 10,297 |
Unrealized Investment Gains (Losses), Net of Related Offsets | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Balance, beginning of period | (5,214) | 8,938 | 8,485 | 10,384 |
OCI before reclassifications | (8,845) | 38 | (26,804) | (1,862) |
Deferred income tax benefit (expense) | 1,872 | 20 | 5,643 | 428 |
AOCI before reclassifications, net of income tax | (12,187) | 8,996 | (12,676) | 8,950 |
Amounts reclassified from AOCI | 186 | (13) | 805 | 46 |
Deferred income tax benefit (expense) | (40) | 2 | (170) | (11) |
Amounts reclassified from AOCI, net of income tax | 146 | (11) | 635 | 35 |
Balance, end of period | (12,041) | 8,985 | (12,041) | 8,985 |
Unrealized Gains (Losses) on Derivatives | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Balance, beginning of period | 1,905 | 1,419 | 1,872 | 1,791 |
OCI before reclassifications | 284 | 228 | (202) | (173) |
Deferred income tax benefit (expense) | (60) | (178) | 42 | (94) |
AOCI before reclassifications, net of income tax | 2,129 | 1,469 | 1,712 | 1,524 |
Amounts reclassified from AOCI | 485 | 233 | 1,013 | 164 |
Deferred income tax benefit (expense) | (102) | 75 | (213) | 89 |
Amounts reclassified from AOCI, net of income tax | 383 | 308 | 800 | 253 |
Balance, end of period | 2,512 | 1,777 | 2,512 | 1,777 |
Foreign Currency Translation Adjustments | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Balance, beginning of period | (89) | (33) | (45) | (53) |
OCI before reclassifications | (88) | 7 | (140) | 31 |
Deferred income tax benefit (expense) | 19 | (2) | 27 | (6) |
AOCI before reclassifications, net of income tax | (158) | (28) | (158) | (28) |
Amounts reclassified from AOCI | 0 | 0 | 0 | 0 |
Deferred income tax benefit (expense) | 0 | 0 | 0 | 0 |
Amounts reclassified from AOCI, net of income tax | 0 | 0 | 0 | 0 |
Balance, end of period | (158) | (28) | (158) | (28) |
Defined Benefit Plans Adjustment | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Balance, beginning of period | (379) | (445) | (395) | (460) |
OCI before reclassifications | 0 | 3 | 0 | 1 |
Deferred income tax benefit (expense) | 0 | 0 | 0 | 0 |
AOCI before reclassifications, net of income tax | (379) | (442) | (395) | (459) |
Amounts reclassified from AOCI | 10 | 7 | 30 | 28 |
Deferred income tax benefit (expense) | (2) | (2) | (6) | (6) |
Amounts reclassified from AOCI, net of income tax | 8 | 5 | 24 | 22 |
Balance, end of period | $ (371) | $ (437) | $ (371) | $ (437) |
Equity (Reclassifications Out o
Equity (Reclassifications Out of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net investment gains (losses) | $ (82) | $ 190 | $ (391) | $ 692 | ||
Net investment income | 2,260 | 3,331 | 7,528 | 9,552 | ||
Net derivative gains (losses) | 454 | 84 | 980 | (906) | ||
Income (loss) before provision for income tax | 1,047 | 1,075 | 3,385 | 3,443 | ||
Income tax (expense) benefit | (174) | (153) | (539) | (510) | ||
Net income (loss) | 873 | 922 | $ 1,973 | $ 2,011 | 2,846 | 2,933 |
Reclassification out of Accumulated Other Comprehensive Income | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net income (loss) | (537) | (302) | (1,459) | (310) | ||
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Investment Gains (Losses), Net of Related Offsets | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net investment gains (losses) | (174) | 17 | (775) | (17) | ||
Net investment income | 1 | (3) | 4 | (10) | ||
Net derivative gains (losses) | (13) | (1) | (34) | (19) | ||
Income (loss) before provision for income tax | (186) | 13 | (805) | (46) | ||
Income tax (expense) benefit | 40 | (2) | 170 | 11 | ||
Net income (loss) | (146) | 11 | (635) | (35) | ||
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Income (loss) before provision for income tax | (485) | (233) | (1,013) | (164) | ||
Income tax (expense) benefit | 102 | (75) | 213 | (89) | ||
Net income (loss) | (383) | (308) | (800) | (253) | ||
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | Interest rate | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net investment gains (losses) | (16) | 8 | 55 | 56 | ||
Net investment income | 15 | 14 | 46 | 41 | ||
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | Foreign currency swaps | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net investment gains (losses) | (485) | (257) | (1,117) | (265) | ||
Net investment income | 1 | 2 | 3 | 4 | ||
Reclassification out of Accumulated Other Comprehensive Income | Defined Benefit Plans Adjustment | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Amortization of net actuarial gains (losses) | (10) | (10) | (31) | (33) | ||
Amortization of prior service (costs) credit | 0 | 3 | 1 | 5 | ||
Income (loss) before provision for income tax | (10) | (7) | (30) | (28) | ||
Income tax (expense) benefit | 2 | 2 | 6 | 6 | ||
Net income (loss) | $ (8) | $ (5) | $ (24) | $ (22) |
Other Revenues (Details)
Other Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 209 | $ 212 | $ 638 | $ 648 |
Other revenues | 501 | 368 | 1,286 | 1,225 |
Prepaid legal plans | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 105 | 99 | 319 | 298 |
Recordkeeping and administrative services | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 40 | 53 | 129 | 158 |
Administrative services-only contracts | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 56 | 54 | 168 | 166 |
Other revenue from service contracts from customers | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 8 | 6 | 22 | 26 |
Other Income | ||||
Disaggregation of Revenue [Line Items] | ||||
Other revenues | $ 292 | $ 156 | $ 648 | $ 577 |
Other Expenses (Other Expenses)
Other Expenses (Other Expenses) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Other Income and Expenses [Abstract] | ||||
General and administrative expenses (1) | $ 675 | $ 566 | $ 2,039 | $ 1,660 |
Pension, postretirement and postemployment benefit costs | 30 | 27 | 89 | 85 |
Premium taxes, other taxes, and licenses & fees | 108 | 77 | 269 | 243 |
Commissions and other variable expenses | 755 | 1,048 | 1,728 | 2,030 |
Capitalization of DAC | (58) | (16) | (120) | (45) |
Amortization of DAC and VOBA | (119) | 99 | 55 | 171 |
Interest expense on debt | 27 | 24 | 76 | 72 |
Total other expenses | 1,418 | 1,825 | 4,136 | 4,216 |
Net change in cash surrender value of investments, net of premiums paid | $ 21 | $ (14) | $ 95 | $ (71) |
Income Tax (Narrative) (Details
Income Tax (Narrative) (Details) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Tax Disclosure [Abstract] | ||||
Effective Income Tax Rate Reconciliation, Percent | 17% | 14% | 16% | 15% |
Contingencies, Commitments an_2
Contingencies, Commitments and Guarantees (Contingencies - Narrative) (Details) $ in Millions | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2022 USD ($) Claims | Sep. 30, 2021 Claims | Dec. 31, 2021 Claims | |
Minimum | |||
Loss Contingencies | |||
Loss Contingency, Range of Possible Loss, Portion Not Accrued | $ 0 | ||
Maximum | |||
Loss Contingencies | |||
Loss Contingency, Range of Possible Loss, Portion Not Accrued | $ 125 | ||
Asbestos Related Claims | |||
Loss Contingencies | |||
Asbestos-Related Claims | Claims | 1,962 | 2,156 | 2,824 |
Contingencies, Commitments an_3
Contingencies, Commitments and Guarantees (Commitments and Guarantees - Narrative) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Contingencies, Commitments and Guarantees [Abstract] | ||
Liabilities for indemnities, guarantees and commitments | $ 2 | $ 2 |
Cumulative maximum indemnities and guarantees contractual limitation | 365 | |
Minimum | ||
Contingencies, Commitments and Guarantees [Abstract] | ||
Indemnities and guarantees contractual limitation range | 1 | |
Maximum | ||
Contingencies, Commitments and Guarantees [Abstract] | ||
Indemnities and guarantees contractual limitation range | 263 | |
Mortgage Loan Commitments | ||
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] | ||
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Liability | 2,500 | 3,100 |
Commitments to Fund Partnership Investments, Bank Credit Facilities, Bridge Loans and Private Corporate Bond Investments | ||
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] | ||
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Liability | $ 4,500 | $ 4,500 |
Related Party Transactions (Ser
Related Party Transactions (Service Agreements - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Related Party Transaction [Line Items] | |||||
Other expenses | $ 1,418 | $ 1,825 | $ 4,136 | $ 4,216 | |
Revenues | 17,386 | 10,194 | 36,273 | 30,089 | |
Net receivables (payables) due from (to) affiliates | (69) | (69) | $ (143) | ||
Affiliated Entity [Member] | Services Necessary To Conduct The Company's Activities | |||||
Related Party Transaction [Line Items] | |||||
Other expenses | 686 | 624 | 2,000 | 1,800 | |
Revenues | $ 13 | $ 11 | $ 36 | $ 32 |
Related Party Transactions (Eff
Related Party Transactions (Effects of Affiliated Reinsurance on Statements of Operations) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Premiums: | ||||
Net premiums | $ 13,769 | $ 5,715 | $ 25,347 | $ 17,971 |
Other revenues: | ||||
Net other revenues | 501 | 368 | 1,286 | 1,225 |
Interest Credited To Policyholder Account Balances [Abstract] | ||||
Net interest credited to policyholder account balances | 624 | 512 | 1,645 | 1,535 |
Other expenses: | ||||
Net other expenses | 1,418 | 1,825 | 4,136 | 4,216 |
Affiliated Entity [Member] | Assumed Reinsurance [Member] | ||||
Premiums: | ||||
Reinsurance assumed | 2 | 3 | 5 | 845 |
Universal life and investment-type product policy fees: | ||||
Reinsurance assumed | 0 | 0 | 0 | 0 |
Other revenues: | ||||
Reinsurance assumed | 23 | 1 | 52 | 3 |
Policyholder benefits and claims: | ||||
Reinsurance assumed | 17 | 1 | 51 | 833 |
Interest Credited To Policyholder Account Balances [Abstract] | ||||
Reinsurance assumed | 26 | 8 | 47 | 22 |
Other expenses: | ||||
Reinsurance assumed | 4 | 0 | 14 | 19 |
Affiliated Entity [Member] | Ceded Reinsurance [Member] | ||||
Premiums: | ||||
Reinsurance ceded | (29) | (26) | (97) | (86) |
Universal life and investment-type product policy fees: | ||||
Reinsurance ceded | (4) | (13) | (11) | (14) |
Other revenues: | ||||
Reinsurance ceded | 106 | 96 | 353 | 379 |
Policyholder benefits and claims: | ||||
Reinsurance ceded | (36) | (43) | (117) | (115) |
Interest Credited To Policyholder Account Balances [Abstract] | ||||
Reinsurance ceded | (3) | (3) | (9) | (9) |
Other expenses: | ||||
Reinsurance ceded | 343 | 713 | 533 | 947 |
Affiliated Entity [Member] | Reinsurance [Member] | ||||
Premiums: | ||||
Net premiums | (27) | (23) | (92) | 759 |
Universal life and investment-type product policy fees: | ||||
Insurance Commissions and Fees, Net Impact from Reinsurance | (4) | (13) | (11) | (14) |
Other revenues: | ||||
Net other revenues | 129 | 97 | 405 | 382 |
Policyholder benefits and claims: | ||||
Net policyholder benefits and claims | (19) | (42) | (66) | 718 |
Interest Credited To Policyholder Account Balances [Abstract] | ||||
Net interest credited to policyholder account balances | 23 | 5 | 38 | 13 |
Other expenses: | ||||
Net other expenses | $ 347 | $ 713 | $ 547 | $ 966 |
Related Party Transactions (E_2
Related Party Transactions (Effects of Affiliated Reinsurance on Balance Sheets) (Details) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Assets | ||
Premiums, reinsurance and other receivables | $ 21,247 | $ 20,505 |
Deferred policy acquisition costs and value of business acquired | 5,379 | 2,598 |
Liabilities: | ||
Policyholder account balances | 97,675 | 94,459 |
Other policy-related balances | 8,104 | 8,094 |
Other Liabilities | 25,950 | 23,796 |
Assumed Reinsurance [Member] | Affiliated Entity [Member] | ||
Assets | ||
Premiums, reinsurance and other receivables | 538 | 25 |
Deferred policy acquisition costs and value of business acquired | 69 | 6 |
Total assets | 607 | 31 |
Liabilities: | ||
Liability for Future Policy Benefit, before Reinsurance | 3,012 | 3,139 |
Policyholder account balances | 3,533 | 366 |
Other policy-related balances | 63 | 14 |
Other Liabilities | 908 | 894 |
Total liabilities | 7,516 | 4,413 |
Ceded Reinsurance [Member] | Affiliated Entity [Member] | ||
Assets | ||
Premiums, reinsurance and other receivables | 11,336 | 11,710 |
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Ceded | (164) | (139) |
Total assets | 11,172 | 11,571 |
Liabilities: | ||
Liability for Future Policy Benefit, before Reinsurance, Ceded | 10 | (10) |
Policyholder account balances | 0 | 0 |
Other policy-related balances | (3) | 0 |
Other Liabilities | 10,380 | 12,190 |
Total liabilities | $ 10,387 | $ 12,180 |
Related Party Transactions (Rei
Related Party Transactions (Reinsurance Transactions - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Reinsurance Disclosures [Abstract] | |||||
Embedded Derivative, Fair Value of Embedded Derivative Liability | $ 266 | $ 266 | $ 1,499 | ||
Other invested assets relating to variable interest entities | 21,532 | 21,532 | 19,860 | ||
Net premiums | 13,769 | $ 5,715 | 25,347 | $ 17,971 | |
Affiliated Entity [Member] | |||||
Reinsurance Disclosures [Abstract] | |||||
Other invested assets relating to variable interest entities | $ 1,200 | $ 1,200 | 1,499 | ||
Affiliated Entity [Member] | Funds Withheld On Ceded Reinsurance [Member] | |||||
Reinsurance Disclosures [Abstract] | |||||
Coinsurance Funds Withheld Basis, Percent | 75% | 75% | |||
Embedded Derivative, Fair Value of Embedded Derivative Liability | $ (31) | $ (31) | 31 | ||
Net derivatives gains (losses) | 15 | 1 | 62 | 14 | |
Affiliated Entity [Member] | Closed Block Liabilities Ceded To MetLife Reinsurance Of Charleston [Member] | |||||
Reinsurance Disclosures [Abstract] | |||||
Embedded Derivative, Fair Value of Embedded Derivative Liability | (464) | (464) | $ 1,000 | ||
Net derivatives gains (losses) | $ 388 | $ 50 | $ 1,500 | $ 279 |